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The acid β-glucocerebrosidase (GC) is a lysosomal hydrolase for β-glucose-terminated 
sphingolipids and reaches the lysosome through binding to its transport receptor the 
Lysosomal Integral Membrane Protein Type-2 (LIMP-2) in a mannose-6-phosphate 
independent manner. Mutations in GC cause the most common lysosomal storage disorder, 
Gaucher disease and represent the highest genetic risk factor for the development of 
Parkinson disease caused by accumulation of α-synuclein.  
In this work properties of LIMP-2 and GC protein structure as well as their binding 
characteristics were analysed. By mutation and interaction studies, the GC-binding site on the 
LIMP-2 protein could be narrowed down to an exposed helical bundle comprised of two 
prominent helices. Surprisingly, a short peptide consisting of the proposed binding region of 
LIMP-2 was sufficient to mediate interaction with GC. Furthermore the LIMP-2-derived 
peptide had an activating effect on enzyme activity in vitro as well as in cell-based studies.  
The respective interaction site of LIMP-2 on the GC protein could also be narrowed down to a 
hydrophobic patch, verified by mutagenesis, interaction studies as well as peptide pulldown 
assays.  
Furthermore, effects of LIMP-2 deficiency in mouse brain were described exhibiting reduced 
levels of GC protein and activity, leading to aggregation of its substrates. Dysfunction of GC 
has been shown to interfere with α-synuclein homeostasis and its lysosomal degradation. In 
brain of LIMP-2-deficient mice α-synuclein accumulation could be observed, which led to 
severe neurological defects. Additionally, in cell-based experiments a distinct relationship 
between LIMP-2 expression, GC-activity and lysosomal degradation of α-synuclein was 
described. Heterologous expression of LIMP-2 in human and murine cell systems resulted in 
an increased lysosomal trafficking and activity of GC leading to a reduction of α-synuclein 
levels. This underscored the importance of the common function of LIMP-2 and GC in the 
intracellular regulation of α-synuclein. 
In summary, this study describes the structural characteristics of the interaction of LIMP-2 
with GC and the impact of LIMP-2 on GC activity. The experiments performed suggest that 
an augmented GC activity represents a promising target for the treatment of GC-associated 
diseases including Gaucher disease and Parkinson disease. This work reveals that this increase 
in GC activity can either be achieved by enhancing the LIMP-2 expression or by small 







Die β-Glukozerebrosidase (GC) ist eine lysosomale Hydrolase, die β-Glukose-ständige 
Sphingolipide umsetzt. Durch die Bindung an den Transportrezeptor, dem lysosomalen 
integralen Membranprotein Typ-2 (LIMP-2) gelangt das Enzym vom Endoplasmatischen 
Retikulum Mannose-6 Phosphat unabhängig an seinen Wirkort –den Lysosomen. Mutationen 
in der GC führen zu der häufigsten lysosomalen Speichererkrankung, der Gaucher 
Erkrankung. Außerdem wurde beschrieben, dass Mutationen im Gen der β-Glukozerebrosi-
dase zu den häufigsten genetischen Risikofaktoren der Parkinson Krankheit zählen. Diese 
neurodegenerative Erkrankung ist durch die Akkumulation des neuronalen Proteins α-
Synuklein charakterisiert. 
In dieser Arbeit wurden die strukturellen Eigenschaften des LIMP-2 Proteins sowie der GC 
untersucht. Dabei war der Fokus auf die strukturelle Untersuchung ihrer Interaktion gerichtet. 
Durch Mutations- und Interaktionsstudien konnte die GC-Interaktionsstelle im LIMP-2 
Protein auf eine exponierte helikale Region eingeschränkt werden. Außerdem konnte gezeigt 
werden, dass ein Peptid, bestehend aus der potentiellen Binderegion von LIMP-2, ausreichend 
ist um mit GC zu interagieren und sogar einen positiven Effekt auf die enzymatische Funktion 
aufweist. Eine erhöhte Enzymaktivität nach Peptid-Zugabe konnte sowohl in vitro, als auch in 
zellkulturbasierten Experimenten bestätigt werden. Zusätzlich konnte die entsprechende 
LIMP-2 Bindedomäne auf dem GC Protein identifiziert und ebenfalls auf einen hydrophoben 
helikalen Bereich im Enzym eingeschränkt werden.  
Des Weiteren wurden die Auswirkungen einer LIMP-2 Defizienz in Mausgehirnen 
untersucht. Es konnte gezeigt werden, dass sich einhergehend mit dem Verlust von LIMP-2 
auch die Proteinmenge sowie die Aktivität von GC drastisch verringern. Dieses hat einen 
negativen Effekt auf den lysosomalen Abbau von α-Synuklein. So konnte in den Gehirnen 
von LIMP-2-defizienten Mäusen erhöhtes und aggregiertes α-Synuklein gefunden werden, 
welches zu weitreichenden neurologischen Defekten in den Tieren führte. Zusätzlich konnte 
in zellbasierten Experimenten der Einfluss von LIMP-2 Expression und GC Aktivität auf die 
lysosomale Degradierung von α-Synuklein gezeigt werden. Eine heterologe Expression von 
LIMP-2 führte in murinen, sowie humanen Zellsystemen zu einem erhöhten lysosomalen 
Transport sowie einer gesteigerten Aktivität der Hydrolase und somit zu einer Verringerung 
der α-Synuklein Proteinmenge.  
Zusammenfassend zeigen die Ergebnisse dieser Arbeit strukturelle Charakteristiken der 
Interaktion von LIMP-2 und GC, sowie den Effekt von LIMP-2 auf die GC Aktivität. Des 





katalytischen Funktion von GC eine vielversprechende therapeutische Maßnahme für GC-
assoziierte Krankheiten wie die Gaucher und die Parkinson Erkrankung darstellt. Eine 
Erhöhung der Enzymaktivität kann dabei durch eine gesteigerte Expression von LIMP-2 oder 
durch eine gezielte Aktivierung des Enzyms, wie hier für das LIMP-2 Peptid gezeigt, 






1.1 The lysosome 
The lysosome is a membrane-bound cell organelle ubiquitously found in mammalian cells, 
except in red blood cells and was discovered in the 1950s by Christian DeDuve (De Duve, 
Pressman et al. 1955). Lysosomes contain acid hydrolases for degradation and subsequent 
recycling of macromolecules. The impact of lysosomes in health and disease is further 
highlighted by a number of diseases resulting from defects in soluble lysosomal proteins and 
proteins of the lysosomal membrane (Eskelinen, Tanaka et al. 2003). In the last decade it has 
been realised that lysosomes are not only a recycling organelle but also play a pivotal role in 
cell metabolism, like repair of the plasma membrane, cell signalling, defence against 
pathogens, cholesterol metabolism and cell death (Saftig and Klumperman 2009, Yamayoshi, 
Yamashita et al. 2009, Schulze and Sandhoff 2011, Settembre, Fraldi et al. 2013). Lysosomes 
emerge from maturation or fusion of early endosomes and are characterised by a pH of 4.6 - 
5. Lysosomal proteins are synthesised as soluble or membrane-integrated glycoproteins in the 
Endoplasmic Reticulum (ER). Mannose-6-phosphate receptors (MPRs) mediate the transport 
of the majority of lysosomal enzymes. Thereby proteins tagged with mannose-6-phosphate 
(M6P) terminal residues are recognized in the Trans-Golgi Network (TGN) by MPRs and are 
delivered to lysosomes (Kornfeld and Mellman 1989, Kornfeld 1992, Ludwig, Le et al. 1995). 
1.1.1 Composition of lysosomes 
1.1.1.1 Soluble lysosomal proteins 
To date up to 60 different lysosomal hydrolases responsible for the degradation of different 
substrates have been described (Settembre, Fraldi et al. 2013). Depending on their degradation 
products lysosomal enzymes can be classified as proteases, lipases, phosphatases, nucleases, 
glucosidases, peptidases and sulphatases (Bainton 1981). They require an acidic environment 
for optimal enzymatic function (De Duve and Beaufay 1959).  
1.1.1.2 Lysosomal membrane proteins 
The lysosomal hydrolases are enclosed by a lysosomal membrane containing highly 
glycosylated membrane proteins, which contribute to the lysosomal glycocalyx (Wilke, 
Krausze et al. 2012, Schwake, Schroder et al. 2013). Most abundant and important for the 
lysosomal biogenesis and integrity are the Lysosomal Associated Membrane Proteins type 1 





the Lysosomal Integral Membrane Protein Type-2 (LIMP-2/SCARB2). A more detailed 
description of the function and structure of LIMP-2 will be provided in chapter 1.2. Amongst 
other lysosomal membrane proteins the vacuolar-type H
+
-ATPase is responsible for 
lysosomal acidification (Ohkuma, Moriyama et al. 1982). The lysosomal cholesterol 
transporter Nieman-Pick Type C1 (NPC1) plays an important role in cellular cholesterol 
homeostasis (Infante, Radhakrishnan et al. 2008). Further major integral components of the 
lysosomal membrane include small molecule transporters like cystinosin and sialin 
(Eskelinen, Tanaka et al. 2003) (Figure 1.1). 
 
 
Figure 1.1: Overview of major lysosomal membrane proteins. 
The lysosomal membrane consists of numerous proteins fulfilling multiple functions like transport across the 
membrane (sialin and cystinosin), acidification (v-type H+-ATPase) and lysosomal transport (LIMP-2) as well 
as membrane stability (LIMP-1/2, LAMP-1/2). Putative N-glycosylation sites are indicated by black branch-like 
structures. The illustration was adapted from Eskelinen, Tanaka et al. 2003. 
 
1.1.2 Trafficking of soluble lysosomal enzymes 
Lysosomal enzymes reach the lysosome via the secretory pathway. They are synthesised with 
an N-terminal signal peptide translocating the proteins into the ER, where the signal sequence 
is cleaved off. In the ER the proteins get N-glycosylated, which typically involves the binding 
of an oligosaccharide composed of N-acetylglucosamine, mannose and glucose to an 
asparagine residue (Kornfeld and Kornfeld 1985). The oligosaccharides undergo further 





recognition marker is added to target most enzymes to the lysosome (see below 1.1.2.1). 
Additionally M6P-independent lysosomal transport mechanisms have been described (see 
1.1.2.2). 
In comparison lysosomal membrane proteins are transported to their target organelle by 
cytoplasmic signal domains (tyrosin or di-leucin). After synthesis in the ER and transport via 
the Trans-Golgi-Network (TGN), small adaptor proteins binding to the signal domains and 
accessorise the packaging of the membrane proteins into clathrin-coated vesicles. By 
vesicular transport, the lysosomal membrane proteins reach the endosomal compartment 
(Bonifacino and Traub 2003, Braulke and Bonifacino 2009). It has been shown that some 
lysosomal membrane proteins can escape the lysosomal targeting pathway and get transported 
to the plasma membrane, where they reach the lysosome by endocytosis (Janvier and 
Bonifacino 2005). 
1.1.2.1 Mannose‐6‐phosphate receptor dependent transport 
Most enzymes destined for the lysosome are marked with mannose-6-phosphate residues in 
the Golgi apparatus. Two enzymes are involved in this process and act sequentially 
(Lazzarino and Gabel 1988): In the first step a GlcNac-1-phosphate is added by N-
acetylglucosamine-1-phosphotransferase (GlcNac-1PT) (Ketcham and Kornfeld 1992). The 
phosphotransferase is composed of three subunits (α2β2γ2) and is encoded by two genes: 
GNPTAB and GNPTG (Tiede, Storch et al. 2005). In the second step, N-acetylglucosamine 
residues are removed by the N-actelyglucosamine-1-phosphodiester α-N-acetyl 
glucosamininidase, also known as uncovering enzyme (USE) exposing the M6P recognition 
marker (Kornfeld, Bao et al. 1999). Subsequent binding of the M6P residue to the M6P-
receptors takes place in the TGN and leads to an exit of the receptor-ligand complex in 
clathrin-coated vesicles, fusing with early endosomes, which further maturate to late 
endosomes. Due to the continuously decreasing pH, receptor and ligand dissociate and MPRs 
get recycled back to the TGN, with MPRs not found in mature lysosomes (Braulke and 
Bonifacino 2009) (Figure 1.3). 
In mammalian cells two different MPRs have been described; the 46 kDa cation-dependent 
MPR (CD-MPR, MPR46) and the 300 kDa cation-independent MPR (CI-MPR, MPR300) 
(Ghosh, Dahms et al. 2003). Both receptors are type-1 glycoproteins but differ in their 
expression patterns, subcellular localisation and ligand binding properties (Figure 1.2) 
(Braulke and Bonifacino 2009). For instance only MPR300 is involved in endocytosis of 
M6P-marked proteins and is also able to bind other ligands lacking glycosylation, like the 












Figure 1.2: Structure of the two mannose-6-
phosphate-receptors (MPR300 and MPR46). 
The cation-independent (CI)-mannose-6-phosphate 
receptor (MPR300/CI-MPR) is a type I trans-
membrane glycoprotein with two M6P-binding 
sites in segment 3 and 9 and a binding domain for 
IGF-II in segment 11. The cation-dependent (CD)-
mannose-6-phosphate receptor (MPR46/CD-MPR) 
forms a dimer before binding phosphorylated 
proteins (yellow circle). The picture was adapted 
from Braulke and Bonifacino 2009. 
 
1.1.2.2 Mannose‐6‐phosphate receptor independent transport 
Some lysosomal proteins can be targeted to the lysosome in an M6P receptor independent 
manner. Such observations could be made in tissues of Inclusion-cell (I-cell) disease patients, 
who suffer from a complete absence of M6P residues added to lysosomal hydrolases due to a 
defective phosphotransferase (GlcNac-1PT) (Tsuji, Omura et al. 1988, Rijnboutt, Aerts et al. 
1991, Rijnboutt, Kal et al. 1991). Also in an MPR-deficient mouse model it could be shown 
that some soluble enzymes are able to reach the lysosome via other transport receptors than 
MPRs in a cell and tissue-specific manner (Dittmer, Ulbrich et al. 1999). An example for such 
a transporter is the type 1 transmembrane protein sortilin, which has been shown to facilitate 
lysosomal trafficking of different ligands including, prosaposin, acid sphingomyelinase and 
potentially cathepsin H (Petersen, Nielsen et al. 1997, Mazella, Zsurger et al. 1998, Nielsen, 
Jacobsen et al. 1999, Lefrancois, Zeng et al. 2003, Canuel, Korkidakis et al. 2008, Markmann, 
Thelen et al. 2015). 
Furthermore the soluble hydrolase β-glucocerebrosidase (GC) has been described to be 
trafficked to the lysosomes in an M6PR-independent manner. In 2007 the lysosomal 
membrane protein LIMP-2 was revealed as the specific trafficking receptor of GC (Griffiths 
2007, Reczek, Schwake et al. 2007). LIMP-2 associates with GC in the ER and travels to the 
endosomal/lysosomal compartment by traversing the Golgi apparatus. Finally, GC dissociates 







Figure 1.3: Transport routes to the lysosome: Mannose-6-phosphate dependent and independent. 
On the top panel the mannose-6-phosphate (M6P)-dependent trafficking is shown. In the cis-Golgi the lysosomal 
hydrolase obtains a M6P-tag transferred by a phosphotransferase. In the trans-Golgi the M6P-receptor binds to 
the M6P-tag mediating further transport. The receptor and ligand dissociate in late endosomes due to a low pH.  
In comparison the bottom panel shows the cellular transport of lysosomal hydrolase β-glucocerebrosidase (GC). 
The hydrolase is transported to the lysosomes in a M6P-independent manner by binding to its transport receptor 
LIMP-2 early in the ER. After reaching the lysosome, the hydrolase dissociates from the receptor due to the 
acidic pH. 
 
1.1.3 Lysosomal storage diseases 
Lysosomal enzymes as well as the lysosomal membrane proteins are important for proper 
lysosomal function including degradation of various molecules in the cell. In lysosomal 
storage diseases (LSD) mislocalisation or dysfunction of lysosomal enzymes or other proteins 
involved in lysosomal integrity or biogenesis result in lysosomal accumulation of the 
respective substrates (Platt, Boland et al. 2012). The incidence of LSDs has been estimated to 
1:5,000 live births (Fuller, Meikle et al. 2006). LSDs comprise a group of around 50 genetic 






 Lipid storage disorders: including sphingolipidoses (e.g. Gaucher disease) and 





The symptoms of the LSDs vary depending on the accumulating substrate and other factors 
like age of onset. The clinical presentation of the disease ranges from mild to severe and can 
include movement disorders, bone abnormalities, organomegaly (spleen and liver), seizures, 
dementia and deafness (Gieselmann 1995, Fuller, Meikle et al. 2006). 
1.1.3.1 Lipid storage diseases: Sphingolipidoses and cholesterol transport deficiencies 
1.1.3.1.1 Sphingolipids and sphingolipidoses 
Sphingolipids are essential components of the plasma membrane and play important roles in 
signalling processes (Hla and Dannenberg 2012). They can be distinguished in three main 
groups: ceramides, sphingomyeline and glycosphingolipids. The latter category can be further 
devided in to cerebrosides and gangliosides. Gangliosides differ from cerebrosides in 
containing a sialic acid. Sphingolipis are synthesised in the ER and Golgi apparatus and reach 
the plasma membrane by vesicular transport. For degradation in the lysosome they are 
endocytosed in a calveolin- or clathrin-dependent manner (Sillence and Platt 2004). Thereby, 
any deficiency in the degradation pathway (e.g. in the responsible hydrolase) leads to a 
buildup of the substrate and subsequently to a pathological manifestation referred to as 
glycosphingolipidosis (Figure 1.4). Since glycosphingolipids are found in high concentrations 
in neurons, glycosphingolipidoses often present with neurological symptoms (Yu, Nakatani et 
al. 2009). Moreover a number of auxiliary proteins are important for proper enzyme function. 
For example a dysfunction in any of the described sphingolipid activator proteins (saposin A-
D) leads to impairments in the lysosomal sphingolipid degradation pathway (Vielhaber, 













Figure 1.4: Overview of sphingolipid degradation and sphingolipidoses. 
Single steps of sphingolipid degradation with respective molecular structures (LacCer: lactosylceramide; Cer: 
ceramide; DiGalCer: digalactosylceramide; GalCer: galactosylceramide). Responsible converting lysosomal 
enzymes are indicated in green and activator proteins/cofactors required for degradation are shown in blue 
(GM2-AP: GM2 activator protein; Sap-B/C: saposin B/C). Disease names associated with the accumulation of 
the respective sphingolipid are indicated in red. The graphic was adapted from Schulze and Sandhoff 2014.  
 
1.1.3.1.2 Lysosomal accumulation of cholesterol: Niemann-Pick Type C (NPC-1) 
Cholesterol is an essential component of the plasma membrane. Approximately 95% of the 
total cholesterol is bound to membranes (Spohn and Davison 1972, Chakravarthy, Spence et 
al. 1985). Cholesterol is also an important precursor for steroid hormones, vitamin D and bile 





density or high density lipoproteins (LDL and HDL). In humans most of the existing 
cholesterol is when required synthesised in the body and only small amounts are taken up by 
intestinal absorption (Ikonen 2006). Cholesterol levels in the body are tightly regulated by 
diverse control and negative feedback mechanisms in the cells. Here the endocytotic pathway 
plays a central role: After cellular uptake of the lipoprotein cholesterol via receptor-mediated 
endocytosis (e.g. by LDL-receptors), it reaches the endocytotic circuits where it gets 
processed and redistributed to the plasma membrane, Golgi compartments and ER (Brown 
and Goldstein 1986). Furthermore the recycled cholesterol functions as a regulator for cellular 
cholesterol uptake, cholesterol synthesis and de novo synthesis of the LDL receptor (Ikonen 
2008). In endosomes the esterified cholesterol gets hydrolysed by the acid lipase (cholesterol 
esterase) to fatty acid and free (unesterified) cholesterol (Brown and Goldstein 1986). The 
export of the cholesterol out of the late endosomes/lysosomes has been suggested to be 
mediated by a direct interaction of the endosomal membrane with the membranes of the ER or 
peroxisomes (Chang, Chang et al. 2006, Chu, Liao et al. 2015). However, the molecular 
mechanisms of endosomal cholesterol export are not well understood.  
Lipids reach the endosomal/lysosomal compartments either as part of the limiting membrane 
or incorporated in the intraendosomal membrane. By inward budding of the endosomal 
membrane multivesicular bodies (intraendosomal vesicles) are formed (Figure 1.5). Further 
metabolising of the lysosomal cholesterol is mediated by two indispensable proteins: 
Niemann-Pick C1 and C2 (NPC1 and NPC2). NPC2 is a soluble protein and removes 
cholesterol from the intraendosomal/-lysosomal vesicles and delivers it to the membrane-
resident NPC1 protein. NPC1, which spans the membrane 13 times, is suspected to facilitate 
the transport of free cholesterol across the endosomal membrane (Figure 1.5). Mutations in 
each of the cholesterol-binding proteins causes Niemann-Pick disease type C (NPC), which is 
characterised by an accumulation of unesterified cholesterol in late endosomes (Patterson, 
Vanier et al. 2001). Other lipids like sphingosines (Rodriguez-Lafrasse, Rousson et al. 1994), 
sphingomyeline and gangliosides GM3 and GM2 (Zervas, Dobrenis et al. 2001) accumulate 
secondary to the storage of cholesterol.  
In addition to NPC1 other lysosomal membrane proteins like LAMP-2 have been reported to 
be involved in the endosomal cholesterol export (Eskelinen, Schmidt et al. 2004, Schneede, 









Figure 1.5: Cholesterol transport in late endosomes: the role of NPC1 and 2. 
Cholesterol can reach the endosomal lumen by inward budding of the endosomal membrane forming 
intraendosomal vesicles. Within late endosomes/lysosomes the esterified cholesterol gets hydrolysed by acid 
lipases to free cholesterol. The soluble NPC2 protein transports free cholesterol within the late endosome to the 
transmembrane protein NPC1. NPC1 transports cholesterol across the endosomal membrane. The mechanisms of 
cholesterol export out of late endosomes are still poorly understood. Cholesterol also gets delivered back to the 
plasma membrane most likely by a transport via the ER or peroxisome. The graphic was adapted from Schulze 
und Sandhoff 2011. 
 
1.1.3.1.3 Membrane transport of fatty acids and cholesterol 
In general, lipids can passively diffuse through cell membranes due to their hydrophobic 
nature. However, specific protein-facilitated transport systems of lipids across the membrane 
exist as well. For example for fatty acids a passive diffusion through the membrane as well as 
an active transport by membrane-bound proteins has been described (Abumrad, Harmon et al. 
1998, McArthur, Atshaves et al. 1999). A transporter of fatty acids is CD36. It belongs to the 
class B scavenger receptor family, which also includes the scavenger receptor B1 (SR-B1) 
and lysosomal integral membrane protein type-2 (LIMP-2) (Calvo, Dopazo et al. 1995). CD36 
was first identified on platelets, where it was initially described to function as a collagen and 
thrombospondin receptor (Greenwalt, Lipsky et al. 1992). To date there is strong evidence 
that CD36 additionally supports the uptake of oxidised lipoproteins (oxLDLs) and fatty acid 
(Abumrad, Harmon et al. 1998). Furthermore, patients suffering from deficiency of CD36 are 
associated with an increased risk of suffering from atherosclerotic cardiovascular diseases 
(Yuasa-Kawase, Masuda et al. 2012). Affected individuals reveal a defective uptake of fatty 
acids emphasising the important role of CD36 in fatty acid uptake (Nakata, Nakahara et al. 





Recently, the scavenger receptor class B, type I (SR-BI) was identified as cell-surface high-
density lipoprotein (HDL) receptor. Thereby, SR-BI selectively mediates the uptake of 
cholesteryl esters into the cell (Rigotti, Miettinen et al. 2003). Additionally, SR-BI has been 
shown to facilitate the bidirectional flux of unesterified (free) cholesterol between cells (de la 
Llera-Moya, Rothblat et al. 1999). 
1.2 The lysosomal integral membrane protein Type-2 (LIMP-2) 
The lysosomal integral membrane protein (LIMP-2/SCARB-2/LGP85) is one of the most 
abundant proteins of the lysosomal membrane. It is proposed to be required for lysosomal 
maintenance and biogenesis (Kuronita, Eskelinen et al. 2002, Kuronita, Hatano et al. 2005). 
LIMP-2 is the receptor for the mannose-6-phosphate (M6P) independent transport of 
β-glucocerebrosidase (GC), a lysosomal sphingolipidase, from the ER to the lysosome 
(Reczek, Schwake et al. 2007). LIMP-2 has been described as a receptor for enterovirus 71, 
the causative pathogen of hand, food and mouth disease (Yamayoshi, Yamashita et al. 2009).  
Lysosomal transport of LIMP-2 is facilitated by a c-terminal dileucin motif ([DE]XXXL[LI]). 
It is thought that LIMP-2 is transported by clathrin coated vesicles mediated by an interaction 
with the adaptor protein complexes AP-1 and AP-3 (Janvier, Kato et al. 2003). By binding of 
the dileucin motif to AP-1, clathrin-mediated endosomal transport from the trans-Golgi 
network is associated. By interacting with another adaptor protein complex (AP-3) trafficking 
of proteins from endosomes to lysosomes is initiated (Honing, Sandoval et al. 1998, Braulke 
and Bonifacino 2009). 
Despite the knowledge of the dependence of GC on LIMP-2, only very little is known about 
the molecular details of their interaction. Moreover the precise role of LIMP-2 in disease 
development and additional functions of this abundant lysosomal membrane protein is still 
poorly understood. 
1.2.1 Protein structure of LIMP-2 
LIMP-2 consists of 478 amino acids representing a total protein size of 85 kDa (glycosylated 
form). It spans the membrane twice with the large luminal domain exhibiting eleven potential 
glycosylation sites (Fujita, Ezaki et al. 1991, Neculai, Schwake et al. 2013). Recently, the 
crystal structure of the ectodomain of LIMP-2 was determined (Neculai, Schwake et al. 2013) 
(PDB: 4F7B). A helix (α5), which has been predicted to be involved in interaction with GC 
(Blanz, Groth et al. 2010), could be identified as being exposed at the apical side of the 





Surprisingly, the crystal structure revealed a cavity reaching through the entire luminal 
domain of the LIMP-2 protein (Figure 1.6). The potential function or substrates of this 
putative channel have not been described yet. As described above, two other family members 
of the scavenger receptor family (CD36 and SR-BI) are known for binding and transporting 
lipid proteins, playing an essential role in the lipid metabolism and cholesterol transport (Gu, 
Trigatti et al. 1998, Rodrigueza, Thuahnai et al. 1999, Liu and Krieger 2002, Rigotti, 









Figure 1.6: Protein model of the human LIMP-2 with the protein cavity indicated. 
A) Structural illustration of the luminal domain of LIMP-2 protein solved by x-ray crystallography. The 
transmembrane domains (green) as well as the membrane do not belong to the initial crystal complex and were 
added subsequently to the model. The exposed helix 5 (α 5) has been proposed to be important for ligand 
binding. B) A cross section of LIMP-2 indicates the opening of a cavity, which traverses the whole protein. The 
structural illustration was performed with UCSF Chimera (PDB: 4F7B) (Neculai, Schwake et al. 2013). 
 
The crystal structure of LIMP-2 was also solved in an independent study revealing a 
mannose-6-phosphate residue at the N325 glycosylation site (Zhao, Ren et al. 2014). This led 
the authors to speculate about an M6P-dependent transport of the lysosomal membrane 
protein and thus GC to the lysosome. The similarities and discrepancies between the two 
different solved crystal structures of LIMP-2 (Neculai, Schwake et al. 2013, Zhao, Ren et al. 





functional importance are the differences in the carbohydrate chain at position N325, which 




Figure 1.7: Comparison of two different LIMP-2 crystal structures.  
Blue protein model: Crystal structure of LIMP-2 with a resolution of 3.0 Å in space group P21 (PDB: 4F7B; 
(Neculai, Schwake et al. 2013)). Green model: LIMP-2 crystal structure solved by Zhao, Ren et al. 2014 (PDB: 
4Q4F) shows a slightly better resolution of 2.8 Å. Mannose-6-phosphate (M6P) residue at the end of sugar chain 
emerging from N325 is marked in orange. An overlay of both crystal structures exhibits the similarities of both 
models, but also the differences, which are predominately in the orientation and length of the glycosylation 
chains. The structural illustration was performed with UCSF Chimera. 
 
1.2.2 LIMP-2 associated diseases 
Mutations in the SCARB2 gene encoding for the LIMP-2 protein have been described to cause 
a severe autosomal-recessive disorder known as Action-Myoclonus Renal Failure Syndrome 
(AMRF; OMIM#254900) (Balreira, Gaspar et al. 2008, Berkovic, Dibbens et al. 2008). 
Patients present a rare form of progressive myoclonic epilepsy (PME) associated with storage 
material in the brain, renal failure, deafness, a demyelinating peripheral neuropathy and 
premature death (Berkovic, Dibbens et al. 2008, Hopfner, Schormair et al. 2011). 
To date, ten disease causing LIMP-2 mutations have been described. Nine of the ten SCARB2 
mutations have been shown to lead to a truncation of the protein, potentially resulting in an 
impaired ER-exit and incapability of transporting GC to lysosomes (Blanz, Groth et al. 2010, 





(Berkovic, Dibbens et al. 2008, Dardis, Filocamo et al. 2009, Dibbens, Michelucci et al. 2009, 
Dibbens, Karakis et al. 2011). 
1.2.3 LIMP-2-deficient mice 
The LIMP-2 knockout mouse was first established and described in the year 2003 by Gamp 
and co-workers. The initial phenotypical observations included deafness, peripheral 
demyelination and hydronephrosis caused by pelvic junction obstruction (Gamp, Tanaka et al. 
2003). These mice further revealed ataxia and slight hyperactivity accompanied by an 
unidentified storage material in the brain (Berkovic, Dibbens et al. 2008). A recent study 
focused on the consequences of LIMP-2 deficiency on the central nervous system (CNS) and 
discovered additional neurological deficits accompanied by a premature death in mice lacking 
LIMP-2 (Rothaug, Zunke et al. 2014). The phenotype of the animal included progressive 
hind-limb clasping starting from three to five months, which is a general indicator of a 
dysfunction of the CNS (Rothaug, Zunke et al. 2014). Moreover, LIMP-2 knockout animals 
presented progressive kyphosis and ataxia, which has been previously reported by Gamp et al. 
 
1.3 The lysosomal hydrolase β-Glucocerebrosidase (GC) 
The lysosomal enzyme β-glucocerebrosidase (GC) is the responsible hydrolase for the 
degradation of the sphingolipid glucosylceramide (GluCer) to ceramide and glucose and is 
encoded by the Glucosidase Beta 1 (GBA1) gene.  The GBA2 gene decodes for the non-
lysosomal form of the β-glucocerebrosidase (Matern, Boermans et al. 2001). It has been 
described to be membrane-associated in the ER and Golgi compartment (Korschen, Yildiz et 
al. 2013). 
The mature human GC protein is composed of 497 amino acids, derived from a precursor 
protein of 517-536 amino acids (Erickson, Ginns et al. 1985). For maximal enzyme activity 
the enzyme needs saposin C (SapC) and negatively charged lipids (Grabowski, Gatt et al. 
1990). In particular the prosaposin-derived SapC is believed to assist GC to access the short 
glucosyl-headgroup of its substrate glucosylceramide by remodeling the lipid membrane 







R,R’ = (CH2)13-21CH3 
Figure 1.8: Enzymatic reaction catalysed by β-glucocerebrosidase. 
Glucosylceramide is hydrolysed by the enzymatic activity of the lysosomal β-glucocerebrosidase resulting in  
β-glucose and ceramide. The reverse reaction is mediated by the glucosylceramide synthase located in the cis-
Golgi. A β-glucose is added to a ceramide in a condensation reaction (adapted from Brumshtein et. al, 2006). 
 
1.3.1 Protein structure of GC 
The GC protein is divided into three main domains: domain I (residues 1-27 and 383-414) 
consists mainly of β-sheets and has been suspected to be important for proper protein folding 
(Beutler & Grabowski, 2001). The glycosylation on N19 seems essential for enzyme activity 
in vivo (Berg-Fussman, Grace et al. 1993). Domain II (residues 30-75 and 431-497) resembles 
an immunoglobin fold with –so far unknown function (Orengo, Michie et al. 1997). The third 
domain (residue 76-381 and 416-430) is the largest of all three domains and exhibits a (β/α)8 
TIM barrel structure containing the catalytic site (Dvir, Harel et al. 2003) (Figure 1.9). The 
amino acids Glu 235 and Glu 340 are involved in catalysis. Thereby the Glu 340 functions as 
the nucleophile, whereas Glu 235 acts as the general acid-base residue (Miao, McCarter et al. 
1994, Lieberman 2011). The enzyme shows five potential N-glycosylation sites, of which four 
are believed to be occupied (N19, N59, N146 and N270) (Erickson, Ginns et al. 1985). 
 
 
Figure 1.9: Protein structure of GC subdivided in three domains. 
Structural illustration of glycosylated recombinant GC protein (Cerezyme ®) performed utilising UCSF Chimera 
(PDB: 2J25). The protein can be divided in three domains: domain I (yellow), domain II (orange) and domain III 
(blue), which includes the active site harbouring the important catalytic amino acids E325 and E340 (shown in 





The first crystal structure of unglycosylated recombinant GC (Cerezyme ®) was published in 
2003 (Dvir, Harel et al. 2003). Today 25 different crystal structures of β-glucocerebrosidase 
exist, varying in the way they were crystallised (incubation and crystallisation conditions). In 
general differences in the protein structures are minor. In the year 2006 recombinant GC 
could be crystallised without any deglycosylation treatment (Brumshtein, Wormald et al. 
2006). As shown in figure 1.9, the glycosylated form of Cerezyme ® exhibits sugar residues 
on residue N19, N59 and N146. No sugar residues were found on N270 probably due to tight 
crystal-packing (Brumshtein, Wormald et al. 2006, Lieberman 2011). 
 
1.3.2 GC-associated diseases  
Almost 300 mutations and polymorphisms have been described in the GBA1 gene. These 
mutations are spread over the whole mature GC protein (Dvir, Harel et al. 2003, Hruska, 
LaMarca et al. 2008) (Figure 1.10). The scattered distribution of mutations underlines the 
complexity of the enzyme and emphasises the importance of the integrity of the whole protein 
for proper protein function. A defective function of GC causes the most common lysosomal 
storage disease ‘Gaucher disease’, which belongs to the class of sphingolipidoses (see chapter 
1.1.3.1.1). Gaucher disease is characterized by an accumulation of glucosylceramide (GluCer) 
(Brady, Kanfer et al. 1966). Most affected by this pathogenic storage are macrophages, 
forming the so called ‘Gaucher cells’, implicating clinical presentations like organomegaly 
(e.g. hepato- and splenomegaly) and problems in blood cell as well as bone development. 
Besides glucosylceramide also the concentration of glucosylsphingosine, another substrate of 
GluCer, which is known to be neurotoxic (Schueler, Kolter et al. 2003), has been found to be 
increased in Gaucher patient brain (Nilsson and Svennerholm 1982).  
Gaucher disease occurs in a frequency of 1:40,000 – 60,000 in the general population and in a 
higher frequency in the Ashkenazi Jewish population (1:1000) (Horowitz and Zimran 1994). 
In general there are three major phenotypes of the disease: type I presents a mild, non-
neuronopathic form (OMIM #230800), whereas type II (OMIM #230900) and type III 
(OMIM #231000) show the involvement of the central nervous system (CNS) including the 
development of myoclonic epilepsy, seizures and dementia. The clinical presentation of the 
disease is highly variable between patients –even in twins, sharing the same genotype- 
indicating that other genetic or environmental factors contribute to the course of diesease. 
Mutations in the LIMP-2 protein have been assumed to act as modifiers in Gaucher disease 





Interestingly, mutations in GC represent also the highest genetic risk factor for the 
development of Parkinson disease (PD) caused by accumulation of α-synuclein (Westbroek, 
Gustafson et al. 2011) (see chapter 1.4.3). 
 
 
Figure 1.10: Overview of pathological mutations in the GC protein. 
Protein structure of GC with known missense and nonsense mutations (indicated in red). The disease-causing 
mutations are spread over the whole protein, with the majority found around the catalytic center with the amino 
acids E325 and E340. The structural illustration was performed utilising UCSF Chimera (PDB: 2J25).   
 
1.3.2.1 Treatment of GC-associated diseases 
A number of therapeutic strategies are applied in lysosomal storage diseases -all with the 
same main goal- to reduce the accumulating substrate. This can be reached by either 
increasing the activity of the respective enzyme or by the decreasing the level of the substrate 
of the defective enzyme. The enzyme replacement therapy (ERT) is the first choice for 
treatment in many lysosomal storage diseases –as described for Gaucher disease (Brady 2006, 
Rohrbach and Clarke 2007). In Gaucher disease, purified enzyme (GC; Cerezym ®) is 
administered to the patients by intravenous infusion. Since the exogenous enzyme is not able 
to cross the blood-brain barrier, ERT is able to improve manifestations of type I Gaucher 
patients only (Weinreb, Charrow et al. 2002).  
The substrate reduction therapy (SRT) represents an alternative way of using small molecules 
in treating LSD. For this approach a drug is designed to inhibit the biosynthesis of the initial 
glycosphingolipid (GSL), glucosylceramide. The imino sugar N-butyldeoxynojirimycin (NB-
DNJ, miglustat) binds the glucosylceramide synthase (Platt, Neises et al. 1994). Therefore, 
any residual enzyme activity can better cope with the lower amount of substrate, which needs 





Lachmann et al. 2000, Elstein, Hollak et al. 2004). However SRT is most likely not be the 
best way to target glucosylceramide storage, since the sphingolipid has been shown to be 
involved in a range of biological processes like cell differentiation, apoptosis, cell growth as 
well as neuronal development (Buccoliero, Bodennec et al. 2002).  
Next to the ERT and SRT, stabilisation of the affected enzymes is a promising strategy to 
enhance enzymatic activity either by promoting the protein folding and lysosomal transport or 
by direct stabilisation of the active site. Several small molecules have been identified to serve 
as ‘molecular chaperones’. For example isofagomine and miglustat act as competitive 
inhibitors for the GC protein, augmenting enzyme stability and activity simultaneously 
(Alfonso, Pampin et al. 2005, Kornhaber, Tropak et al. 2008, Shen, Edwards et al. 2008).  
1.4 Lysosomal dysfunction and neurodegenerative diseases 
There is increasing evidence for a role of the lysosome as the main digestive and recycling 
organelle of the cell to contribute to age-related neurodegenerative diseases, such as 
Alzheimer Disease, Huntington Disease and Parkinson disease. 
An efficient degradation of metabolic substrates (e.g. proteins, lipids, carbohydrates, etc.)  is 
essential for neuronal survival, since neurons are particularly sensitive to alterations in the 
lysosomal degradation pathway. It could be shown that abnormal protein accumulation lead to 
intraneuronal inclusions and subsequently to neuronal cell death (Hara, Nakamura et al. 2006, 
Komatsu, Waguri et al. 2006). Also, in postmortem brain from PD patients an impairment of 
lysosomal activity, including a reduced number of intraneuronal lysosomes, decreased levels 
of lysosomal-associated proteins and aggregations of autophagosomes have been observed 
(Chu, Dodiya et al. 2009, Dehay, Bove et al. 2010).  
1.4.1 Parkinson Disease 
Parkinson disease is a slowly progressive neurodegenerative disorder, that is most common in 
the elderly population  affecting about two percent of adults above the age of 65 and with a 
prevalence of one in 300 in the general population (Schapira, Bezard et al. 2006). The early 
causes of PD are characterized by movement abnormalities including tremor, bradykinesia 
and rigidity. In later stages also non-motor symptoms may arise including dementia, 
behavioral problems and depression (Chaudhuri, Healy et al. 2006). Clinical manifestations 
result from the loss of dopaminergic neurons in the substantia nigra, which is a part of the 
midbrain (Davie 2008). This loss of neurons observed in PD patient brains may be due to an 
accumulation of Lewy bodies, which are intraneuronal aggregates of proteins mainly 





intraneuronal Lewy bodies, its aggregation is considered as a hallmark of PD and other 
synucleinopathies, like demetia with Lewy body and multiple system atrophy (Baba, Nakajo 
et al. 1998, Xia, Liao et al. 2008).    
1.4.2 α-Synuclein: structure and metabolism within the cell  
α-Synuclein is a small soluble neuronal protein consisting of 140 amino acids (Figure 1.11) 
encoded by the SNCA gene. The synuclein protein family further consist of β- and γ-synuclein 
with all three forms being present in the cytosol and predominantly found in the pre-synaptic 
terminals of neurons (George 2002). It seems that α- and β-synuclein play an important role in 
synaptic transmission and stability with their exact function remaining elusive (Chandra, 
Fornai et al. 2004). α- and β-synucleins seem to be able to compensate each other’s function 
(Chandra, Gallardo et al. 2005). However to date, only the accumulation of α-synuclein is 
associated with PD disease progression (Han, Weinreb et al. 1995, Polymeropoulos, Lavedan 
et al. 1997). 
 
 
Figure 1.11: Structure of the α-synuclein protein. 
Protein model of α-synuclein crystal structure subdivided in different regions. Met1-Lys60: Amphipathic 
structure including disease-related mutants (Ala30P, Glu46K and Ala53T). Lys60-Val95: Hydrophobic region 
with aggregation prone area. Val95-Ala140: proline rich C-terminus. The structural illustration was performed 
using UCSF Chimera (PDB: 1XQ8). 
 
In aqueous solution α-synuclein exists as an unfolded protein. It forms α-helical structures 
when α-synuclein binds to negatively charged lipids and β-sheet rich structures indicating its 
affinity to form aggregates (Davidson, Jonas et al. 1998). Disease-related mutants (A30P, 
E46K and A53T (Figure 1.11)) but also wild-type α-synuclein are able to lead to formation of 
amyloid-like fibrils (Conway, Lee et al. 2000). During the formation of the fibrils various 
intermediate forms of α-synuclein appear including soluble as well as insoluble oligomers. 
The soluble oligomeric form is likely more neurotoxic than the insoluble fibrillary forms 





possible explanation is the ability of soluble oligomeric α-synuclein to block the release of 
proteins from the endoplasmic reticulum (ER) by interaction with respective SNARE protein 
complexes, important for vesicular fusion (Mazzulli, Xu et al. 2011). Specifically, α-synuclein 
was found to interact with the SNARE-protein synaptobrevin-2/VAMP2 (Burre, Sharma et al. 
2010, DeWitt and Rhoades 2013). Furthermore, the smaller oligomeric forms of α-synuclein 
have been shown to induce mitochondrial fragmentation inducing mitochondrial dysfunction 
and cell death (Kamp, Exner et al. 2010, Nakamura, Nemani et al. 2011). 
In general it is assumed that α-synuclein leads to pathological manifestations through a toxic 
gain-of-function mechanism when critical levels of the aggregation-prone protein are reached 
(Lashuel, Petre et al. 2002, Lashuel and Lansbury 2006). 
Additionally it has been revealed that aberrant α-synuclein exerts a negative effect on the 
protein degradation systems. α-Synuclein itself is degraded after import in the lysosome by 
chaperone-mediated autophagy (CMA) and by macroautophagy (Webb, Ravikumar et al. 
2003, Cuervo, Stefanis et al. 2004, Vogiatzi, Xilouri et al. 2008, Mak, McCormack et al. 
2010, Ebrahimi-Fakhari, Cantuti-Castelvetri et al. 2011) as well as by the proteasome 
(Tofaris, Layfield et al. 2001, Webb, Ravikumar et al. 2003). Thus, dysfunction in either 
degradation pathway contributes to α-synuclein accumulation creating a vicious loop resulting 
in the different types of synucleinopathies (Xilouri, Vogiatzi et al. 2008).  
1.4.2.1 Lysosomal degradation of α-synuclein 
Monomeric α-synuclein is thought to be degraded mostly through chaperone-mediated 
autophagy (CMA), oligomeric and aggregated forms of the protein are degraded via 
macroautophagy (Verhoef, Lindsten et al. 2002, Webb, Ravikumar et al. 2003, Cuervo, 
Stefanis et al. 2004). Degradation of the monomeric α-synuclein, involves binding to the 
CMA transporter LAMP-2 after being recognised by the cytosolic chaperone HSc70 (Cuervo, 
Stefanis et al. 2004). In contrast, the aggregated and in most cases mutant α-synuclein is 
polyubiqutinated by PARKIN and sequestered into autophagic vacuoles to be directed to 
lysosomes. For degradation these vesicles fuse with lysosomes (Komatsu, Waguri et al. 
2006). This process is called macroautophagy. Inside the lysosome cathepsin D is discussed 
as an important protease for α-synuclein degradation (Qiao, Hamamichi et al. 2008, Cullen, 
Lindfors et al. 2009, Cullen, Sardi et al. 2011). 
1.4.2.2 Proteasomal degradation of α-synuclein 
Monomeric wild-type α-synuclein can also be degraded by the proteasomal system (Tofaris, 





(Kitada, Asakawa et al. 1998) and Ubiquitin Carboxy-terminal Hydrolase Like-1 (UCHL-1) 
(Leroy, Boyer et al. 1998) have been identified to be responsible for tagging α-synuclein for 
degradation. Once the protein is aggregated it cannot be degraded by the proteasomal system 
but can be a substrate for removal by macroautophagy (Verhoef, Lindsten et al. 2002).  
1.4.3 Relationship between GC and α-synuclein accumulation  
Recently it could be shown by genetic and clinical studies that mutations in GBA1 are linked 
to aberrant α-synuclein degradation. The precise role of GC in the pathogenesis of the 
accumulation of α-synuclein and the development of synucleinopathies is still a mystery. It 
was shown that mutations in the GBA1 either in homo- or heterozygous form are linked to a 
about 20-fold increase in the risk to develop PD (Beavan and Schapira 2013). Genetic studies 
suggest that 5-10 % of PD patients carry mutations in GBA1 (Sidransky, Nalls et al. 2009, 
Lesage, Anheim et al. 2011, McNeill, Duran et al. 2012). In these patients neuropathological 
findings including α-synuclein positive Lewy bodies were described similar to those found in 
brains of PD patients without GBA1 mutations (Goker-Alpan, Lopez et al. 2008). However, 
increased α-synuclein levels have been described in brains of sporadic PD cases, exhibiting 
also reduced GC activity (Murphy, Gysbers et al. 2014). 
Gaucher disease patients also show a higher risk to develop PD. In genetic screens it was 
revealed that especially first-degree relatives of Gaucher disease patients are prone to develop 
PD (Goker-Alpan, Schiffmann et al. 2004, Lwin, Orvisky et al. 2004). Patients with mutations 
in GBA1 seem to develop earlier symptoms of PD with a higher frequency of cognitive 
changes (Sidransky, Nalls et al. 2009).  
 
There are two major ideas describing how GC impacts α-synuclein homeostasis. The ‘gain-of-
function’ theory implies that the mutant enzyme has a direct effect on α-synuclein aggregation 
through a biochemical interaction of both proteins. Cullen et al. supported this view showing 
overexpression of different GC mutants triggering the accumulation of α-synuclein in cell 
culture (Cullen, Sardi et al. 2011) and in a transgenic mouse model (Sardi, Clarke et al. 2011).  
However, there are more data in support of the ‘loss-of-function’ theory. It is thought that the 
consequences of the GC dysfunction of the enzyme cause an imbalance in the metabolism of 
α-synuclein. GC mutations lead to a progressive build-up of its substrate glucosylceramide, 
which possibly stabilises oligomeric α-synuclein thus promoting α-synuclein aggregation 
(Mazzulli, Xu et al. 2011) (Figure 1.12). Furthermore a negative pathogenic loop has been 
suggested, where soluble oligomers of α-synuclein may block ER-Golgi trafficking (Cooper, 





intracellular trafficking also leads to an impairment of the transport, maturation and function 
of lysosomal enzymes including GC creating a negative feedback loop (Figure 1.12).  
Another model is linked to the increased cell stress caused by the accumulation of mutant GC 
in the ER leading to unfolded protein response (UPR) and ER-associated degradation (ERAD) 
(Ron and Horowitz 2005, Mu, Ong et al. 2008). Increased levels of UPR markers were found 
in brain of PD patients independently of the presence of GBA1 mutations, indicating a general 
role for the ERAD-pathway in the clinical course of PD (Bendikov-Bar and Horowitz 2012, 
Gegg, Burke et al. 2012).  
 
 
Figure 1.12: The role of LIMP-2 and GC in lysosomal degradation and aggregation of α-synuclein. 
(1) GC gets transported to the lysosome by interaction with LIMP-2. Both proteins associate in the ER and 
dissociate in the lysosome. (2) In the lysosome GC fulfils its enzymatic function by hydrolysing 
glucosylceramide to ceramide and glucose. (3) Glucosylceramide itself is able to interact and stabilise 
α-synuclein oligomers. Initially it has been proposed that α-synuclein gets transported into the lysosome for 
degradation by CMA via LAMP-2A. (4) The soluble oligomers of α-synuclein possibly exhibit a negative effect 
on ER-Golgi transport. To date it is not known how the α-synuclein oligomers manage to leave the lysosome. A 
possible way of lysosomal exit may be the rupture of the lysosomal membrane. Since α-synuclein is an 
accumulation-prone protein the soluble oligomers are highly susceptible to form insoluble fibrils. The 
interference of the intracellular trafficking by α-synuclein further leads to decreased levels and activity of 
lysosomal GC accompanied by an increase in glucosylceramide, which is able to further stabilise α-synuclein 






2 Objectives  
 
The central aim of this study is to characterise structural and functional properties of the 
Lysosomal Integral Membrane Protein Type 2 (LIMP-2) and its ligand the lysosomal 
hydrolase β-glucocerebrosidase (GC). Biochemical analyses including site-directed 
mutagenesis of the LIMP-2 and GC proteins followed by molecular interaction studies as well 
as subcellular localisation should be applied to identify the interaction sites of both proteins. 
 
Additionally, a small peptide comprising the GC-binding region of LIMP-2 and its ability to 
mediate a specific interaction with GC was analysed. A putative chaperone-like effect of the 
LIMP-2 protein as well as the LIMP-2-derived peptide on GC should be assessed. To verify 
the potential positive effect of LIMP-2 on GC function, stabilisation and GC activity assays 
are performed in vitro and in cell-based studies. Further studies to validate a specific 
interaction of the LIMP-2-derived peptide and GC were designed to support a potential 
application of the peptide in a therapeutic context. 
 
The identification of a close relationship between GC activity and lysosomal degradation of 
α-synuclein, the accumulating protein in Parkinson disease, was a further aim of this project 
to clarify the role of LIMP-2 -the transport receptor of GC- in α-synuclein metabolism. In this 
respect, the consequences of LIMP-2 deficiency in the central nervous system of mice will be 
analysed in detail. 
 
In addition therapeutic approaches to enhance GC activity in order to decrease neuronal 
α-synuclein protein levels should be studied. Under the assumption that an increase in the 
expression of LIMP-2 is followed by enhanced lysosomal trafficking and activity of GC 
leading to increased turnover of a-synuclein, the therapeutic potential of LIMP-2 –as well as 
the LIMP-2-derived peptide- will be evaluated.  
  




3 Material and methods 
3.1 Materials 
3.1.1 Cell lines 
The cells were kept in a sterile incubator at 37°C and 5 % CO2. Human fibroblasts (AMRF, 
patient cells and NPC patient cells) were cultivated in RPMI® media (GE Healthcare) 
including 10 % FCS and 1 % Penicillin/Streptomycin. Human H4 neuroglioma cells were 
grown in Opti-MEM® (Thermo Fisher Scientific) with 5 % FCS, 1 % Penicillin/ 
Streptomycin, 200 μg/ml G418 and 200 μg/ml Hygromycin. All other murine embryonic 
fibroblasts and standard cell lines were cultivated in DMEM® High Glucose media (GE 
Healthcare) and 10 % FCS and 1 % Penicillin/Streptomycin. Human midbrain dopaminergic 
neurons were cultivated in SM1-NB media (additive: 10% FCS) without phenol red (Thermo 
Fisher Scientific). Cultivation of these cells was performed in the laboratory of Dr. Dimitri 
Krainc (Harvard Medical School/MGH, Boston, USA).  
A table of utilised cell culture media can be found in the appendix (Table 7.7). 
 
Table 3.1: Cell lines utilised in this study. 
Name Description  Reference 
LIMP‐2 KO MEFs (E5) Primary murine embryonic 
fibroblasts; LIMP-2 deficient 
(Reczek, Schwake et al. 2007) 
LIMP‐2 KO MEFs (583-2) Primary murine embryonic 
fibroblasts; LIMP-2 deficient  
Dr. J. Schröder, laboratory of 
Prof. Saftig,University of Kiel; 
(Blanz, Groth et al. 2010) 
WT MEFs (583-3) Wild‐type murine embryonic 
fibroblasts 
Dr. J. Schröder, laboratory of 
Prof. Saftig CAU Kiel; (Blanz, 
Groth et al. 2010) 
AMRF patient cells (EH, OR) Human fibroblasts from skin 
biopsy of two AMRF patients 
(EH, OR) 
(Berkovic, Dibbens et al. 2008) 
CD/CI MPR deficient MEFs Primary murine embryonic 
fibroblasts; deficient for CD- 
and CI-MPR 
Laboratory of Prof. Thomas 
Braulke, UKE Hamburg; 
(Kollmann, Damme et al. 2012) 
Cos7 Kidney cell line from African 
green monkey; SV40 
immortalised 
ATCC / DSMZ, 
established cell line 
Gnptab
c.3082insC
 MEFs Primary murine embryonic 
fibroblasts; GlcNAc-1-
Phosphotransferase defective  
Laboratory of Prof. Thomas 
Braulke, UKE Hamburg; 
(Kollmann, Damme et al. 2012) 
H4  Human neuroglioma cells stably 
overexpressing wild-type α-
synuclein under the control of a 
tetracycline-inducible promoter 
(‘tet-off’) 
Provided by Pamela J. McLean, 
Mayo Clinic, Jacksonville, USA 
and Dr. Joseph R. Mazzulli, 
University of Chicago; 
(Mazzulli, Xu et al. 2011) 
HeLa Cervical carcinoma cells 
(Henrietta Lacks)  
DSMZ, 
established cell line 







iPSC: cultured and maintained 
(over 90 days) as described in 
(Mazzulli, Xu et al. 2011). 
Differentiation into midbrain 
dopamine neurons according to 
(Kriks, Shim et al. 2011)  
Cultured, maintained and kindly 
provided by Dr. Joseph R. 




J774E Murine macrophages, optimised 
for endocytosis 
Originally from Dr. Philip Stahl, 
Washington University School of 
Medicine, St Louis, USA; 
(Fiani, Beitz et al. 1998) 
LAMP 1/2 dKO MEFs Primary murine embryonic 
fibroblasts; LAMP-1 and 
LAMP-2 double deficient 
Laboratory of Prof. 
Saftig,University of Kiel 
mGBA KO MEFs Primary murine embryonic 
fibroblasts, GC-deficient 
Dr. E. Sidransky, NIH  
Bethesda, MD USA 
N2a Murine neuroblastoma cell line ATCC / DSMZ, 
established cell line 
Nieman-Pick Type C (NPC) 
fibroblasts 
Human fibroblasts from biopsy 
of two NPC-1 patients 
Laboratory of Prof. 
Kohlschüttler, UKE Hamburg 
 
3.1.2 Mouse strains 
LIMP-2 knockout mice were first established and described in the year 2003 by Gamp et al.. 
The LIMP-2-deficient mice contain a neomycin cassette, which disrupts the transcription of 
LIMP-2 within exon 8. The animals were maintained in a mixed genetic background 
(SVJ129_C57BL/6J Harlan) (Gamp, Tanaka et al. 2003, Berkovic, Dibbens et al. 2008). In 
this mouse model no cognitive decline –like seen in AMRF-patients, lacking functional 
LIMP-2 protein- was observed. An explanation might be the chromosomal deletion of the α-
synuclein locus in the C57BL/6J strain from Harlan (Specht and Schoepfer 2001). For the 
studies shown in this work, LIMP-2 knockout mice were backcrossed into C57BL/6N from 
Charles River exhibiting normal α-synuclein level (Rothaug, Zunke et al. 2014). An 
immunoblot of brain lysates of the two different mouse strains indicates a drastic drop of α-
synuclein protein in C57BL/6J compared to C57BL/6N strain (Figure 3.1A). Quantitative 
real-time PCR shows the decrease of α-synuclein transcript level. For the LIMP-2 mRNA a 
constant expression could be identified in all different mouse strains (Figure 3.1 B).   
Before mice in the age of 2-10 months were sacrificed for biochemical and histological 
analyses, they were monitored for behavioural and movement abnormalities including ataxia 
and hind-limb clasping.  
The animals were maintained in a conventional animal facility (University of Kiel) and all 
experiments were carried out under guidelines of the National Animal Care Committee of 
Germany. 
 









Figure 3.1: Analysis of α-synuclein levels in mice of two different genetic backgrounds. 
A) Comparison of α-synuclein protein levels in brain lysates from C57BL/6J and C57BL/6N mouse strain 
utilising the Syn-1 antibody, showing a drop in the absence  in α-synuclein protein expression in the C57BL/6J 
background. B) Quantitative real-time PCR reveals mRNA levels of α-synuclein being decreased in C57BL/6J 




3.1.3.1 Primary antibodies 
Table 3.2: Overview of primary antibodies. 
Immunofluorescence (IF), Western-Blot (WB), immunohistochemistry (IHC),  
immunohistology-fluorescence (IH-IF). 
Name Source Host 
Dilutions 
IF WB IHC IH -IF 
α-Actin Sigma Aldrich, 
Steinheim, DE 






Lakes, NJ, US 




Scientific, Rockford, US 






rabbit - 1:500 1:1000 1:200 
α-Alpha-synuclein 
(4D6) 
Abcam mouse - 1:500 1:1000 1:200 
α-Biotin (labelled 




mouse 1:200 - - - 
α-CD68 
 
Serotec, Oxford, UK rat - - 1:3000 - 
α-mGC (4171) Sigma Aldrich, 
Steinheim,DE 
rabbit 1:100 1:1000 - - 
α-hGC (4171) Prof. Johannes Aerts, 
NL 
mouse 1:250 1:500 - - 




- - 1:3000 - 
α-HA (3F10) 
 
Roche, Penzberg, DE rat - 1:500 - - 
α-LAMP-1 (1D4B)  DSHB, Iowa City, US  rat 1:50 1:500 - - 






DSHB, Iowa City, US  rat 1:100 1:500 - - 
α-LIMP-2 (Tier 2; 
L2T2) 
Pineda, Berlin, DE rabbit 1:500 1:2000 1:3000 1:200 
α-myc (9B11) Cell Signalling, Boston, 
US 
mouse 1:250 1:1000 - - 
α-myc (GTX) Santa Cruz, 
Biotechnology, Santa 
Cruz, US 
goat 1:250 1:1000 - - 
α-NeuN (MAB 
377) 










Abcam, Cambridge, UK rabbit 1:750 - - - 
α-Tubulin Sigma Aldrich, 
Steinheim, DE 




Abcam, Cambridge, UK rabbit - - 1:3000 - 
 
3.1.3.2 Secondary antibodies 
Table 3.3: Overview of secondary antibodies. 
Immunofluorescence (IF), Western-Blot (WB), immunohistochemistry (IHC),  
immunohistology-fluorescence (IH-IF). 
Name Source Host 
Dilutions 



















































1:500 - - 1:2000 
 





All primers used for site-directed mutagenesis, cloning and sequencing were obtained from 
Sigma Aldrich (Steinheim, DE) in a concentration of 100 μM, diluted in ddH2O and stored at 
4°C or -20°C. 
 
Table 3.4: Overview of primer for cloning and site-directed mutagenesis. 
Name Sequence (5‘-3‘) 
pfrog forward gagaacccactgcttactgg 
pfrog reverse gagactccattcgggtgttct 
hGC_L91E forward gacagatgctgctgctGAGaacatccttgccctg 
hGC_L91E reverse cagggcaaggatgttCTCagcagcagcatctgtc 
hGC_L94E forward gctgctctcaacatcGAGgccctgtcaccccct 
hGC_L94E reverse agggggtgacagggcCTCgatgttgagagcagc 
hGC_L156E forward gaggaagataccaagGAGaagatacccctgattc 
hGC_L156E reverse gaatcaggggtatcttCTCcttggtatcttcctc 
hGC_R211E forward accagacctgggccGAAtactttgtgaagttcctg 
hGC_R211E reverse caggaacttcacaaagtaTTCggcccaggtctggt 
hGC_P159L forward ataccaagctcaagataCTTctgattcaccgagc 
hGC_P159L reverse gctcggtgaatcagAAGtatcttgagcttggtat 
hGC_I161S forward agctcaagatacccctgTCGcaccgagccctgcag 
hGC_I161S reverse ctgcagggctcggtgCGAcaggggtatcttgagct 
hGC_R213E forward gacctgggccagatacGAAgtgaagttcctgga 
hGC_R213E reverse tccaggaacttcacTTCgtatctggcccaggtc 
 
3.1.5 Expression vectors and constructs 
3.1.5.1 pcDNA3.1 and pfrog vector 
Two expression vectors were utilized in this study: pFrog3 (Gunther et al., 1998) and 
pcDNA3.1 Hygro
+
 (Invitrogen, Darmstadt, DE) (Table 3.5). The pFrog vector (Figure 3.2) 
was derived from the pcDNA3 vector (Invitrogen, Darmstadt, DE) and was cloned by Dr. 
Michael Schwake (Faculty for Chemistry/Biochemistry III, University of Bielefeld, DE). A 
T7-promoter and cytomegalovirus (CMV) promoter control transcription and a poly-
adenylation signal from bovine growth hormone (BGH) stabilising the RNA after 
transcription. The Simian Virus 40 (SV40) promoter controls transcription of a neomycin 
resistance gene for selection in eukaryotic cells. A CoIEI gene allows replication in bacteria 
and an ampicillin resistance gene growth and selection of the vector in E.coli. All LIMP-2 and 
human GC mutants were expressed in the pFrog-vector and tagged on the N-terminus with a 
myc-sequence (EQKLISEEDL). The LIMP-2 constructs as well as the human GC-wild-type-
construct were previously generated by Dr. Michael Schwake (Faculty for 
Chemistry/Biochemistry III, University of Bielefeld).  




The vector pcDNA3.1 Hygro
+
 has 3 promoters that allow a high expression of the transcript 
including the CMV-promoter a T7-promoter and an SV40 promoter, which allows 
transcription of hygromycin and thus selection of transfected cells. It also exhibits an 
ampicillin resistance gene and pUC origin for growth and selection in E. coli. 
The human α-synuclein (SNCA) construct was cloned in the pcDNA3.1 Hygro
+
 vector by Dr. 
Michelle Rothaug (Institute of Biochemistry, University of Kiel, DE) containing an HA-tag 
(YPYDVPDYA) at the C-terminus. 
Additionally, an α-synuclein construct was used for lentiviral transduction and generated by 
Dr. Joseph Mazzulli (Northwestern University of Chicago, US) using a gateway cloning 
system (Invitrogen, LR recombination reaction). The α-synuclein cloning sequence was 
transferred from the pENTRA1A-vector (Invitrogen) to the SIN-W-PGK lentiviral vector 









Figure 3.2: Map of pfrog3 vector. 
Vectormap indicating genes for resistance, 





Table 3.5: Overview of utilised expression constructs. 
α-Synuclein (SNCA), wild-type (WT), ER-retention mutant (ERret), murine LIMP-2 (mLIMP-2), human GC 
(hGC). 
 
Name and description: 
Vector name—construct- tag 
 
Resistance in e.coli Source 
 
SIN-W-PGK- SNCA  Kanamycin generated by Dr. Joseph R. Mazzulli 
pcDNA3.1-Hygro
+
 - SNCA- HA 
 
Ampicillin generated by Dr. Michelle Rothaug 
pFrog-mLIMP2-WT- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-ERret- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-L155D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-I156D- myc 
 
Ampicillin generated by Dr. Michael Schwake 






Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-L160D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-A162D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-Y163D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-K166D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-I184D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-L187D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-F191D- myc 
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-mLIMP2-D400K- myc  
 
Ampicillin generated by Dr. Michael Schwake 
pFrog-hGC-WT- myc 
 




pFrog- hGC-L94E- myc 
 
Ampicillin self-produced 
pFrog- hGC-L156E- myc 
 
Ampicillin self-produced 
pFrog- hGC-L211E- myc 
 
Ampicillin self-produced 
pFrog- hGC-P159L- myc 
 
Ampicillin self-produced 
pFrog- hGC-I161S- myc  
 
Ampicillin self-produced 
pFrog- hGC-N188S- myc  
 
Ampicillin generated by Dr. Christina Zachos 














3.2.1 Molecular biology 
3.2.1.1 Polymerase-Chain-Reaction (PCR) 
In general, the polymerase-chain-reaction (PCR) is utilized to amplify specific DNA regions. 
Specific oligonucleotides (primers) bind to single-stranded template DNA and determine the 
starting point for the DNA-polymerases (see Table 3.6: Annealing temperature usually 3-5°C 
below melting point of primers). These enzymes synthesise the complementary DNA strand 
in 5’ → 3’ direction and work most efficiently at a temperature optimum at 72°C (see Table 
3.6: Elongation step). The forward and reverse primers span the sequence to be amplified. 
PCRs consist of three cyclically repeating annealing steps (usually 30-45 times).  
 










total 50 μl 
 
10x PCR-buffer 
dNTPs (2 μM) 
DMSO 
forward-Primer (20 μM) 
reverse-Primer (20 μM) 
Template (20 ng - 1 μg) 






































The fusion-PCR is a special method used to insert a point mutation within a DNA sequence. 
The PCR was performed following the above described PCR-protocol. Primers with the 
desired point mutation were designed (see Table 3.4). The primers are usually around 30 
base-pairs long and exhibit the mutation (three base-pairs encoding for one amino acid) in the 
middle of the oligonucleotide sequence. In two single PCR reactions the forward primer 
including the mutation (FM) is incubated with the external reverse primer (R) and vice versa 
the mutated rewards primer (RM) is incubated with the external forward (F) primer. As 
annealing temperature a standard temperature of 62°C was applied. In the end of the first two 
reactions there are two overlapping PCR-reaction products, which are incubated in the same 
PCR-reaction together with the external forward and reverse primers (fusion-PCR). The PCR-




result is a DNA-fragment including the desired point-mutation (Figure 3.3). Subsequently this 
fragment was cloned into the respective vector in the presence or absence of a myc- or HA-
tag by digestion with restriction enzymes (for more details see 3.2.1.3). All here described 
point-mutants (LIMP-2 and GC) were designed following this protocol. 
 
 
Figure 3.3: Principle of fusion-PCR. 
The red bar indicates the desired point mutation. Primers including the mutated sequence (red triangle; FM and 
RM) are utilised in two separate PCR-reaction steps. The two single PCR-products exhibiting the desired 
mutation (red triangle) and are mixed in the subsequent fusion-PCR. Together with the framing forward (F) and 
reverse (R) primer this PCR-approach results in a DNA-fragment with desired point-mutation (red triangle). 
 
3.2.1.2 Agarose electrophoresis 
Agarose-gel electrophoresis is used for separation of DNA molecules according to their 
molecular weight. DNA/PCR products were detected and analysed using 1-2% agarose gels in 
1x TAE buffer (see Table 7.6) and including ethidium bromide (endconcentration of 1%), 
which visualises DNA by its intercalation with the oligonucleotide strengths. The DNA/PCR 
products were mixed with loading buffer (Thermo Fisher Scientific, Waltham, US) in a ratio 
of 6:1 and loaded onto the gel. A size-reference of 100 bp or 1 kb ladders (Thermo Fisher 
Scientific, Life Technologies) was additionally applied on the agarose-gel. DNA fragments 
were separated at 90-120 mV for 30-45 minutes and visualised under UV light (Gel Jet 
Imager; λ=312 nm). For cloning DNA-fragments were cut out of the gel and purified 
according to instructions of the kit manual (High Pure PCR-Purification Kit, Roche).  




3.2.1.3 Cloning experiments: Restriction enzyme digestion and DNA ligation 
In this work several cDNA constructs were utilised for overexpression studies. Changes on 
the cDNA level were made by PCR and point-mutations were introduced by fusion-PCR (see 
3.2.1.1.1). For cloning of a specific PCR-fragment/cDNA sequence (insert) into an expression 
vector, the insert (50 μl PCR-product) as well as the vector (~2 μg) were digested with the 
respective restriction enzymes (Thermo Fisher Scientific). Restrictions enzymes are able to 
cut specific palindromic DNA-sequences resulting in so called ‘sticky ends’. The amount and 
relation of enzymes and buffer were applied as recommended in the manufacturer’s manual 
(Thermo Scientific) or suggested by the ‘DoubleDigest Calculator’ on the Thermos Fisher 
Scientific webpage (www.lifetechnologies.com). To prevent re-ligation, the vector was 
dephosphorylated by adding 1 μl FastAP (Thermo Fisher Scientific) to approximately 20 ng 
of a cDNA plasmid. For ligation of the insert and the cDNA vector, 1 μl plasmid-DNA and 7 
μl of the insert were mixed with 1 μl T4-ligase and 1 μl 10x ligation buffer and incubated at 
37°C overnight. As a negative control ddH2O was added instead of the insert. The ligase has 
to be deactivated by incubating the sample at 62°C for 15 minutes according to the 
manufacturer’s manual (Thermos Scientific). 
3.2.1.4 Amplification and purification of expression vectors in Escherichia Coli  
For amplification of ligated expression plasmids (see above) or for retransformation of 
established expression vectors, electro competent XL1-Blue Escherichia Coli (E. coli) were 
transformed with the DNA plasmids by electroporation (2.5 kV, 400 Ω and 25 μF; Biorad, 
Hercules, US). After thawing the cells on ice, 1 µl of plasmid cDNA were added to 50 µl 
cells, no cDNA was added to negative controls. The cells were then resuspended in 1 ml LB 
media and incubated at 37°C for 30 mins. Following, electroporated cells were squirted onto 
the centre of a LB agar plate with antibiotics (100 µg/ml ampicillin). Plates were inverted and 
incubated at 37°C overnight. The following day single colonies were picked and grown over 
night either in 3 ml or in 100 ml LB-medium (see appendix Table 7.6) in a 37°C shaking 
incubator. 
After growing single colonies overnight in 3 ml or 100 ml LB medium, the DNA was isolated 
and purified using the ‘plasmid miniprep kit’ (Thermos Fisher Scientific) for small volumes 
and the ‘plasmid midiprep kit’ (Promega) for larger volumes. The plasmid isolation was 
performed as suggested in the manufacturers’ protocols.  




3.2.1.5 Measurement of DNA-concentration 
The DNA concentration was measured with the help of a Synergy HT microplate reader 
(BioTec). Nucleic acids exhibit a specific absorption spectrum between 250 and 280 nm 
(maximum at 260 nm). An optical density (OD) of 1 at 260 nm reveals a concentration of 50 
μg/ml. Furthermore a quotient of the absorption at 260 nm and 280 nm (A260/A280) was 
determined to control for contaminations with proteins or solvents. A value between 1.8 and 
2.0 is a generally excepted value for pure DNA. 
3.2.1.6 Mouse perfusion 
For histochemical analyses of brain samples, LIMP-2-deficient as well as wild-type animals 
were perfused before harvesting of the tissue. Animals were anaesthetised with 10 μg/mg 
weight of a mixture of 1.2 % xylazin/0.16 % ketamine in phosphate buffered saline (PBS). By 
checking for the pinch-withdrawal reflexes of the animals, the depth of the narcosis was 
monitored. The mouse was fixed on a clean platform and opened by a lateral incision from the 
neck to the torso. To get access to the heart the diaphragm and the rib-cage were cut. Next a 
butterfly needle was inserted to the left ventricle and the right atrium was cut. The animal was 
perfused with 0.1 M PBS until the inner organs turned pale. Subsequently mice were perfused 
with 4 % paraformaldehyde (PFA) in PBS. 
3.2.1.7 Isolation and dissection of murine brain 
Mice were perfused or subjected to CO2 and sacrificed by cervical dislocation. The head was 
detached and the brain was isolated by removing skin and scull caudal to rostral utilising a 
bone-scissor and forceps. If brains were used for histological analysis, they were post-fixed at 
room temperature for 4 hours in 4 % PFA in PBS. For separation of specific brain areas the 
whole brain was cut sagittally. Under the microscope the different regions (Figure 3.4) were 
separated, frozen in liquid nitrogen and stored at -80°C. This study mainly focuses on the 
pons and the midbrain including the substantia nigra (Figure 3.4). 
 





Figure 3.4: Different brain regions in a sagittal murine brain section. 
A mouse brain roughly subdivided in the different main brain regions indicated in a brain section in brightfield 
modus. The brain sections focused on in this work (pons and midbrain including the substantia nigra) are 
highlighted in red. The illustration was modified from the ‘gensat brain atlas’ (www.gensat.org). 
 
3.2.1.8 Tissue and section preparation 
For further histological analysis the brain sections were either embedded in paraffin or 
sucrose. 
3.2.1.8.1 Paraffin embedding, sectioning and removal of paraffin 
The fixed brains were dehydrated in an ascending alcohol series (30 min. in 50 %, 60 %, 70 % 
ethanol, 15-30 mins in 96 % and finally 45-60 mins in 100 % ethanol). Subsequently they 
were cleared with xylol (2 x 1 hour), incubated with RotiPlast® paraffin (Roth) and heated to 
~60°C. The sections were cut sagittally in 5 μm thick slices using a Leica SM 2000R 
microtome (Leica). 
For all performed histological stainings the paraffin embedded sections were deparaffinised in 
Rotihistol® (Roth) two times for 10 minutes. Subsequently the sections were rehydrated in a 
descending alcohol series (5 minutes each in 100 %, 96 %, 70 % and 50 % ethanol) and rinsed 
in ddH2O.   
3.2.1.8.2 Succrose embedding 
For immunohistology stainings (see section 3.2.1.9.1) the tissue was incubated in 30 % 
sucrose in 0.1M PB for at least 24 hours at 4°C. To generate free-floating sections, the brain 
samples were cut sagittally utilising the Leica SM 2000R microtome (Leica).  





To visualise morphological changes in the brains of LIMP-2-deficient and wild-type animals, 
histochemical stainings were performed.  
3.2.1.9.1 Immunohistology 
For immunohistological analysis antibodies are applied for visualisation. It can be 
distinguished between a direct and indirect staining. A direct staining deciphers the 
application of a fluorophore-coupled secondary antibody, which is targeted against the 
constant region (Fc) of a primary antibody. If an amplification of the signal is needed, a 
streptavidin/biotin system may be used (ABC-system; Vector Laboratories, Enzo Life 
Sciences). Hereby, a biotinylated primary antibody is applied. To each biotin-labelled 
antibody multiple streptavidin molecules coupled to horse-radish peroxidases (HRP) are able 
to amplify the signal.  
 
An indirect staining utilises a chromogenic substrate as for example the chemical reagent 3,3'-
diaminobenzidine (DAB). The DAB staining was followed after using the ABC kit. The HRP, 
which is coupled to streptavidin molecules, is able to cause a reduction of the DAB leading to 
an insoluble brown precipitate. This precisely indicates where a primary antibody has bound. 
ABC as well as DAB stainings were performed as suggested in the manufaturer’s handbooks 
(Vector Laboratories, Enzo Life Sciences).  
 
Free floating and human paraffin sections were subjected to immunohistological stainings 
either utilising DAB or fluorophore-labelled secondary antibodies. To retrieve the epitopes in 
paraffin sections, the samples were boiled in citrate buffer (pH6) for 10 minutes. Before 
immunohistochemistry stainings were performed, endogenous peroxidase activity was 
stopped by incubation in 0.3 % H2O2 in 0.1M PB for 30 minutes. The sections were rinsed in 
0.1 M PB and blocked in 0.1 M PB with 4 % normal goat serum, and 0.25 % triton x-100 for 
30 minutes at room temperature. The first antibody was incubated overnight, and the 
secondary biotinylated antibody was incubated for one hour at room temperature. After 
washing the sections with 0.1 M PB/0.25 % triton x-100, 0.1M PB followed by 0.01 M PB 
and finally ddH2O the ABC kit was applied. Subsequently the DAB staining kit was utilized. 
DAB sections were dehydrated and prepared for mounting before microscopical analysis 
using a BX50 microscope (Olympus). Hereby the sections were dehydrated by incubation in 
ascending ethanol concentrations (5 minutes each in 50 %, 70 %, 96 % and 100 ethanol). The 




alcohol was removed by incubating two times 10 minutes in RotiHistol® (Roth) before 
mounting of the sections with Eukitt® (Sigma). 
 
Sections for immunofluorescence were mounted in a mixture of 1, 4-diazabicyclo [2, 2, 2] 
octane (DABCO)/Mowiol (17 % Mowiol, 33 % Glycerol), 50 mg/ml DABCO, 1 µg/ml 4',6-
diamidino-2-phenylindole (DAPI) and hardened in the dark at room temperature. The 
immunohistologically stained sections were visualised using a confocal laser scanning 
microscope (CLSM) FV1000 (Olympus). 
 
3.2.1.9.2 TUNEL staining 
By Terminal deoxynucleotidyl Transferase (TdT) deoxyuridine triphosphate (dUTP) Nick 
End Labeling (TUNEL) apoptotic cells were stained within brain tissue. This is a method, 
which detects DNA fragments resulting from apoptotic cell death by labelling the terminal 
end of fragmented DNA. The enzyme TdT catalyses the transfer of dUTPs, that are 
secondarily labelled by a marker onto the 3’ end of a DNA strand.  
Paraffin sections (section 3.2.1.8.1) were stained using the ApopTag®Peroxidase In situ 
Apoptosis Detection Kit (Millipore) according to the manufacturer´s instructions. After 
deparaffinising and rehydrating of the paraffin sections they were incubated in 20 µg/ml 
proteinase K diluted in PBS for 15 minutes. Subsequently, endogenous peroxidase was 
quenched by incubating the sections in 3 % H2O2 in PBS for 5 minutes. Following the 
samples were incubated with equilibration buffer before adding the TdT enzyme for an hour 
at 37 °C. In this step the labelled dUTP (digoxigenin) was conjugated to the ends of nicked 
DNA strands and the reaction was terminated by adding the “stop buffer”. The sections were 
washed with PBS before incubation with an anti-digoxigenin antibody attached to a 
peroxidase for 30 minutes. Following the sections were washed again in PBS for (4 x 2 
minutes). The 3,3'-diaminobenzidine (DAB) staining was utilised according to the 
manufacturer’s instructions (Vector Laboratories, Enzo Life Sciences) to visualise the 
antibody signals. Finally, the sections were dehydrated and prepared for mounting before 
analyzing the samples microscopically by using a BX50 microscope (Olympus). 
3.2.1.9.3 Periodic acid-Schiff staining 
To detect glycogen or carbohydrate conjugates (also attached to lipids or proteins) in tissue 
the Periodic acid-Schiff (PAS) was utilised. This reaction selectively oxidises 
glucose/galactose residues creating aldehydes, which react with the Schiff’s reagent resulting 




in a magenta positive signal. Thus, an increased staining may indicate a metabolic disorders 
leading to storage e.g. glycolipids or glycoprotein. The staining was in deparaffinised sections 
from murine brain tissue following the protocol outlined in table 3.7. The stainings were 
analysed microscopically by using a BX50 microscope (Olympus). 
 
Table 3.7: Protocol for PAS-staining of brain sections. 
Reagents 0.05 % periodic acid 
Schiff’s reagent 
Haematoxylin 
Basic water (NaOH pH 7.8) 
Acid Alcohol (1 % HCl in 70 % ethanol) 
Alcohol dilution series (50 % - 100 %) 
Rotihistol® 
 
Protocol - 5 minutes periodic acid 
- Rinse in ddH2O 
- Schiff’s reagent 30 minutes 
- Wash in running water 5 minutes 
- Haematoxylin 5 minutes 
- Wash in running water 5 minutes 
- Acid alcohol: dunk 2-3 times until the sections turn pink. 
- Tap water: rinse 3-5 minutes 
- Basic water 5-6 slow dunks; until sections darken  
- Dehydrate in alcohol: 2 minutes each - 50 %, 70 %, 96 %, 100 % 
- Clear in Rotihistol® and mount in Eukritt® 
 
3.2.2 Molecular structural analyses 
3.2.2.1 LIMP-2-derived peptides 
All peptides were purchased from jpt Peptide Technologies (Berlin) in a purity of >95%. A 
biotin-tag was N-terminally coupled to the peptides via a Ttds linker (TTDS = 1,13-diamino-
4,7,10-trioxatridecan-succinic acid) (Figure 3.5). The peptide sequences were derived from 
the LIMP-2 interaction site. The 3xD helix 5 peptide was utilised as a negative binding 
control. The helix 5, 3xD helix 5 as well as helix 7 peptide end with an acid COOH-group at 
the C-terminus. In addition uptake-optimised ‘TAT-peptides’ of helix 5 and 3xD helix 5 were 
designed. Auxiliary they exhibit a CMA-sequence (KFERQ) linked to the N-terminus and 
TAT-sequence (YGRKKRRQRRR) on the C-terminus. Both of the peptides were designed to 
have an amide-group at the end of the C-terminus to make the peptides more stable for cell 
culture experiments. All peptides and the recombinant GC (Cerezyme ®, Genzyme 
Therapeutics, Boston, US) were dissolved in NaPhosphate buffer (50mM, 150mM NaCl, 
pH7). The peptides were solved in 0.1% HCl before dilution in 10% volume of the total 
amount of NaPhosphate buffer (e.g. the peptide was solved in 30 μl 0.1% HCl and 




subsequently 270 μl buffer was added). For peptide studies including pulldown, activity and 
uptake assays, recombinant GC was incubated with 10 times higher concentrated peptides (in 
molarities). The concentration of the peptides as well as recombinant proteins was assessed 
spectroscopically by using a nanodrop (see paragraph 3.2.2.3). 
 





Helix 5 Biotin-Ttds-LREIIEAMLKAYQQKLFVTHTVDE (acid) 
M=3404 g/mol; Ԑ=0.45 
 
3xD Helix 5 Biotin-Ttds-LREDDEAMDKAYQQKLFVTHTVDE (acid) 
M=3409 g/mol; Ԑ=0.45 
 
Helix 7 Biotin-Ttds- TVDELLWGYKDEILSLIHVFRPD (acid) 
M=3287 g/mol; Ԑ=2.53 
 
Helix 5 TAT Biotin-Ttds-
KFERQLREIIEAMLKAYQQKLFVTHTVDEYGRKKRRQRRR (amide) 
M=5107 g/mol; Ԑ=0.50 
 
3xD Helix 5 TAT Biotin-Ttds-
KFERQLREDDEAMDKAYQQKLFVTHTVDEYGRKKRRQRRR 
(amide) 
M=5113 g/mol; Ԑ=0.50 
 
 
Figure 3.5: Structure of the Ttds-linker. 
The Ttds-linker was incorporated N-terminally between the biotin-tag and the sequence of the helices through an 
amide linkage. 
 
3.2.2.2 Recombinant enzymes  
In this study recombinant enzymes were utilised in a number of different experimental 
approaches including peptide-pulldown, enzyme-activity and cell-based uptake assays. For 
example the recombinant GC (Cerezyme ®) was used to validate the ability the LIMP-2-
derived peptides to specifically interact with this enzyme in vitro. To validate the binding 
specificity of the LIMP-2-derived peptides, the recombinant lysosomal acid α-mannosidase 
(LAMAN; Zymenex) was applied as negative control. In addition the effect of the whole 
luminal domain of LIMP-2 on GC function was assessed.  
Information about the individual recombinant enzymes can be found in table 3.9.     
 








hLIMP-2 LD Luminal domain of LIMP-2 with c-terminal human IgG-tag;  
R&D Systems (Minneapolis, US) diluted in 100 μg/ml in PBS 
 
GC (Cerezyme ®) Imiglucerase for injection (enzyme replacement therapy),  
produced in CHO cells; 
Genzyme (Sanofi Company, Boston, US).  
Diluted in 50 mM NaPhospate buffer, 150 mM NaCl, pH7; 
Gift of Dr. med. Eugen Mengel (University paediatric clinic of Mainz) 
M = 60,430 g/mol; Ԑ = 1.67 
 
rhLAMAN Recombinant human α-mannosidase for injection (enzyme replacement 
therapy) diluted in PBS; 
Zymenex (Hillerod, DK) 
(Roces, Lullmann-Rauch et al. 2004, Blanz, Stroobants et al. 2008) 
M = 113,744 g/mol; Ԑ = 1.71 
 
3.2.2.3 Nanodrop: Proteinconcentration measurement 
After getting recombinant protein and peptides into solution, they were quantified by utilising 
a NanoDrop® spectrophotometer (ND-100, Thermo Fisher Scientific, US). After calibrating 
and blanking with 1 µl nuclease-free water, 2 µl protein/peptide solution was applied and a 
spectrum from 220 - 350 nm measured. Aromatic amino acids in protein/peptides absorb light 
at 280nm. The more light is absorbed, the higher is the protein concentration in the sample. 
Using the Beer-Lambert law it is possible to relate the amount of absorbed light to the 





   (E = Exctinction and Ԑ = specific extinction coefficient) 
 
The extinction coefficient of each peptide/recombinant protein was identified by using the 
protein calculator (online version 3.3 on the server of the Scripps Research Institute, La Jolla, 
US). 
3.2.2.4 Peptide-pulldowns 
In vitro pulldown: for the pulldown of recombinant protein utilising LIMP-2-derived peptides, 
2 nmol of protein (GC, LAMAN and BSA) were incubated overnight at 4°C or 1-2 hours at 
room temperature with the tenfold molecular amount (20 nmol) of biotinylated LIMP-2-
derived peptides (helix 5, 3xD and helix 7 as well as TAT-peptides (see Table 3.8)). The total 
incubation volume was filled up to 250 μl with NaPhosphate buffer (50 mM, 150 mM NaCl, 
pH7). Simoultaneously ‘High Capacity Streptavidin Beads’ (Thermo Fisher Scientific, Life 
Technologies) were blocked with 1 % BSA solution. The next day the beads were equilibrated 




with the respective buffer (50 mM NaPhosphate, 150 mM NaCl, pH7) by washing them four 
times (centrifugation step at 4000 rpm, 4°C). For each pulldown 50 μl of beads were utilised 
and incubated with 200 μl enzyme/peptide mixture for 30 minutes at room temperature. The 
remaining 50 μl of the enzyme/peptide samples were prepared for SDS-PAGE (25 μl + 5 μl 
5x Laemmli → ‘LOADED fraction’) and kept in the fridge for further analysis (e.g. GC 
activity assay or nanodrop analysis). After incubation of the beads with the enzyme/peptide 
mixture the samples were centrifuged for 1 min. at 1,500 x g at 4°C. 
The supernatant was removed from the beads and stored at 4°C as ‘UNBOUND fraction’. 
Following, the beads were washed three times for 10 minutes with 250 μl of NaPhosphate 
buffer and centrifugation at 4000 rpm at room temperature. Finally, the washing buffer was 
removed from the beads and incubated with 30 μl 1x laemmli buffer at 60°C for 20 minutes. 
In this step the precipitated enzyme and peptide were released from the streptavidin agarose 
beads (‘BOUND fraction’). The LOADED and BOUND fractions of the pulldown-down 
experiments were loaded on a NuPAGE ® Novex ® 4-12 % Bis-Tris gel with NuPAGE ® 
MES buffer (NuPAGE system: Thermo Fisher Scientific, Life Technologies), subjected to 
electrophoresis (paragraph 3.2.3.5) and stained with coomassie (Brilliant Blue, R-250; 
BioRad; for protocol see 3.2.3.7). The gels were destained (for buffer ingredients see 
appendix Table 7.9) until the background staining was minimised. Gels were kept air-locked 
in a humid plastic bag at 4°C and digitalised by scanning. 
 
Pull down from cell lysates: for pulldown of endogenous and overexpressed GC from N2a 
cell lysates 20 nmol of LIMP-2-derived peptide (Helix 5 and 3xD) were incubated with 50 μl 
cell lysate at 4°C overnight. The cells were harvested in EBC-buffer. As described above the 
‘High Capacity Streptavidin Beads’ (Thermo Fisher Scientific, Life Technologies) were 
blocked with BSA and equilibrated in NaPhosphate buffer as described above. The cell 
lysate/peptide mixture was incubated with the streptavidin beads for 30 minutes at room 
temperature. The supernatant was removed and the beads were washed three times in 
NaPhosphate buffer. The bound enzyme was released from the streptavidin agarose beads by 
incubation with 40 μl 1x Laemmli and incubation at 60°C for 20 minutes. After centrifugation 
for 2 minutes at 17,000 x g the supernatant was removes (‘BOUND fraction’) and subjected 
to SDS-Page (section 3.2.3.5) and western-blotting (chapter 3.2.3.6). An antibody against the 
human variant of GC (anti-hGC, for details see Table 3.2) was used to detect the pulldown of 
the overexpressed GC mutants, whereas an antibody against the murine form of GC (anti-
mGC, for details refer to Table 3.2) was applied to detect the endogenous GC enzyme. 




3.2.2.5 Protein modelling 
Molecular analyses, graphics and animations were performed with the UCSF Chimera 
package (http://www.cgl.ucsf.edu/chimera) (supported by NIGMS P41-GM103311). 
3.2.2.6 Circulardichroismus (CD-Spectroscopy) 
In this study the CD-spectroscopy was applied to characterise the secondary structure of 
recombinant proteins and LIMP-2-derived peptides. The principle of this technique is based 
on the difference in the absorption of left- and right-handed circularly polarised light and 
occurs when a molecule contains one or more chiral chromophores. 
Every single protein secondary structure including α-helices, β-sheets and random coils 
reveals a specific CD-spectrum (Figure 3.6). Thus every protein exhibits a characteristic CD-
spectrum, which is a mixture of the spectra of the individual secondary structures. 
 
 
Figure 3.6: Characteristic CD-spectra of individual secondary structures. 
Every protein secondary structure exhibits a characteristic UV CD-spectrum (250 nm-190 nm). A spectrum of a 
random coil (lack of structure) is shown in red, a typical β-sheet curve progression is exposed in blue and a 








The CD-measurements were carried out with a Jasco-J-720-CD spectropolarimeter (Japan 
Spectroscopic Company) at 20°C.The LIMP-2-derived peptides (helix 5, 3xD helix 5 and 
helix 7) were dissolved in 50 mM NaPhosphate buffer (+ 10 mM NaCl, pH7) in a 
concentration of 0.2 μg/μl in a total volume of 300 μl and measured from 250 nm – 200 nm 
with settings as depicted in table 3.10. 
Furthermore the CD-spectrum of GC and its changes in the presence and absence of the helix 
5 peptide was assessed.  Initially 2 nmol GC (Cerezyme ®) were incubated with 20 nmol of 
helix 5 and 3xD peptide overnight at 4°C. For CD-analysis the samples were diluted 1:15 
resulting in a concentration of 0.05 – 0.07 μg/μl in a total volume of 300 μl. For stabilisation/ 




melting curve analysis the temperature was increased from 20°C to 90°C (1°C/min) and 
spectral changes were recorded every degree at a wavelength of 220 nm (for further settings 
of measurements see table 3.10).  
 
Table 3.10: Settings of CD-spectrum measurements. 
Settings:  
Data pitch 1 nm 
Scanning mode continuous 
Speed 5 nm/min 
Response 8 sec. 
Band width 2.0 nm 
Accumulation 3 measurements 
Wavelength 250 nm – 200 nm; for melting curve analysis: 220 nm 
Width of cuvette 0.05 cm 
 
3.2.2.7 Dynamic light scattering (DLS) 
This technique is applied to determine the size distribution of small molecules (down to 1 nm 
diameter) in solution. The principle of this experimental setup relies on the fact, that the 
moving particles hit the monochromatic light (laser) and diffract it in all directions. Together 
with the frequency of passing the laser beam it is possible to conclude the size of these 
particles. The set-up of a DLS-experiment is shown in figure 3.7   
In this study it was assessed if the presence of the GC-binding helix 5 peptide is causing 
changes in the quaternary structure (e.g. multimerisation or aggregation) of the GC protein. 
Protein and peptide were pre-incubated overnight in a molar ratio of 1:10 in 50 mM 
NaPhosphate buffer (+ 10 mM NaCl, pH7). The measurements were carried out at room 
temperature in a laser-spectroscatter 201 (RiNA GmbH). The best signals were obtained when 
GC was applied in a concentration of 50 μM. 
 
 
Figure 3.7: Principle of dynamic light scattering technique. 
A monochromatic light source (laser) is shot through a polariser (lens). The light hits the molecules in the sample 
(orange circles) and gets diffracted in all directions. At a certain angle (θ) the light is detected by going through 
another lens and a photon detector. The repetition of events and thus the change in wavelengths can be correlated 
to a specific size of the particle (calculated by the correlator/computer). 





For crystallisation experiments recombinant GC (Cerezyme ®) and the peptide were solved in 
MES-buffer (50mM MES, 100 mM NaCl). By using spin columns (Vivaspin 500, Sartorius) 
GC was concentrated to approximately 4 mg/ml and GC was incubated with the peptide (10 
fold higher molarity compared to GC) at 4°C overnight. The crystallisation buffers were 
modified from a published protocol for crystallisation of glycosylated GC (Brumshtein, 
Wormald et al. 2006). 
On 96 well crystallisation plates the best conditions were screened by variation of the buffer 
in pH and concentration of the different buffer components. Best results were observed under 
following crystallisation buffer conditions: 100 mM Bis-Tris buffer, 2.0-2.4 M Ammonium 
sulphate, pH4.9-5.1. Crystals were grown and kept consistently at 20°C. In addition, growing 
the crystals under oil (Al’s oil; Paraffin and Silicon oil (50:50); Hampton Research) had a 
positive impact on the number and size of the crystals (experimental set-up see Figure 3.8). 
After 3-5 days first crystals could be observed, gaining in size over time. An Izit ® (Hampton 
Research, CA, US) staining was performed to verify the protein content of the cultured 
crystals. The GC/peptide mixture (in MES buffer) and crystallisation solution (Bis-Tris 
buffer) were mixed 1:1 (100 nl each) and then covered by 2-3 μl of oil. The neighbouring 
reservoir was filled with 50 μl crystallisation solution (Bis-Tris) and the batch was sealed with 
plastic tape (Figure 3.8). The obtained crystals were monitored every second day and 
harvested at a size around 50 μm. Utilising a mounted cryoloop (MicroMesh 400/50, Jena 
Bioscience) the crystals were harvested, stored in liquid nitrogen and measured at the BESSY 
II in Berlin (Helmholtz Zentrum Berlin, DE) using the MX_beamline_14.1. The BL14.1 is a 
tunable energy beamline for macromolecular crystallography. It can perform X-ray diffraction 
experiments of very small crystals up to 15 μm (for further properties of the beamline see 
Table 3.11).  The crystallisation experiments were performed in the laboratory of Prof. Dr. 
Axel Scheidig (‘Zentrum Molekulare Biowissenschaften’, University of Kiel, DE) and 




Figure 3.8: Side view of under oil 
crystallisation batches. 
The protein (in MES buffer) was mixed 
with the same amount of crystallisation 
buffer (Bis-Tris) and covered by oil. A 
neighbouring reservoir was filled with 50 
μl crystallisation buffer and the batch was 
sealed with plastic tape.  
 
 










Energy range 5- 15.5 keV 





Divergence horizontal 0.5 mrad 
Divergence vertical 0.5 mrad 





Distance Focus/last valve 300 mm 
Height Focus/floor level 1400 mm 
Free photon beam available Yes 
Fixed end station Yes 
 
 
3.2.3 Protein biochemistry 
3.2.3.1 Lysis of cells and tissue 
Cells harvested from cell culture dishes were pelleted (1,500 g, 4°C) and lysed in a lysing 
buffer, which is specific for each experiment. As a standard lysis buffer PBS (pH7.4) 
including protease inhibitors (Complete®, Roche) and 1 % of the detergent triton-x-100 was 
utilised. For Co-IP the cells were lysed in EBC-buffer (Table 7.6). Depending on the size of 
the cell pellets 20-150 μl lysis buffer was applied and the samples were sonicated 2 x 10 
seconds, incubated on ice for 30 minutes and sonicated again 2 x 20 minutes. Lysates were 
then centrifuged at 17,000 g for 10 minutes at 4°C. The lysed cell sample (supernatant) was 
transferred to a clean tube and used for protein concentration quantification (see next 
paragraph).  
In addition, a special lysing buffer and a sequential extraction protocol was used for cells and 
tissue analysed for α-synuclein (brain samples and H4 cells). For studies of midbrain and pons 
it was distinguished between soluble and insoluble fractions utilising two different buffer 
systems (triton-x-100 and Sodium-Dodecyl-Sulfate (SDS)) carried out as described in 
Mazzulli et. al, 2006. Briefly, cells/brains were lysed in triton buffer (10 volumes; 1 % triton 
x-100, 20 mM HEPES, 10 % glycerol, 150 mM NaCl, 1 mM MgCl2, 50 mM NaF, 2 mM 
NaVO3, protease inhibitors;  pH 7.4). Lysates were subjected to 4 freeze and thaw cycles (on 
dry ice) and ultracentrifuged (Optima
TM
 TLX ultracentrifuge, Beckman) at 100,000 g for 30 




minutes. This step was repeated twice and the two supernatants were pooled as the triton 
soluble fraction. The remaining pellets were lysed in 5 volumes of SDS-lysis buffer (2 % 
SDS, 50 mM Tris-HCl-pH7.4), boiled for 10 minutes, sonicated 4 times with 3 seconds 
pulses, at 50 % power, boiled for 10 minutes and centrifuged at 20,000 g for 30 minutes, 
resulting in the SDS (insoluble) fraction. 
3.2.3.2 Proteinquantification 
Protein quantification was performed by using a BCA-kit (Pierce 
TM
, Thermo Fisher 
Scientific) according to the manufacturer’s manual. This method relies on the ability of 




in an alkaline medium. 
Subsequently the Cu
+
 reacts with the bicinchoninic acid (BCA) resulting in a purple-coloured 
reaction product. The absorbance can be measured in a plate reader (Synergy HAT, BioTek) 
at a wavelength of 562 nm together with a standardised protein curve.  
3.2.3.3 Deglycosylation of proteins 
Glycoproteins like LIMP-2 and GC can be characterised by two enzymes able to cleave N-
linked glycosylations: endoglycosidase H (endo H) and Peptide-N-Glycosidase F (PNGase F). 
Both enzymes exhibit a unique specificity in the digestion of N-glycosylations, which makes 
it possible to monitor protein trafficking. The core N-glycosylation occurs in the ER, where 
the glycoproteins are still sensitive to endoglycosidase H digestion (high mannose and hybrid 
structures; Figure 3.9). After entering the Golgi-compartment complex modifications are 
made to the glycans (complex glycan structures; Figure 3.9) and the proteins get resistant to 
EndoH digestion. In contrast the PNGaseF enzyme is still able to cleave these complex N-
linked carbohydrates and thus provides a positive control for digestion assays (Figure 3.9). 
 
To study the subcellular localisation and transport of the various GC mutants (ER, post ER 
localisation) an endoglycosidase H as well as PNGaseF digestions were performed utilising a 
glycosidase-kit from New England Biolabs (NEB). For both reactions 20 μg of protein was 
applied and the experimental procedure was performed according to the manufacturer’s 
handbook (NEB). Briefly, the protein samples were denatured by adding a denaturing buffer 
and boiling the samples (95°C, 10 minutes). After cooling down 1 μl of the enzyme 
(EndoH/PNGaseF) was applied together with the respective amount of buffer and incubated at 
37°C for 1 hour. Reducing laemmli buffer (appendix Table 7.9) was added to the samples, 
heated at 60°C for 20 minutes and analysed by SDS-PAGE and immunoblotting. A positive 
digestion resulted in a molecular size shift of the protein. 





Figure 3.9: Illustration of endoglycosidase H/PNGaseF cleavage. 
N-Glycosylation it protein modification and occurs in the ER resulting in high mannose carbohydrate chains. 
Endoglycosidas H (endoH) and PNGaseF are able to cleave the glycosylation chains. During protein trafficking 
from the ER to the Golgi compartment, modifications on the carbohydrate chains take place. A hybrid glycan 
structure is still cleaved by both enzymes, whereas the complex glycan residue is only sensitive to the PNGaseF 
enzyme. Since this form of glycosylation can only be found in the Golgi, it is possible to monitor protein 
trafficking by performing endoglycosylation H digestion. Illustration was modified from www.promega.de. 
 
3.2.3.4 Co-immunoprecipitation (Co-IP) studies 
Co-IP studies are performed to analyse the interaction of one protein with another. Hereby 
one target protein is precipitated utilising a specific antibody. In this study LIMP-2 was 
precipitated and the ability of its interaction with GC and numerous GC mutants was assessed.   
For Co-IP studies cells were lysed in EBC-buffer (Table 7.6) including protease inhibitor 
(complete ®, Roche). Next, 500-1000 μg protein lysate (approximately one 10 cm cell culture 
dishes needed) was incubated with 1.5 μl of LIMP-2 antibody overnight at 4°C. At the same 
time the 30 μl/sample magnetic agarose G beads (Thermo Fisher Scientific, Life 
Technologies) were blocked with 1 % BSA. The next day the beads were incubated with the 
lysate/antibody mixture for 30 minutes at room temperature. During this step the antibody 
interacts with the protein G of the beads. Subsequently, the beads were washed 4 times with 
200 μl EBC buffer/complete. The supernatant was discarded and the beads were incubated 
with 60 μl of 1x laemmli and heated at 60°C for 15 minutes. Finally, the Co-IP samples were 
analysed by SDS-PAGE and immunoblotting (see following chapters). The co-precipitated 
GC was visualised using an anti-human GC antibody (Table 3.2). 
 





Figure 3.10: Principle of Co-Immunoprecipitation. 
A sample containing a mixture of proteins (A, B, C and D) is incubated with an antibody against protein B 
(blue). Since protein B interacts with protein C (green), both proteins get precipitated by the antibody. Protein G 
agarose beads then interact with the antibody. The agarose beads can be precipitated by centrifugation and the 
proteins are released from the antibody by heating. In this way a primary and secondary target of the antibody 
can be precipitated from a protein mixture (e.g. cell lysate). 
 
3.2.3.5 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique to 
separate proteins according to their molecular weight regardless of their electric charge. 
Extracted proteins were denaturated beforehand in a SDS-containing reducing buffer 
containing DTT (Laemmli, see appendix Table 7.9 ). The protein samples were then heated at 
60°C for 10 minutes. Samples for α-synuclein analysis were incubated 10 min. at 95°C.  
Together with a protein-size standard (Thermo Fisher Scientific) the protein samples were 
loaded on a polyacrylamid gel (10% selfmade and 4-12% NuPAGE gradient gels; Thermo 
Fisher Scientific, Life Technologies) and exposed to voltage: 120 V for first 10 minutes 
followed by 140V. 
3.2.3.6 Western Blotting 
To visualise proteins by antibodies after separation by SDS-PAGE, the proteins were 
transferred onto membranes (nitrocellulose (GE Healthcare) and PVDF for α-synuclein) by 
applying voltage. The PVDF-membranes (Millipore) are equilibrated in methanol before use. 
In this study the TANK-blot system was performed. The SDS-gels were assembled with the 
respective membrane together with whatman-filter papers between cathode (-) and anode (+) 
as shown in figure 3.10. The complete ‘sandwich’ of SDS-gel, membrane and filter papers 
was placed in a TANK-blotting chamber (Bio-Rad), filled with blotting buffer and subjected 
to voltage as follows:  
 




1) Over night (4°C): 20 V constant; next morning: 30 mins 70 V 
2) 2hrs (4°C): 0.85A constant 
3) 1 hr (4°C): 100 V constant 
 
 
Figure 3.11: Set-up of TANK-blot system. 
In a tank-blot system proteins are transferred from the SDS-gel to membrane by attaching voltage. This picture 
illustrates the assembly of the SDS-gel, the respective membranes and filter papers between the cathode and 
anode. 
 
After transferring the proteins onto membranes they were blocked for 30 minutes at room 
temperature in 5 % milk in TBS-T. For studying α-synuclein the membranes were post-fixed 
20 minutes in 0.4 % PFA (room temperature) before blocking in milk. 
3.2.3.7 Incubation with antibodies and stripping of immunoblots 
After blocking the membranes with milk, they were subjected to antibody incubation. The 
antibodies were diluted in the respective concentration (Table 3.2) in 5 % milk in TBS-T (0.1 
% tween-20). Primary antibodies were incubated overnight at 4°C. After three washing steps 
in TBS-T the membranes were incubated for 1 hour with the respective secondary antibody at 
room temperature. This antibody was diluted 1:10,000 in 5 % milk (TBS-T) and linked to a 
horseradish peroxidase (HRP). After washing the membrane three times, the signal of the 
antibody was detected in a chemiluminescence detection system (LAS4000, Fujifilm). Hereby 
a chemiluminescent substrate (ECLadvanced, Amersham) was applied. The antibody bound 
peroxidase (HRP) converts hydrogen peroxide to water and reactive oxygen, which oxidises 
luminol. This oxidisation is followed by a release of light, which is detected by the detection 
system. 
For re-probing the membrane with another antibody it is possible to strip off the initially 
bound antibodies. The membranes were incubated either in stripping buffer containing β-
mercaptoethanol (β-ME) or SDS (Table 7.9). For stripping in the β-ME containing buffer, the 
membranes were heated to 70°C for 20 minutes, and subsequently washed in ddH20 and TBS-
T until the smell of β-mercaptoethanol was negligible. The membranes were incubated in the 
SDS-stripping buffer (pH 2.2) for 1 hour at room temperature. After both stripping protocols 




the membranes were blocked again in 5 % milk in TBS-T and re-probed with a new round of 
primary and secondary antibodies as described above. 
3.2.3.8 Coomassie stainings 
After subjecting proteins samples to SDS-PAGE analyses, it is also possible to visualise 
proteins in-gel by incubation of the SDS-gels with a coomassie blue staining. This stain is a 
triphenylmethan dye and binds to all basic side chains of amino acids. 
SDS-gels were incubated with coomassie brilliant blue (R-250, Bio-Rad) for 30 minutes at 
room temperature. Subsequently the gels were destained with a destaining solution containing 
10 % methanol and 10 % acetic acid until the background signal was negligible. Gels can be 
kept in water at 4°C for a few days and scanned for analysis. 
3.2.3.9 Densitometric analysis of immunoblots/coomassie-stained SDS-gels 
The signal intensities released from individual protein bands either by indirect 
chemiluminescence recations or by direct protein stains with coomassie can be determined. 
Usually for immunoblot-analysis the band intensity was normalised to the respective signal of 
the loading control. For statistical analysis the intensity of each individual protein band, the 
Image J software (Table 3.12) was utilised. A rectangle was placed around the signals and the 
intensity was calculated by integral calculus. In addition the background signal was subtracted 
from the signal of the protein band.    
3.2.3.10 Enzyme activity assasy 
Using artificial substrates the activity of enzymes (for example hydrolases) can be assessed. 
In this study 4-nitrophenyl-conjugated carbohydrates were applied. The activity of enzymes 
leads to the hydrolytic cleavage of both components (sugar and 4-nitrophenyl) under acid pH. 
When a basic stop solution was added the reaction of the enzymatic reaction was stopped and 
the p-nitrophenols become fully deprotonated. This leads to a yellow colour shift, which can 
be detected in a plate reader (Synergy HAT, BioTek) at 405 nm.  
In this study activity of GC and α-mannosidase (LAMAN) were measured using 10 mM 4-
nitrophenyl β-D-glucopyranoside and 10 mM p-nitrophenyl-N-acetyl-ß-D-glucosaminide, 
respectively. The artificial substrates were solved in citrate buffer (0.2 M Na-Citrate, 0.4 % 
BSA, pH 4.6). All activity assays were performed in 1.5 ml Eppendorf tubes and in 
duplicates. 
To assess the enzymatic activity of cell or tissue lysates 20-200 μg of protein was applied to 
and incubated with 100 μl of the specific substrate. To determine GC activity the assay was 




incubated approximately 2 hours at 37°C and for α-mannosidase activity the assay was 
incubated for 5 hours at 37°C. The reaction was stopped applying 500 – 1000 μl of the stop 
solution (0.4 M Glycine, pH10.4). To determine the enzymatic activity of the recombinant 
enzymes 0.2 nmol of Cerezyme ® and LAMAN (Table 3.9) were applied (in absence or 
presence of 2 nmol LIMP-2-derived peptides) and incubated for 15-30 minutes at 37°C and 
the enzymatic reaction was stopped as described above. After centrifugation of the samples at 
full speed for 10 minutes 161 μl of the supernatants were pipetted onto a 96 well plate and 
measured at 405 nm in a plate reader (Synergy HAT, BioTek). The absolute enzyme activities 









t ×  ε × d × Vlysate
) ÷ clysate 
 
U enzyme activity (μmol/minute) 
ΔE change in absorbance at 405 nm 
Vend final volume in the reaction tube 
Vlysate volume of lysate used 
d path-length of 1 cm 
T time in minutes 
Ԑ molar absorption coefficient 
 
3.2.3.11 In vivo lysosomal activity assay 
Since the above described activity assay only detects GC activity in whole cell lysates, the 
development of an assay where it could be distinguished between lysosomal and non-
lysosomal enzyme activity has advantages. Furthermore this newly developed assay is able to 
measure enzyme activity in living cells by pulse-chasing a fluorescent substrate.  
GC activity was also assessed in living H4-cells as well as in living human midbrain neurons. 
Cells were plated in 96 well dishes (BD, black well) at 8^E4 cells/well. On the day of the 
assay, neurons were treated with DMSO or lysosomal inhibitor bafilomycin A1 (Calbiochem, 
Millipore) at 200 nM for 1 hr. Subsequently, cells were loaded with 100 ug/ml of the cell-
permeable artificial enzyme substrate 5-(pentafluoro-benzoylamino) fluorescein di-ß-D-
glucopyranoside (PFB-FDGlu) (Thermo Fisher Scientific, Life Technologies) that fluoresce 
upon cleavage. After 1 hour of incubation of the substrate the cells were washed with warm 
media 3 times, and replaced with fresh media. The fluorescence intensity was recorded every 
30 minutes for 3-4hrs in a spectramax i3 plate reader (Molecular Devices) (PFB-FDGlu: 
Ex=485nm, Em=530nm). After the final read, cells were fixed in 4% formaldehyde / PBS, 
stained with draq5 and sapphire 700 as described (Mazzulli, Xu et al. 2011) to ensure for 
integrity of cells and measure cell volume. The plate was scanned on an odyssey infrared 
imager (Li-cor). Fluorescence intensities were graphed as fluorescence intensity versus the 




time, and analysed by measuring the area under the DMSO and bafilomycin (Baf) curves 
(AUC). Total cellular activity was obtained by calculating the AUC of the DMSO curve. 
Non-lysosomal activity was obtained by calculating the AUC of the bafilomycin curve. And 
lysosomal activity was obtained by subtracting the AUC of the bafilomycin from the DMSO 
curve (Figure 3.12). 
 
 
Figure 3.12: Principle of measuring and calculating lysosomal GC activity. 
Living cells were chased with a fluorescent artificial substrate and GC activity was measured on a plate reader 
over 3.5 hours. Cells treated DMSO (black) exhibit total cell activity, whereas cell treated with the lysosomal 
inhibitor bafilomycin (Baf; red) reveal the non-lysosomal activity. For calculation of the lysosomal activity the 
areas under the curves (AUC) were calculated. By subtracting the non-lysosomal (Baf) AUC from the total 
(DMSO) AUC, the lysosomal activity could be determined (grey area). 
 
3.2.4 Cell biological methods 
3.2.4.1 Cultivation of adherent cells  
The cells utilised in this work are listed in table 3.1 and were kept consistently in an incubator 
at 37°C and 5 % CO2. The cells were maintained in the respective media additionally 
containing 1 % Penicillin/streptomycin and 10 % FCS (see 3.1.1and appendix Table 7.7) and 
grown on 6 to 10 cm cultivation dishes. For immunofluorescence studies cells were grown on 
glass coverslips in 6 well dishes. To maintain the cells in cell culture over a longer time 
period they were passaged (usually 1:10) by adding 0.5 – 1 ml trypsin (0.5 mg/ml)/EDTA to 
the cells. After incubation of 10-30 min at 37°C the cells detached from the cell culture dish 
and could be cultivated in a new dish with fresh media. To prevent contamination, all cell 
culture work was performed under a sterile hood utilising only sterile utensils.  
 
H4 cells: The H4 cell line (human neuroglioma) stably overexpresses wild-type α-synuclein 
under the control of a tetracycline-inducible promoter (“tet-off”). Cells were cultured in 
OptiMEM® media (Thermo Fisher Scientific, Life Technologies). To suppress de novo α-
synuclein transcription the H4 cells were treated with 2 μg/ml of doxycycline (Invitrogen). 




For the α-synuclein turnover assay cells were harvested after 0, 8, 24, 48 and 72 or 74 hours 
of doxycycline treatment (ice cold PBS with protease inhibitors) and lysed in a triton-x-100 
lysis buffer (Mazzulli, Xu et al. 2011) (refer also to 3.2.3.1) and prepared for western-blot 
analysis as well as GC activity assays. 
3.2.4.2 Transfection of cells 
Transfection is the process of introducing nucleic acids into eukaryotic cells. Transfection of 
animal cells typically involves opening transient pores in the cell membrane to allow the 
uptake of material. This can be achieved by mixing a cationic lipid with the material to 
produce liposomes. These then fuse with the cell membrane and deposit their cargo (e.g. DNA 
plasmids) inside the cell. Cells given in 3.1.1 were transfected with plasmids utilising 
Turbofect ® (Thermo Fisher Scientific), FuGene ® HD (Promega) or Polyethylenimin (PEI; 
Sigma). Standard cell lines as Cos7, HeLa and N2a cells were transfected using PEI or 
Turbofect ®. For murine and human fibroblasts like GC-deficient and LIMP-2-deficient MEF 
cells and fibroblasts from patients, FuGene was utilised for transfection. The respective 
amount of plasmid DNA (3 μg for a 10 cm dish and 1 μg for a 6 cm dish) was incubated with 
twice (Turbofect and PEI) and three times (FuGene) the amount of transfection reagent and 
incubated for 20 minutes in 100 – 500 μl DMEM only (without any addition of FCS or 
antibiotics) before pipetting the transfection sample on the cells. When Turbofect or PEI was 
applied for transfection the cell culture media was changed after ~6 hours. The constructs 
were expressed 24 – 72 hours (depending on the expression constructs).  
3.2.4.3 Transduction of neurons 
Since neurons do not undergo any cell division, they were transduced utilising a lentiviral 
strategy. This experiment was carried out in the laboratory of Dr. Dimitri Krainc (to that time: 
Medical School Harvard/MGH, Boston, USA). The cloning and establishing of the lentivirus 
was done by Dr. Joseph R. Mazzulli (to that time: Medical School Harvard/MGH, Boston, 
USA) and the procedures have been described in detail in Mazzulli, Mishizen et al., 2006. 
Briefly, the supernatant from transfected HEK-FT cells was concentrated 500 times in 
neurobasal medium containing 10% fetal bovine serum. Viral titers were determined using a 
p24 ELISA kit (Zeptometrix). Aged human midbrain dopaminergic neurons (> 90 days old) 
were grown in 96-well plates and infected with lentiviral constructs. Analysis of lentiviral 
experiments were done at 14 days post infection at a multiplicity of infection (MOI) of 5 for 
wild-type-α-synuclein. Expression of the construct was verified by western blot analysis (data 




not shown here). Furthermore cells were subjected to live cell lysosomal GC activity assays 
(as described in section 0).  
3.2.4.4 Cryopreservation and thawing of cells 
Cells can be cryopreserved in liquid nitrogen. Adherent cells were trypsinised as described 
above and resuspended in freezing media (see appendix Table 7.7). The cells were centrifuged 
at 200 g for 10 minutes in a tabletop centrifuge (Universal 32, Typ 1605, Hettich) and the 
pellet was resuspended in 1 ml freezing media per 10 cm dish (each ~80 % confluency) and 
transferred into cryotubes. The cells were gently frozen by cooling them down on ice, dry ice 
and for 24 hours at -80°C. The next day the cells were frozen and stored in liquid nitrogen. 
For thawing the samples, cryotubes were removed from the liquid nitrogen tank and slightly 
opened. Cells were incubated shortly in a 37°C water bath and subsequently suspended in 5 
ml fresh media. The samples were then centrifuged at 200 g for 10 minutes and the pellet was 
dissolved in fresh media and plated on 10 cm dished. The next day the cells were briefly 
washed with PBS and the media was changed again.    
3.2.4.5 Harvesting of cells 
Before harvesting the cells were washed two times in PBS in order to remove residual media. 
Then 1 ml of ice cold PBS including a cocktail of protease inhibitors (Complete®: 1 tablet in 
50 ml PBS; Roche) was applied and cells were scraped on ice using a cell scraper. 
Subsequently cells were pelleted at 1,500 g for 10 minutes (4°C). The pellets were either 
stored at -20°C or directly processed by lysing in the respective lysing buffer (see section 
3.2.3.1).  
3.2.4.6 Uptake assays with recombinant enzymes/LIMP-2-derived peptides 
For the uptake of recombinant GC and LIMP-2-derived peptides three different cell lines were 
utilised: The murine macrophage cell line J774E, GC-deficient MEF cells and the human 
brain neuroglioma cell line H4. In initial experiments J774E cells were incubated with 50 μM 
peptides applied to 2 ml media in a 6 cm dish and incubated for ~12 hours. To control for the 
uptake of the peptide, cells were prepared for immunofluorescence studies using a 
fluorophore-labelled (Alexa Fluor, 488 nm) antibody targeted against biotin (1:200; Jackson 
Immuno Research). In a second approach GC-deficient murine fibroblasts were incubated 
with 0.2 nmol of recombinant GC (Genzyme) pre-incubated wit 10x molar amount of 
peptides (2 nmol). The mixture was incubated in a total amount of 40 μl 50 mM NaPhosphate 
buffer including 100 mM NaCl (pH7) and incubated at least 2 hours at room temperature or 




overnight at 4°C. Subsequently the protein/peptide mixture was added to 2 ml cell medium in 
a 6 cm dish. Success of uptake was confirmed by SDS-PAGE and immunoblotting (see 
chapter 3.2.3.6) utilising an anti-mGC antibody (Sigma, 4171, Table 3.2). 
H4 cells constantly overexpressing α-synuclein were incubated with 2 nmol of uptake-
optimised TAT-peptides (helix 5 and 3xD helix 5; see 3.2.2.1) in 2 ml cell medium of a 6 cm 
dish. New TAT-peptides were applied to the cell media every 24 hours if a longer incubation 
time was needed. 
3.2.5 Microscopical methods 
3.2.5.1 Fixing and staining of cells for immunofluorescence 
Applying an immunofluorescence (IF) staining protocol proteins can be specifically labelled 
and visualised by microscopy. For IF stainings of cells, they were grown in 6-well dishes on 
glass cover-slips. If necessary the cells were treated or transfected according to the established 
protocols. When reaching a confluency of ~80 % the cells were fixed with 4 % PFA/PBS for 
20 minutes at room temperature. Following they were washed three times with PBS. To 
permeabilise the cells they were incubated 5 minutes in 0.2 % saponin/PBS and subsequently 
10 minutes in 0.2 % saponin/0.12 % glycine/PBS at room temperature. To reduce unspecific 
binding of the antibodies the cells were incubated for 20 minutes in 0.2 % saponin/10 % 
FCS/PBS. The primary as well as the secondary antibody was diluted in this blocking 
solution. A dark, wet chamber was prepared, where the primary as well as secondary antibody 
was pipetted onto parafilm and the coverslip was put on top (the side with the cells facing the 
antibody drop). The primary antibody was either incubated one hour at room temperature or 
overnight at 4°C. Before incubating in secondary antibody the coverslips were washed four 
times in 0.2 % Saponin/PBS. The secondary antibody exhibits a fluorophore-labelling (Alexa 
Fluor 488 nm, 594 nm or 647 nm) and was applied in a concentration of 1:500 (see Table 3.3) 
for 1 hour at room temperature. After washing the cover slips three times in 0.2 % 
saponin/PBS and one time in ddH2O they were embedded on microscope slides with a 
mixture of Dapi/Dabco/Mowiol (see appendix Table 7.10). The next day the samples could be 
analysed by laser scanning microscopy. 
3.2.5.2 Filipin stainings 
To stain for free (unesterified) cholesterol in cells a filipin staining was performed. Filipin 
(Sigma) is a fluorescing antibiotic (extremely sensitive to light), which specifically stains free 
cholesterol and therefore can be used for molecular studies analysing the cholesterol 




metabolism. In this study filipin stainings were performed in cells exhibiting increased 
cholesterol storage in lysosomes: Niemann-Pick Type C (NPC) patient fibroblasts, LIMP-1/2 
double deficient MEF cells and HeLa cells treated with 0.3 – 3.0 μM U18666A for 24 hours 
according to manufacturer’s manual (Cayman Chemicals). This chemical blocks the exit of 
free cholesterol from lysosomal compartments resulting in cholesterol accumulation (Liscum 
and Faust 1989). According to each individual protocol the cells were transfected and 
prepared for immunofluorescence stainings as described above. A 100 x stock of filipin (= 50 
mg/ml) was prepared in DMSO and stored in the dark in liquid nitrogen.  After fixing the 
cells in 0.4 % PFA, they were incubated in the dark with 750 μl of filipin solution (1:100 
dilution of the filipin stock). The cells were washed with PBS and if needed antibody-stained 
(following the protocol as described above). Before embedding the coverslips in 
Mowiol/Dapco (no Dapi, since filipin likewise exhibits blue fluorescence), they were washed 
three times in ddH2O. For visualising filipin the blue Dapi channel was applied at the 
Axiovert 200 M (Carl Zeiss Jena GmbH). Filipin exhibits an extinction of 240 nm – 380 nm 
and an emission between 385 nm – 470 nm. 
3.2.5.3 Microscopical recording 
After embedding and hardening of the cover slips, they could be analysed by using confocal 
laser microscopy (Fluoview 1000; Olympus) or -in the case of filipin stainings- an inverted 
epifluorescence microscope (Axiovert 200 M; Zeiss). Depending on the utilised secondary 
antibody and staining of cell the respective laser was utilised. The pictures were taken in the 
‘sequential mode’ to prevent an overlay of the different colour channels. Cells were visualised 
60 – 100 times enlarged utilising oil objectives. The pictures were compiled by the FV1000-
ASW 3.0 Viewer-Software and exported to Photoshop (Adobe) for further changes e.g. in the 
contrast. 
3.2.6 Computer software 
Table 3.12: List of utilised software for data handling and analysis. 
Programme Supplier 
Adobe Illustrator Adobe Systems Inc., San Jose, US 
Adobe Photoshop Adobe Systems Inc., San Jose, US 
Chimera USCF www.cgl.ucsf.edu/chimera 
DNASTAR Lasergene 8 Lasergene, Madison, US 
EndNoteX6 Thomson Reuters, Carlsbad, CA, US 
Fluo View 1000 ASW 3.0 Olympus, Hamburg, DE 
Image J http://rsbweb.nih.gov/ij/  




MS-Office 2010 Microsoft Corporation, Redmond, US 
GraphPad Prism 5 Graphpad Incorporated, LaJolla CA, US 
 
3.2.7 Statistical analysis 
All data is expressed as mean ± standard error of the mean (s.e.m.), where n equals the 
number of independent repetitions of experiment. To determine significance between two 
groups a two-tailed independent Student’s t-test was utilised, if data was parametric. For 
comparing more than two groups a one-way analysis of variances (ANOVA) was applied. A 
value of p<0.05 was considered to indicate statistical significance. *, ** and *** denote 
p<0.05, p<0.01 and p<0.001. All statistical calculations were perfomed in GraphPad Prism 











4.1 LIMP-2: What does the crystal structure of its luminal domain tell us?  
Since the crystal structure of the extracellular domain of LIMP-2 (amino acids 252-255) was 
solved in 2013 (Neculai, Schwake et al. 2013), the three dimensional information was applied 
to analyse the structural and functional characteristics of the protein. For instance it was used 
to verify the interaction site to its ligand, the lysosomal enzyme GC (see chapter 4.1.3). 
Furthermore, the LIMP-2 protein exhibits properties pointing to additional function(s) of this 
lysosomal membrane protein (section 4.1.2). To date only its function as a GC transport 
receptor has been studied in detail.  
Recently an independent crystal structure of LIMP-2 was published, differing mainly by a 
mannose-6-phosphate (M6P) residue at the end of the N325 carbohydrate chain (Zhao, Ren et 
al. 2014). This led the authors to the assumption that LIMP-2 is transported in an M6P-
dependent pathway to lysosomes (section 4.1.1). 
 
4.1.1 Lysosomal trafficking of LIMP-2: does it need an M6P-tag? 
Data on LIMP-2 trafficking consistently showed an M6P-independent transport of LIMP-2 
and its ligand GC to the lysosome (Reczek, Schwake et al. 2007, Braulke and Bonifacino 
2009). However, a recently solved crystal structure of LIMP-2 is questioning this 
understanding: in the three-dimensional structure of Zhao et al. an M6P-residue is found 
attached to the carbohydrate chain linked to N325. Experiments using plasmon resonance and 
fluorescence lifetime imaging led the authors to claim that an M6P-dependent transport of 
LIMP-2 and GC exists by forming a trimeric complex with the M6P-receptor (MPR) (Zhao, 
Ren et al. 2014). To resolve the paradox between the previous data and the study by Zhao et. 
al, LIMP-2 trafficking was reanalysed in cell-based experimental set-ups utilising 
immunofluorescence stainings and immunoblotting. To study the impact of the putative M6P-





) as well as mouse embryonic fibroblasts (MEFs) lacking activity of the 
phosphotransferase GlcNAc-1PT (Gnptab
c.3082insC
) (Kollmann, Damme et al. 2012) were 
analysed. The presence of MPRs as well as the GlcNAc-1PT, which catalyses the formation 
of the M6P-residues, is crucial for proteins, which are trafficked to the lysosomes in an M6P-
dependent manner. Immunofluorescence stainings of LIMP-2 together with a lysosomal 
marker (LAMP-1) were performed, revealing endogenous LIMP-2 in LAMP-1 positive 
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Figure 4.1: Subcellular localisation of endogenous LIMP-2 in dependence of MPR and M6P. 





 (B)), and fibroblasts lacking GlcNAc-1PT-activity (Gnptab
c.3082insC
; (C)). A costaining with 
the lysosomal marker LAMP-1 (green) indicates colocalisation of both proteins (yellow) implying unimpaired 
cellular transport and lysosomal localisation of LIMP-2 in all three cell types. Scale bars indicate 5 μm. 
 
In another approach, immunoblots of purified liver lysosomes from wild-type, LIMP-2- and 
GlcNAc-1PT-deficient mice were stained for LIMP-2, its ligand GC as well as NPC2 and 
LAMP-1 to control for an additional lysosomal membrane protein. The expression level of 
LIMP-2 and GC were unchanged in GlcNAc-1PT-deficient (Gnptab
c.3082insC
) samples in 
comparison to wild-type lysosomes. As expected the signal for LIMP-2 as well as the GC 
protein was strongly reduced in LIMP-2 KO samples (Figure 4.2). This result indicates that 
lysosomal GC transport is facilitated by LIMP-2, in an M6P-independent manner. Confirming 
this conclusion, the transport of NPC2 was found to be MPR-mediated, displaying reduced 
protein levels in the absence of M6P residues (Gnptab
c.3082incC







Figure 4.2: Immunoblot analysis indicating MPR-
independent transport of LIMP-2 to the lysosome. 
Western blot staining of lysates from enriched liver 
lysosomes derived from wild-type (WT), LIMP-2 and 
GlcNAc-1PT-deficient (Gnptab
c.3082insC
) mice. The 
GC protein level is unchanged when M6P residues 
are absent (Gnptab
c.3082insC
). On the other hand no 
signal for NPC2 could be observed, indicating MPR 
dependence. No change was seen for the expression 






In conclusion, the results clearly reveal a lysosomal localisation of LIMP-2 together with GC 
independent of the existence of MPRs (CD and CI) or M6P residues. This supports the idea of 
an M6P-independent trafficking of LIMP-2 and its ligand GC to lysosomes (Reczek, Schwake 
et al. 2007, Braulke and Bonifacino 2009). 
 
4.1.2 An exciting finding in the three-dimensional structure of LIMP-2:  
does LIMP-2 exhibit additional functions? 
Having solved the crystal structure of the luminal domain of LIMP-2, new structure-function 
assumptions could be drawn from the three-dimensional protein model. An outstanding 
finding was the presence of a cavity traversing the entire protein (Figure 1.6), indicating a 
putative role of LIMP-2 in transport processes.  
4.1.2.1 Is LIMP-2 a transporter of cholesterol? 
Since members of the CD36 superfamily have been shown to play an important role in lipid 
transfer, a potential function of LIMP-2 in cholesterol transport was investigated (Rodrigueza, 
Thuahnai et al. 1999, Liu and Krieger 2002, Rigotti, Miettinen et al. 2003, Neculai, Schwake 
et al. 2013). To study the impact of LIMP-2 in lysosomal cholesterol transport, filipin 
stainings were performed on fixed cells. Filipin is an antibiotic able to bind to free 
(unesterified) cholesterol (Katzenstein, Spielvogel et al. 1974). A mixture of LIMP-2-
deficient and wild-type cells was incubated with filipin showing no differences in staining 
intensities (Figure 4.3). As a positive control LAMP-1/LAMP-2 double-deficient MEFs, 
known to accumulate free cholesterol in lysosomes were used (Schneede, Schmidt et al. 
2011), exhibiting stronger filipin signals when compared to wild-type cells (Figure 4.3). Wild-
type cells could be distinguished from knock-out cells using antibodies against the respective 
endogenous proteins (LIMP-2 or LAMP-2) (Figure 4.3 A). Absence of LIMP-2 did not affect 

















   
 
Figure 4.3: Filipin stainings in LIMP-2 KO and LAMP-1/2 double KO MEFs. 
A) Wild-type (WT) and knockout cells were mixed, cultured on coverslips and stained against the respective 
endogenous proteins (LIMP-2 (red) or LAMP-2 (green)) to identify wild-type cells (indicated by asterisks). 
Subsequently filipin stainings were performed. B) The quantification of the fluorescence intensity of each single 
cell was performed using ImageJ. Scale bars indicate 10 μm. No difference in staining of free cholesterol could 
be observed between LIMP-2 WT and LIMP-2-deficient cells but a more intense signal could be detected for 
LAMP-1/2 double knockout (dKO) cells validating the assay. The mean filipin intensity of single cells was 
normalised to the respective WT cell line. Statistical analysis was performed using an independent two-sided 
Student‘s t-test with * denoting p<0.05 (LIMP-2 KO: n=6-10 and LAMP-1/2 dKO: n=4-7). 
 
Having observed no effect of the LIMP-2 deficiency on endogenous cholesterol, the ability of 





enhanced lysosomal cholesterol levels. The elevated lipid storage in these cells was induced 
by treatment with a chemical or by a genetically modified background. In the first 
experimental setup HeLa cells were incubated with 0.3-3.0 μM U18666A for 24 hours, which 
blocks the exit of free cholesterol from lysosomal compartments resulting in cholesterol 
accumulation (Liscum and Faust 1989). In this case overexpression of LIMP-2 could reduce 
the lysosomal cholesterol levels, as revealed by a reduced intensity of filipin staining (Figure 
4.4). Secondly, LAMP-1/LAMP-2 deficient cells, which accumulate free cholesterol in 
lysosomes (Schneede, Schmidt et al. 2011), were transfected with LIMP-2. Cells positive for 
LIMP-2 exhibited a significant decrease in filipin signal (Figure 4.4). Finally, lysosomal 
cholesterol accumulation could also be decreased in Niemann-Pick disease type C patient 
(NPC) fibroblasts positive after overexpression of LIMP-2 (Figure 4.4). For densitometric 
analysis of the filipin signal intensities see figure 4.4 B on the next page. 
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Figure 4.4: Filipin staining in HeLa, LAMP-1/2 dKO cells and NPC fibroblasts after overexpression of 
LIMP-2. 
A) Three different cell models with lysosomal cholesterol accumulation were transfected with LIMP-2-myc. 
Upper panel: HeLa cells were treated with 0.3 mM U18666A for 24 hours, leading to impaired lysosomal 
cholesterol export and cholesterol accumulation. Cells positive for LIMP-2 (myc; green) were able to overcome 
this effect and show a significant reduction in the filipin signal. Middle panel: LAMP-1/2 dKO cells, which are 
characterised by accumulation of cholesterol, show a reduction in filipin signal after transfection of LIMP-2-myc 
(green). Lower panel: NPC patient cells transfected with LIMP-2-myc (green), show significant reduction in 
cellular cholesterol, when transfected with LIMP-2. White asterisks indicate cells positive for LIMP-2-myc. 
Scale bars indicate 10 μm.  B) Densitometric analysis of mean filipin intensities of single cells was performed in 
ImageJ. For statistical analysis an independent two-sided Student‘s t-test was applied. *; ** denote p<0.05; 0.01 
(HeLa: n=14-37; LAMP-1/2 dKO: n=6; NPC-fibroblasts: n=6-19). 
 
To control for unspecific effects, for example induced by transfection, HeLa cells were 
transfected with LAMP-1 and treated with 3.0 μM U18666A for 24 hours. Subsequent filipin 
stainings revealed no decrease in cholesterol levels in LAMP-1 positive cells in contrast to 
those after transfection of LIMP-2 (Figure 4.5). The densitometric analysis of the filipin 














Figure 4.5: Filipin stainings in HeLa cells treated 
with U18666A after overexpression of LAMP-1. 
A) HeLa cells induced with 3μM U18666A for 24 
hours were transfected with LAMP-1-myc and stained 
for the overexpressed protein (anti-myc; green). No 
effect of LAMP-1 on intracellular cholesterol levels 
was observed. The white asterisk indicates a LAMP-1 
positive cell. Scale bars indicate 10 μm. B) Statistical 
analysis of filipin signals in single cells. A two-sided 
Student‘s t-test was applied. n.s.: not significant; n=3. 
 
In the structure of LIMP-2 (Figure 4.6 A) a continuous cavity inside the protein is found, 
which is known to be large enough to accommodate free or esterified cholesterol (Neculai, 
Schwake et al. 2013). To further analyse the role of LIMP-2 being involved in direct 
cholesterol transport, a ‘tunnel mutant’ was designed. The rationale of this approach was to 
block the tunnel and perform a rescue experiment as outlined before. The two amino acids 
V415 and A379 are located within the tunnel pointing towards the inside of the cavity (see 
magnification in Figure 4.6 A). Both amino acids were substituted with a bulky tryptophan 
(V415W, A379W) aiming to block the putative channel. An endoglycosidase H digestion 
reveals post ER localisation of the mutant similar to the LIMP-2 wild-type situation, 
indicating structural integrity of the mutant protein (Figure 4.6 B). The ability of this mutant 
to transport cholesterol was verified in a similar set-up as shown above. HeLa cells were 
transfected with the LIMP-2 tunnel mutant (anti-myc; green) and treated with 3.0 μM 
U18666A for 24 hours. The subsequent filipin staining revealed no differences between 
untransfected cells and cells positive for the ‘tunnel mutant’ (Figure 4.6 C). This indicates that 
the mutant is not able to rescue the lysosomal cholesterol accumulation as observed for the 
LIMP-2 wild-type. Additionally, these results point to a direct transport of the lipid through 















Figure 4.6: Mutational analysis of the LIMP-2 tunnel mutant (V415W, A379W). 
A) The protein model reveals a cross section of the ectodomain of LIMP-2 visualising a tunnel traversing the 
whole protein. The opening to the cavity is indicated by an arrow and the helical bundle is depicted in red. 
Amino acids V415 and A379 (blue) are located at a narrow part of the cavity. Both amino acids were substituted 
to a tryptophan. A box indicates the area of magnification. Molecular illustrations were performed using UCSF 
Chimera; (PDB: 4F7B). B) Immunoblot analysis of endoglycosidase H and peptide-N-Glycosidase F (PNGaseF) 
digestions of LIMP-2 WT (myc) and LIMP-2 tunnel (myc) mutant lysates (V415W, A379W) revealing 
comparable post ER and ER-protein levels. The PNGaseF digestion was applied to control for a complete 
digestion. C) HeLa cells were transfected with the LIMP-2 wild-type and tunnel mutant (anti-myc; green) and 
treated with 3 μM U18666A for 24 hours. Cells were stained for free cholesterol with filipin showing no 
differences in staining intensities. Transfected cells are marked with white asterisks. Scale bars indicate 10 μm. 
 
This result part can be summarised as follows: firstly, no endogenous free cholesterol 
accumulation could be observed in LIMP-2-deficient MEFs. Secondly, overexpression of the 
LIMP-2 wild-type protein was able to rescue lipid storage when lysosomes were loaded with 
cholesterol. Thirdly, there are indications that the tunnel traversing the entire LIMP-2 protein 





4.1.3 A closer look: where exactly is the GC-binding site on LIMP-2? 
An outstanding finding in the crystal structure of LIMP-2 (PDB: 4F7B) was the identification 
of a distinct and apical ‘helical bundle’ consisting of helix 4, 5 and 7. This triple-helical fold 
is found opposite of the transmembrane domains. Finally, especially helix 5 and 7 seem to be 




Figure 4.7: Crystal structure of LIMP-2 with an exposed helical bundle. 
The crystal structure of LIMP-2 (PDB: 4F7B) (Neculai, Schwake et al. 2013) presented in a ribbon view with α-
helical structures shown in red, β-sheets highlighted in blue. An enlargement of the helical bundle shows the 
orientation of helix 4, 5 and 7 indicating helix 5 and 7 being most surface exposed. The transmembrane domains 
of LIMP-2 (green) and the lysosomal membrane were modelled into the crystal structure by using UCSF 
Chimera. 
 
4.1.3.1 Characterisation of the LIMP-2-GC binding mutants 
Since helix 5 and 7 of the helical bundle in LIMP-2 were suspected to be important for the 
interaction with GC, site-directed mutagenesis was applied. Subsequently the mutants were 
characterised regarding their subcellular localisation and GC-binding properties. Single point 
mutations were introduced into helix 5 and 7 of the helical bundle of LIMP-2. To disturb the 
hydrophobic character of the proposed GC-binding site, hydrophobic amino acids were 
substituted by negatively charged aspartates (D) (Helix 5: L155D, I156D, M159D, L160D, 
A162D, Y163D and helix 7: L184D, L187D, F191D, see also Figure 4.10 A, B). The protein 





immunofluorescence microscopy (Figure 4.8) and endoglycosidase H digestion (Figure 4.9, 
see also 3.2.3.3). For immunofluorescence stainings Cos7 cells were transfected with myc-
tagged LIMP-2 mutants. The cells were labelled with an antibody against myc (red) and for 
the lysosomal membrane protein LAMP-2 serving as a lysosomal marker. All analysed 
LIMP-2 constructs with mutations in helix 5 and helix 7 co-localised with endogenous 
LAMP, confirming their correct lysosomal localisation (Figure 4.8). In addition, 
endoglycosidase H and peptide-N-Glycosidase F (PNGaseF) digestions were performed after 
transfection of the LIMP-2 mutants into Cos7 cells. Comparable to the LIMP-2 wild-type, all 
helix 5 mutants (L155D, I156D, M159D, L160D, Y163D) showed partial resistance to the 
endoglycosidase H (Figure 4.9). Sensitivity to endoglycosidase H indicates ER localisation of 
proteins. Since insensitive to the enzyme suggests a post ER localisation, it can be concluded 
that the helix 5 LIMP-2 mutants have left the ER comparable to wild-type LIMP-2 (Figure 
4.9). The helix 7 mutants (I184D, L187D, F191D) were also found in post ER compartments 
–although to a lesser extent as compared to the wild-type situation (Figure 4.9). A PNGaseF 
digestion was included to control for a complete removal of carbohydrates, resulting in 
migration of the backbone of the protein at ~58 kDa in electrophoresis.  
 
 
Figure 4.8: Subcellular localisation study of LIMP-2-GC binding mutants. 
Cos7 cells were transfected with the indicated LIMP-2-myc construct (wild-type (WT) or point mutants in helix 
5 and 7) and stained against anti-myc (488 nm; green). To validate cellular localisation of the mutants a co-
staining with the lysosomal marker LAMP-2 (495 nm; red) was performed. An overlay of both colour channels 
revealed co-localisation (yellow) of all mutants similar to the expressed wild-type indicating lysosomal 







Figure 4.9: Endoglycosidase H and PNGaseF digestion of LIMP-2 mutants. 
Analysis of LIMP-2 mutants by endoglycosylation H and PNGaseF digestion after overexpression in Cos7 cells 
verifying their subcellular localisation. For the following immunoblot analysis an anti-myc antibody was utilised. 
Protein fractions resistant or partly resistant to the endoglycosylation H enzyme indicate post ER localisation 
(~65-90 kDa), whereas fully deglycosylated proteins suggests localisation in the ER (~58 kDa).  
 
4.1.3.2 GC-binding properties of LIMP-2 mutants  
Since LIMP-2 is the described transport receptor of the lysosomal enzyme GC from the ER to 
the lysosome (Reczek, Schwake et al. 2007), the interaction of the LIMP-2 mutants with the 
lysosomal enzyme was assessed. Therefore co-immunoprecipitation (co-IP) studies and GC-
activity assays in LIMP-2-deficient cells transfected with the indicated LIMP-2 point-mutants 
were performed (Figure 4.10).  
For the direct interaction studies the LIMP-2 constructs were overexpressed in Cos7 cells and 
precipitated utilising an anti-myc antibody. Expression of each construct was validated by 
immunoblot before co-IP was performed. Only LIMP-2 wild-type and the control mutant 
D400K, which is not located in the predicted interaction site of LIMP-2 are able to bind and 
precipitate GC (Figure 4.10 D). None of the other mutants in helix 5 and 7 could co-
precipitate GC. This suggests a complete loss of GC-interaction highlighting the important 
role for both helices in GC-binding (Figure 4.10). 
Taking advantage of LIMP-2 deficient cells, the capability of the artificially engineered 
LIMP-2 mutants to bind and transport GC was assessed by measuring the enzyme activity. 
In the case of the expressed LIMP-2 wild-type a rescue effect could be observed with almost 
full recovery of GC activity. This is due to proper interaction of both proteins and transport of 
the enzyme to the lysosome, where optimal enzymatic conditions are present. Consequently, 
only mutants still able to bind and transport GC to the lysosome will show GC activity above 
background. A mutant localised outside the suspected interaction site (D400K; Figure 4.10 B) 
showed GC activity comparable to the wild-type (Figure 4.10 E). GC activities in the low 





















Figure 4.10: Structural overview of LIMP-2 mutants and interaction studies to determine the binding site 
of LIMP-2 to GC. 
A) The human and murine amino acid sequence of the LIMP-2 binding region with indication of selected point 
mutations in helix 5 and 7. B) The three dimensional protein structure of LIMP-2 shows mutated amino acids 
and indicates their surface exposure. The helical bundle is shown in red (PDB: 4F7B; designed in UCSF 
Chimera). C) For direct interaction studies of LIMP-2 to GC, murine LIMP-2 constructs were expressed in Cos7 
cells and binding abilities of the mutants were assessed by co-immunoprecipitation studies. Immunoblots stained 
for LIMP-2 (anti-myc) show precipitated LIMP-2. Below each LIMP-2 blot the respective immunoblot of the 
co-IP (anti-GC) is presented. Interaction of the enzyme could only be observed for wild-type LIMP-2 and the 
control mutant D400K. Asterisks denote the antibody heavy chains. D) Densitometry of the GC co-IP. Data are 
presented as bound GC in relation to precipitated LIMP-2, normalised to LIMP-2 wild-type (n=3). E) GC 
activity after transfection of individual LIMP-2 point mutants in LIMP-2 deficient MEFs. Only LIMP-2 
constructs, which are still able to bind and transport GC to the lysosome, are able to rescue GC activity similar to 
the LIMP-2 wild-type. The GC background activity was deducted from the determined GC activity and values 
were normalised to LIMP-2 wild-type (n=4-7). A one-way ANOVA with a subsequent Tukey-Kramer posthoc 
test was utilised for all statistical tests. *; **; *** denote p<0.05; 0.01; 0.001 comparing all mutants to cells 






In conclusion, the point mutants in helix 5 and 7 of LIMP-2 exhibit a comparable lysosomal 
localisation as observed for the LIMP-2 wild-type. In direct interaction studies the inability of 
the mutants to precipitate GC or rescue GC activity in GC-deficient cells emphasises the 
important role of helix 5 and 7 in GC binding.  
 
4.2 Is the helical bundle of LIMP-2 sufficient to mediate interaction with 
GC? 
The GC binding site in the LIMP-2 protein could be narrowed down to the helical bundle 
especially involving helix 5 and 7. These two helices seem to be most likely involved in the 
interaction with GC. To test this hypothesis, peptides consisting of each single helix were 
designed and synthesised by JPT Peptide Technologies GmbH (Berlin, Germany). Each 
peptide consists of 23-24 amino acids resembling either helix 5 (amino acid 152-175) or helix 
7 (amino acid 172-194) of the helical bundle of LIMP-2 (Figure 4.7; Table 4.1). Previously, 
the substitution of three hydrophobic amino acids within helix 5 (I155, I156 and L160) to 
highly charged aspartic acid (D) has been shown to disable the interaction of LIMP-2 with GC 
(Blanz, Groth et al. 2010). Thus, a control peptide was designed in the same way with a triple 
D motif (3xD) included into the helix 5 amino acid sequence. A biotin-tag was attached n-
terminally to all peptides by a linker (TTDS = 1,13-diamino-4,7,10-trioxatridecan-succinic 
acid; consisting of 19 atom bonds). The c-terminus was left unprotected (negatively charged). 
  





Helix 5 Biotin-Ttds-LREIIEAMLKAYQQKLFVTHTVDE (24 aa) 
3xD Helix 5 Biotin-Ttds-LREDDEAMDKAYQQKLFVTHTVDE (24 aa) 
Helix 7 Biotin-Ttds- TVDELLWGYKDEILSLIHVFRPD (23 aa) 
 
The structural properties of the synthetic peptides were analysed by circular dichroism (CD) 
spectroscopy. For determination of the secondary structure the ‘far-UV’ spectral region 
(λ=200-250 nm) was used. Each secondary structure (α-helix, β-sheet or random coil) gives 
rise to a characteristic shape and magnitude of CD spectrum. The helix 5 as well as the helix 7 
peptide exhibited a clear α-helical folding (Figure 4.11). In comparison the CD spectrum of 
the control peptide (3xD helix 5) did not reveal a helical structure anymore (Figure 4.11 A). 
This indicates that the residues I155, I156 and L160 are important for helix 5 to form an α-





found in the crystal structure can be recapitulated in the form of biotin-tagged 23-24 amino 








Figure 4.11: Circular dichroism (CD) spectroscopy of the LIMP-2-derived peptides. 
CD spectroscopy in the "far-UV" spectral region (200-250 nm) was utilised to determine the secondary structure 
of the LIMP-2-derived peptides (helix 5, 3xD helix 5 and helix 7). The spectra of the helix 5 (A; red spectrum) 
and helix 7 (B) exhibit a helical folding. In comparison the 3xD helix 5 peptide loses the helical structure and 
indicates a random coil folding (A; black spectrum). The CD-measurements were performed in 50 mM sodium-
phosphate buffer and 150 mM NaCl at pH7 and 20°C and are shown in ellipticity (θ) as the legacy of 
polarimetry. 
 
To determine if helix 5 and helix 7 directly interact with GC, we used purified GC (Cerezyme 
®) in an in vitro binding assay. GC was co-incubated with biotin-bound LIMP-2 peptides, and 
precipitated with agarose-bound streptavidin (Figure 4.12 A). This revealed a preferential 










Figure 4.12: Pulldown experiment using LIMP-2 peptides and recombinant GC. 
A) Principle of the in vitro pulldown of recombinant GC: peptides were incubated with enzyme and then 
subjected to precipitation using streptavidin coupled agarose beads. Binding of GC to peptide was validated by 
subjecting loaded and bound fraction to SDS-PAGE. Proteins were visualised by coomassie blue staining 
(recombinant GC: ~65 kDa) (B). Binding efficiencies of each peptide were densitometrically evaluated (ImageJ) 
and normalised to GC bound to buffer only. Precipitation of GC with the helix 5 peptide is significantly 
increased compared to the buffer control (C). A One-Way ANOVA with a subsequent Tukey-Kramer posthoc 
test was utilised for statistical analysis. ** denotes p< 0.01; n=3-5. 
 
To control for the binding specificity of the LIMP-2-derived peptides, interactions to 





were assessed. A precipitation experiment revealed no specific interaction between the LIMP-







Figure 4.13: Specificity control: precipitation experiment of recombinant LAMAN and BSA. 
A) Loaded and bound fractions of the peptide pulldown from recombinant LAMAN (~ 130 kDa) and bovine 
serum albumin (BSA) (~ 61 kDa). The samples were subjected to SDS-PAGE and visualised by coomassie blue 
staining. B) Densitometric analysis (ImageJ) of LAMAN and BSA fractions bound to helix 5 were normalised to 
protein bound to the peptide after incubation with buffer only (n=2). 
 
Peptide pulldown assays were also performed directly from endogenous cellular GC (Cos7 
cells). Following the same protocol as for the in vitro precipitation (see above), helix 5 
peptide and buffer only were incubated with cell lysates and subjected to precipitation with 
streptavidin linked agarose beads (Figure 4.14 A). The loading after cell lysis and the bound 
fractions were separated on an SDS-PAGE. The GC protein was visualised after immunoblot 
analysis, demonstrating successful binding of the endogenous enzyme to the synthetic helix 5 









Figure 4.14: Pulldown experiment revealing endogenous GC-precipitation from Cos7 cellular lysate. 
A) Sketch of the used precipitation assay: Pulldown of endogenous GC from cell lysate after incubation with 
biotin-tagged helix 5 peptide. Binding of enzyme to the peptide was validated by subjecting loaded and bound 
fractions to SDS-PAGE followed by western-blotting utilising an antibody against human GC (B). Binding 
efficiencies of endogenous GC to helix 5 peptide was analysed by densitometry indicating a significant pulldown 
of enzyme with the helix 5 peptide (C). An independent two-sided t-test was utilized for statistical analysis. *** 
denotes p<0.001; n=3-5. 
 
These results indicate that helix 5 alone is sufficient to interact with recombinant GC as well 





4.2.1 Do LIMP-2-derived peptides also modify the function of GC?  
Having shown that the helix 5 peptide can be used to precipitate recombinant and cellular GC 
it was interesting to analyse if the LIMP-2-derived peptides additionally affecting the function 
of GC. To determine if these peptides are able to modify enzymatic activity, recombinant GC 
was incubated with 10 fold excess of peptides. GC activity was assessed using an artificial 
substrate. After incubation with the helix 5 peptide a fourfold increase in GC activity was 
found. In comparison the buffer control and the non-binding 3xD control peptide, only a 2-3 
fold enhancement of GC activity could be observed when the helix 7 peptide was co-
incubated with GC (Figure 4.15 A). In addition a random helical control peptide consisting of 
24 amino acids was applied to control for the specificity of this assay. This peptide was not 
able to increase GC activity like observed for the helix 5 peptide (Figure 4.15 A). As a further 
negative control recombinant lysosomal acid α-mannosidase (LAMAN) was subjected to 
incubation with LIMP-2 peptides. No change in GC activity was detected (Figure 4.15 B). To 
determine if LIMP-2 peptides also enhance the activity of endogenous GC enzyme, the effect 
of the peptides on N2a lysate was assessed through an activity assay. For this experiment the 
N2a cell lysate was incubated with 20 nmol of helix 5 and 3xD control peptide and 
subsequently subjected to a GC activity assay. As shown in Figure 4.15 C the helix 5 peptide 
was able to increase endogenous GC activity ~1.6 fold compared to the buffer and the non-











Figure 4.15: Activity assays of recombinant and endogenous enzymes after incubation with LIMP-2-
derived peptides. 
Activity assay of recombinant GC (A) and LAMAN (B). Both enzymes were incubated with 10 fold molar 
excess of the indicated peptide. Whereas the helix 5 peptide was able to increase GC activity > 4 fold, no change 
in LAMAN activity could be observed after incubation with the peptides (GC: n=2-4; LAMAN: n=2). C) 
Activity assay of endogenous GC. N2a cell lysate was incubated with helix 5 and 3xD control peptides. The 
helix 5 peptide was able to increase GC activity of the enzyme derived from the N2a cell lysate ~1.6 fold (n=2-
9). All enzyme activities were normalised (norm.) and compared to buffer only. A one-way ANOVA with a 
subsequent Tukey-Kramer posthoc test was utilised for statistical analysis. *, ** denote p< 0.05, 0.01. 
 
In an additional experiment the effect of the complete LIMP-2 ectodomain -which includes 





Recombinant GC was incubated with increasing molarities of the LIMP-2 ectodomain as well 
as the helix 5 peptide and as a negative control bovine serum albumin. The incubation with 
the recombinant LIMP-2 led to an increased GC activity immediately after mixing both 
recombinant proteins (same molarities; 1x mol; Figure 4.16 A).  The helix 5 peptide starts to 
enhance enzyme activity from a 5 fold molar excess of the peptide compared to GC (5x mol, 
Figure 4.16 A). After adding a 10 molar excess of the peptide or the LIMP-2 ectodomain (10x 
mol) the augmentation of GC activity was most efficient (Figure 4.16 A). In contrast, no 
activation of LAMAN was detected after incubation with the LIMP-2 ectodomain or the helix 









Figure 4.16: Effect of the recombinant LIMP-2 ectodomain and the helix 5 peptide on GC activity. 
Activity assays of recombinant GC (A) and LAMAN (B). Recombinant GC was incubated with different 
molarities (1x -10x) of helix 5 peptide or the recombinant luminal domain of LIMP-2 (n=2-5). GC activities 
were normalised and statistical analyses * and ** denote p<0.05 and 0.01 referring to a comparison to the 0 
value [0 x mol] of the respective sample. For statistical analysis a one-way ANOVA with a subsequent Tukey-
Kramer posthoc test was performed. 
 
The effect of peptide binding on GC protein stability was also assessed by measuring GC 
activity at increasing temperatures (20-60°C) at pH7. Therefore a 10 fold molar excess of the 
peptides was applied and GC activity was measured every 10°C. As shown above (Figure 
4.15) the helix 5 peptide is able to increase GC activity ~4 fold after incubation at room 
temperature. When the temperature was increased up to 40°C, the enhancement of GC activity 
remained stable compared to buffer and 3xD control. Helix 7 peptide alone was able to 
increase GC activity slightly (Figure 4.17). When reaching > 40°C the enzyme was denatured, 
resulting in a loss of activity. Sigmoidal dose-response curves were fitted to the graphs (see 
small inlay, Figure 4.17) and inflexion points of curves are presented as LogEC50 underneath 
the diagram. LogEC50 deciphers the temperature of half maximal GC activity and describes 










Figure 4.17: Impact of LIMP-2 peptides on protein stability and function. 
Protein stability assay: GC was incubated with buffer only, helix 5, 3xD helix 5 and helix 7 peptide and the 
temperature was increased in 10°C steps from 20-60°C. Samples were subjected to GC activity assays. 
Sigmoidal response curves were fitted (see inlay at top right corner) and LogEC50 values are shown in the table 
underneath. A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was used to describe increase in 
GC activity after incubation with helix 5 peptide compared to buffer. * denotes p<0.05; n=3. 
 
Since the detectable effect of the helix 5 peptide on GC stability was minor in the assay 
above, another approach was used to assess the consequences of peptide binding to GC. A 
mixture of enzyme and peptide was incubated at 37°C and pH7. The activity of the enzyme 
was measured over a time period of 270 hours (Figure 4.18). The GC activity indicates that 
the helix 5 peptide is able to increase the activity of the enzyme at early time points (0-40 
hours). After ~40 hours of incubation at 37°C a drop in GC activity was detected for all 
samples. However, when compared to the buffer and non-binding 3xD helix 5 peptide the 
decrease in enzyme activity was not as strong in the sample incubated with helix 5. 
Furthermore, the GC activity stays constant from ~80 hours on; whereas the control samples 
(buffer and 3xD helix 5 peptide) showed complete loss of activity after 60 hours of incubation 
at 37°C. The half maximal enzyme activity (LogEC50) for GC incubated with buffer only and 
3xD control peptide were reached for both samples after 24 hours, whereas the time point for 
the helix 5 incubated sample was twice as high (~48 hours). This indicates the ability of the 
interacting LIMP-2-derived peptide (helix 5) to stabilise GC. The helix 5 peptide can increase 








 buffer Helix 5 3xD 
LogEC50 23.9 47.6 24.3 
 
Figure 4.18: Stabilisation assay of GC after incubation at 37°C. 
GC activity was measured after incubation of the enzyme with buffer, helix 5 and the 3xD helix 5 control 
peptide at 37°C for 270 hours. Incubation with helix 5 peptide led to stabilisation of the enzyme indicated by a 
constantly higher activity of the enzyme compared to buffer and 3xD control peptide. Response curves were 
fitted with LogEC50 values indicating half maximal enzyme activity (values are depicted in the table underneath 
the graph). A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was used to describe increase in 
GC activity after incubation with the helix 5 peptide compared to buffer and the 3xD peptide. *, **, *** denote 
p<0.05, 0.01, 0.001; n=2-3. 
 
Having observed that the helix 5 peptide specifically interacts with GC, it was of interest to 
analyse if the complete α-helix is required for this interaction or if a small fragment of the 
helix 5 is sufficient to mediate binding to GC. The 24 amino acid long helix 5 peptide was 
fragmented into four small peptides consisting of 5-7 amino acids. Each small peptide 
contains at least two hydrophobic amino acids (Table 4.2).  
 





Helix 5 full sequence 152-LREIIEA-MLKAYQ-QKLFV-THTVDE-175 
 
Helix 5, Peptide 1 - LREIIEA - (7 aa) 
Helix 5, Peptide 2 - MLKAYQ - (6 aa) 
Helix 5, Peptide 3 - QKLF - (5 aa) 
Helix 5, Peptide 4 - THTVDE - (6 aa) 
 
To evaluate the interaction of the small unlabeled peptides 1-4 with GC, a GC activity assay 
was applied. None of the fragmented peptides could affect the activity of GC after co-
incubation with recombinant GC. It is likely, that the whole helical structure of helix 5 is 







Figure 4.19: GC activity assay after incubation with fragmented peptides derived from the helix 5 
sequence. 
Activity assay of recombinant GC incubated with a 10 fold molar excess of the indicated helices. Whereas 
helix 5 is able to increase GC activity > 4 fold, no statistically significant effects could be observed for the 
smaller peptides 1-4. Enzyme activity was normalised (norm.) to the buffer-incubated sample. A One-Way 
ANOVA with a subsequent Tukey-Kramer posthoc test was utilised for statistical analysis. *** denotes p< 0.001 
comparing the helix 5-incubated sample with the buffer the buffer control; n=4-5. 
 
4.2.1.1 Can the LIMP-2-derived helix 5 peptide be exploited to therapeutically increase 
GC activity? 
As shown above especially helix 5 is able to efficiently enhance the enzymatic function of 
GC. Thus, the peptide might be considered as a therapeutic tool to increase GC activity in 
cells exhibiting impaired enzyme function. To test the therapeutic potential of helix 5, it was 
determined if this peptide could be internalised by cells and subsequently reach the lysosomal 
compartment. This was tested by incubating murine macrophages (J774E) with 50 μM of the 
helix 5 peptide. Endocytic uptake of the peptide was visualised by staining cells with a 
fluorescently labelled biotin antibody (488 nm; green) and co-staining for endogenous GC 
(anti-murine GC; red) revealing co-localisation (Figure 4.20 A). Furthermore, the effect of the 








Figure 4.20: Uptake and effect of helix 5 peptide in J774E mouse macrophages. 
A) Immunofluorescence stainings of J774E macrophages incubated with 50 μM helix 5 peptide. Biotin-labelled 
helix 5 peptide (anti-biotin; 488 nm, green), which was taken up by the cells show co-localisation with 
endogenous GC (anti-murine GC; red) confirming lysosomal localisation of the peptide in cells. Scale bars 
indicate 10 μm. B) GC activity assay showing a ~1.3 fold increase in enzyme activity after uptake of 50 μM 
helix 5 peptide. A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was used for statistical 





To further enhance the cellular uptake of the helix 5 peptide, recombinant GC (0.2 nM) was 
pre-incubated with the peptide (2 nM) and then added to the media of GC-deficient MEFs 
cells. Uptake of the enzyme pre-incubated with the respective peptides was visualised by 
immunoblotting (Figure 4.21 A). The uptake rate of the enzyme/peptide mixtures was similar 
for the different peptides tested (helix 5, 3xD helix 5 and helix 7) (Figure 4.21). However, the 
cellular GC activity was significantly increased when the helix 5 peptide was applied (Figure 
4.21 B). The advantage of the pre-incubation of recombinant enzyme is that a much smaller 
concentration (1 μM) of peptide is necessary to improve enzyme activity (compare with 
Figure 4.20).  
In summary, these results indicate that a positive effect of the helix 5 peptide on GC function 










Figure 4.21: Uptake and effect of GC pre-incubated with LIMP-2 peptides into GC KO MEFs. 
A) Immunoblot analysis of uptake of recombinant enzyme pre-incubated with the indicated peptide visualised by 
an anti-mGC antibody. A densitometric analysis reveals an equal uptake of GC independent of the peptide. 
Subsequently GC activity of cell lysate was measured showing a significant increase after uptake of the GC-
helix 5 peptide mixture compared to buffer only (B). A one-way ANOVA with a subsequent Tukey-Kramer 
posthoc test was used for statistical analysis. *, ** denotes p< 0.05, 0.01; n=4. 
 
4.2.2 What causes the positive effect of LIMP-2 peptides on GC function? 
To explain the positive effect of the LIMP-2 peptide helix 5 on GC function, analyses to 
understand potential structural changes of GC protein after peptide binding were performed. 
This included studies evaluating the secondary as well as quaternary structure of the protein 
after incubation with the LIMP-2-derived peptides by CD-spectroscopy and dynamic light 
scattering (DLS).  
4.2.2.1 CD-spectroscopy: changes in secondary structure of GC after helix 5 binding? 
To analyse conformational changes in the secondary structure of GC in order to control for a 





stability assay was performed. In this assay, recombinant GC was incubated with buffer, with 
helix 5 or with 3xD helix 5 peptides, subjected to ascending temperatures (20-90°C). Starting 
from ~40°C the protein began to denature (Figure 4.22 B). The CD-spectrum (λ=250-200 nm) 
of GC after heating to 90°C revealed a loss of the secondary structure of the protein (Figure 
4.22 A). To follow the melting/denaturing of the GC protein when it is subjected to increasing 
temperatures, CD-spectra at 220 nm were recorded. The values measured at 220 nm were 
plotted against the temperature resulting in a melting curve of the GC protein. These graphs 
were fitted to a sigmoidal dose-response curve (Figure 4.22 B; red graphs). The inflexion 
points in the curves are shown as LogEC50 in the table underneath the graph. These values 
decipher the temperature where half of the GC protein was still properly folded. For the 
different GC samples similar LogEC50 values could be observed (Figure 4.22 A). This 
indicates that the binding of the helix 5 peptide to GC does not lead to a permanent change in 




4.2.2.2 Dynamic light scattering: changes in quaternary structure of GC after helix 5 
binding? 
To investigate potential changes in the quaternary structure of GC after incubation with the 
helix 5 peptide (e.g. on the level of multimerisation of the protein), dynamic light scattering 
(DLS) experiments were performed. As shown in Figure 4.23 no difference in the molecule 








Figure 4.22: Thermal protein stability: CD-analysis of GC after incubation with helix 5 peptide. 
A) CD-spectrum of GC protein before and after heating, indicating the denaturation of the protein after exposing 
the protein to heat (90°C; red graph). The arrow indicates a wavelength of 220 nm, at which the following 
measurements were performed to track the denaturation of the protein. B) GC incubated with buffer, helix 5 and 
3xD peptide subjected to temperatures from 20-90°C. CD-spectroscopic analyses were performed at 220 nm. 
Sigmoidal curves (red) were fitted to the graphs and the LogEC50 values could be determined and used as a 
measurement of the stability of secondary protein structure. The CD-measurements were performed in 50 mM 





conditions the mean effective diameter of GC molecules remained in the same range (~8 nm). 
It can be concluded, that the incubation of the enzyme with the interacting helix 5 peptide did 







Figure 4.23: Dynamic light scattering (DLS) of GC in the presence or absence of the helix 5 peptide.  
DLS analysis of the quaternary structure of GC after adding buffer (A) and helix 5 peptide (B), respectively. The 
upper graph presents the incidence (time in seconds) of GC molecules passing and staying in the laser beam. 
Analysis of this data, radius of particles (GC) can be plotted (lower graph) and mean radius distribution was 
calculated (middle graph), revealing a size of ~8 nm per particle. No obvious difference in the size of GC 
molecules could be observed after incubation with the helix 5 peptide. The DLS-measurements were performed 
in 50 mM sodium-phosphate buffer and 150 mM NaCl at pH7. 
 
In summary, the molecular mechanism of the positive effect of the LIMP-2 peptide (helix 5) 
on GC function still remains elusive. With the applied assays no changes in the secondary 
structure of GC protein or multimerisation could be observed. 
4.3 Structural analyses of GC: Where does LIMP-2 bind? 
Since the LIMP-2 interaction site on the GC enzyme is not known, co-crystallisation 
experiments with recombinant GC and the LIMP-2 helix 5 peptide were performed. Protein 
and peptide were mixed (10 fold molar excess of the peptide) and incubated on crystallisation 
plates. The protein solutions were covered with oil (details of crystallisation procedure see 
material and methods paragraph 3.2.2.8). First crystals with a diameter of around 20 μm could 
be observed after a few days. Further incubation resulted in a size of up to 50 μm in the 
following days. Blue Izit® staining (Hampton research, CA, USA) confirmed that grown 
crystals were proteins (Figure 4.24 B). Single crystals were then frozen in liquid nitrogen and 





the beam line please see material and methods Table 3.11) with a beneficial diffraction and a 
resolution of ~2 Å. Further parameters including the length (sides: a, b, c) and the angles (α, 
β, μ) of the unit cell of the crystal are depicted in table 4.3. Overlays of electron densities of 
GC only and GC incubated with helix 5 peptide revealed exact conformity, indicating that 
helix 5 peptide was not present in the analysed crystals. 
  
Table 4.3: X-ray parameters of the protein crystals. 





a: 111.26 alpha: 90 
b: 286.03 beta: 90 






Figure 4.24: Crystallisation approach showing shape and properties of GC crystals. 
A) The shape of crystals raised under oil at pH 5 displaying a size of ~50 µm. The space group of crystals was 
C2221. For further parameters of the crystals see table 4.3. B) A blue Izit ® staining of ‘young’ crystals confirms 
protein content of the crystals. 
 
Since a co-crystallisation approach was not successful to determine the LIMP-2 binding site 
on GC, further structural and molecular studies were applied to narrow down the interaction 
site on GC.  
For the design of the following experiments the crystal structures of the glycosylated GC 
protein (Cerezyme ®; PDB: 2J25) and the luminal domain of LIMP-2 (PDB: 4F7B) were 
studied. On the basis of this structural information, experimental approaches as well as site-
directed mutagenesis experiments were designed.  
By surface charge analyses hydrophobic interfaces, indicated by little to no surface charge 
(white colour; Figure 4.25), could be found on LIMP-2 and GC. In the LIMP-2 protein this 
hydrophobic patch is exactly localised to the exposed helical bundle - the GC interaction site, 





protein could be located in a helical bundle as well (helix 1: T86-S110; helix 2: P150-A168). 
This helical motif is found on the opposite side of the catalytic pocket. The crystal structure of 
GC (Cerezyme ®; PDB: 2J25) exhibits three sugar residues bound to asparagines via N-
glycosylation, showing no interference with the potential hydrophobic interaction site (Figure 
4.25).  
 
Considering the structural surface analysis, GC point mutants in the helical bundle, likely 
involved in protein-protein interaction, were designed (Figure 4.26, Table 4.4). Surface 
resident hydrophobic amino acids (leucines) were substituted by highly charged amino acids 
(glutamic acid; L91E, L94E, L156E). A mutant on the other side of protein (R211E) was used 
as a negative control. The chosen R211E mutation is in close proximity to the patient mutant 
F213I (Kawame and Eto 1991, He, Grace et al. 1992) but is exposed to the surface of the 
protein and thus could have a direct impact in protein-protein interaction (Figure 4.26 A, C). 
Furthermore, Gaucher disease clinical mutants were designed and analysed as well (I161S, 
P159L, F213E and N188S) (Eyal, Firon et al. 1991, Cormand, Harboe et al. 1998, Demina 
and Beutler 1998, Hodanova, Hrebicek et al. 1999, Filocamo, Mazzotti et al. 2004). From the 
two patient mutations located in the predicted binding region of GC (I161S, P159L) only one 
amino acid was found to be exposed to the outside of the protein (P159L) and thus might be 
 
 
Figure 4.25: Surface charge analysis of LIMP-2 and GC protein. 
Surface charge of the LIMP-2 structure (PDB: 4F7B) and the GC protein (PDB: 2J25) with hydrophobic patches 
(Leu, Ala, Val, Ile, Met and Phe) indicated in white. Negatively charged amino acids are shown in red, whereas 
positively charged amino acids are shown in blue. Additionally the GC structure contains three sugar residues 
indicated in yellow. On the right hand side the clusters of hydrophobic amino acid are indicated in red suspecting 





directly involved in LIMP-2 binding (Figure 4.26 D, E). Two clinical mutants located on the 
opposite side of the predicted binding area were established as well (N188S and F213I). Only 
the N188 mutant exhibits protein surface exposure (Figure 4.26 D, E) (Kawame and Eto 1991, 
He, Grace et al. 1992, Kim, Liou et al. 1996, Park, Orvisky et al. 2003, Montfort, Chabas et 
al. 2004). An overview of all inserted GC point mutations can be found in table 4.4. 
To validate the integrity of the mutant proteins and to exclude indirect changes of the protein 
structure on binding properties by the inserted point mutations, each mutant was analysed for 
its enzymatic activity (Figure 4.26 F, G). N2a cells were transfected with the individual GC 
mutants. Since N2a cells express endogenous GC, the activity of mock transfected cells 
indicates the background/endogenous GC activity of the cell lysates.  
All analysed mutants reveal activity above background suggesting their structural integrity. 
They were further subjected to direct LIMP-2 interaction studies and cellular localisation 
analyses. 
 
Table 4.4: Overview of the introduced GC point mutations. 











R211E opposite of the proposed interaction site 
P159L  































Figure 4.26: Structural and functional characterisation of GC mutants analysed in this study.  
A) A model of the interaction of LIMP-2 and GC. Helical bundles in both proteins as potential interaction sites 
are shown in red and the introduced point mutants of GC to demonstrate the GC-LIMP-2-interaction are 
indicated. Hydrophobic amino acids (leucins) were substituted to highly charged glutamic acids. B) 
Magnification and surface view of the GC protein reveals exposed localisation of the analysed amino acids 
(cyan: L91E, yellow: L94E, blue: L156E). C) A control mutant R211E (orange) was introduced on the other side 
of the protein. D) Human Gaucher disease mutants located in the potential helical interaction site: P159L 
(turquoise) and I161S (yellow). Also control patient mutants outside of the predicted interaction site were 
designed: N188S (surface exposed; orange) and F213E (no surface exposure; orange). E) Surface view exhibits 
exposed localisation of the mutated amino acids P159 and N188S. F) ‘Glutamic acid’ mutants shown in A and 
(G) Gaucher patient mutants shown in D were subjected to enzyme activity assays after overexpression in N2a 
cells. The background/endogenous GC activity was subtracted before the enzyme activity was normalised to GC 





4.3.1 Binding properties of GC mutants towards LIMP-2 
The ‘Glutamic acid mutants’ (in the potential binding site: L91E, L94E, L156E and control 
mutant on the opposite protein side: R211E) were analysed to determine their binding affinity 
towards LIMP-2. A co-immunoprecipitation study followed by subsequent immunoblot 
analysis was performed. The GC mutants were overexpressed in N2a cells. Endogenous 
LIMP-2 was precipitated using a monoclonal antibody against LIMP-2. The amount of GC 
protein bound to LIMP-2 indicates the ability of each GC mutant to interact with LIMP-2. 
When compared to GC wild-type and the control mutant R211E, GC point mutants within the 










Figure 4.27: Co-Immunoprecipitation studies of GC ‘glutamic acid mutants’. 
A) Co-immunoprecipitation studies in N2a cells after transfection of the indicated GC. For IP an anti-LIMP-2 
antibody was used and interaction to GC could be determined using an antibody specific for the human 
(transfected) variant of GC (anti-hGC). * indicates a signal of the antibody used for IP (AB ctrl: antibody 
control). The dotted lines indicate splicing within the same blot. B) Quantification of the co-IP study (n=2-10). 
GC mutants located in the predicted interaction site are shown in red. Bound GC was normalised to precipitated 
LIMP-2 (IP). GC mutants within the predicted interaction site (L91E, L94E, L156E) show impaired binding to 
LIMP-2. Control mutant R211E has a similar interaction towards LIMP-2 as compared to wild-type (WT) GC. A 
one-way ANOVA with a subsequent Tukey-Kramer posthoc test was utilised for statistical analyses. *; ** 
denote p<0.05; 0.01 with comparison of the mutants to cells transfected with GC wild-type. 
 
 
A similar type of experiment was performed for the Gaucher patient mutants (P159L and 
I161S) including the clinical control mutants, which are located on the opposite protein side 
(N188S, F213I). In this set-up, all analysed mutants showed a reduced binding towards 
LIMP-2. The two GC mutants located within the predicted interaction site (P159L and I161S) 
were the most affected revealing a binding capacity of less than 10 % compared to the wild-















Figure 4.28: Co-Immunoprecipitation study of Gaucher patient mutants. 
A) Co-immunoprecipitation study of GC patient mutants transfected into N2a cells. For IP an anti-LIMP-2 
antibody was used and interaction to GC was determined using an antibody specific for the human 
(overexpressed) variant of GC (anti-hGC). * indicating a band of the antibody used for IP (AB ctrl: antibody 
control). The dotted lines indicate splicing within the same blot. B) Densitometry of the co-IP studies. The signal 
of co-precipitated GC was normalised to the IP of LIMP-2 (n=2-9). Amino acids located within the predicted 
binding site are presented in red and show impaired binding to LIMP-2. A one-way ANOVA with a subsequent 
Tukey-Kramer posthoc test was utilised for statistical analyses. *** denote p<0.001 with comparison of the 
mutants to cells transfected with GC wild-type. 
 
4.3.2 Subcellular localisation of GC mutants 
The interaction of the described GC mutants to LIMP-2 was further validated by cellular 
localisation studies utilising immunofluorescence microscopy (Figure 4.29 and Figure 4.32) 
and an endoglycosidase H digestion (Figure 4.31 and Figure 4.34). Both experimental 
approaches investigate the impact of the helical binding domain in GC and the cellular 
localisation of the enzyme. 
The ‘glutamic acid mutants’ were overexpressed in GC-deficient mouse embryonic 
fibroblasts and visualised by an anti-human GC antibody (Figure 4.29). A co-staining against 
endogenous LIMP-2 was performed, indicating a co-localisation of LIMP-2 with GC wild-
type and R211E mutant (Figure 4.29 A). For the mutants localised in the potential binding site 
of GC (L91E, L94E and L156E) almost no lysosomal localisation could be observed (Figure 
4.29 A). To further validate the cellular localisation of the expressed GC a triple staining 
including LAMP-2 as an independent lysosomal marker was included (Figure 4.30). Co-
localisation of endogenous LIMP-2 and LAMP-2 is indicated by purple colour. ER-retention 
of the LIMP-2 binding-deficient mutants was visualised by co-staining with the ER marker 
PDI (protein disulfid isomerase). Mutants showing no interaction towards LIMP-2 (L91E, 
L94E and L156E) did co-localise with PDI. In contrast, GC wild-type and the control mutant 
(R211E) showed considerably less overlay with the PDI staining (Figure 4.29 B). The level of 





defines the highest value for co-localisation (Figure 4.29 C, D). An interaction of GC (green) 
with both lysosomal markers LIMP-2 (blue) and LAMP-2 (red) led to a white signal, as seen 












Figure 4.29: Analysis of cellular localisation of GC ‘glutamic acid mutants’ by immunofluorescence. 
Immunofluorescence stainings of GC mutants transfected into GC-deficient cells. A) An anti-human GC 
antibody (594nm, red) was used together with an antibody against endogenous LIMP-2 (488nm, green). 
Interaction of both proteins indicates lysosomal localization of GC and is visualized by a yellow colour. The area 
of magnification is indicated by a white box. B) To validate ER localisation of the GC constructs costaining with 
the ER-marker PDI (488nm, green) was performed. The intensity of co-localisation of GC with either LIMP-2 
(C) or PDI (D) was presented as a Pearson‘s index. A value of one defines the highest value for co-localisation 
(n=2-10). Point-mutants within the predicted interaction site are indicated in red. A one-way ANOVA with a 
subsequent Tukey-Kramer posthoc test was utilised for statistical analyses. *; **; *** denote p<0.05; 0.01; 0.001 







Figure 4.30: Triple stainings of GC constructs with LIMP-2 and an additional lysosomal marker LAMP-2. 
For further validation of lysosomal localisation of GC mutants a triple staining including LAMP-2 was 
performed, indicating GC in green, LAMP-2 in red and LIMP-2 in blue. The interaction LAMP-2 and LIMP-2 is 
shown in purple. Additionally, the interaction of GC (green) with the two lysosomal markers is indicated in 
white as seen for GC wild-type and R211E, but not for the LIMP-2 binding deficient L91E mutant. The scale 
bars indicate 10 μm.  
 
To further biochemically analyse the cellular localisation of the LIMP2-binding-deficient GC 
mutants L91E, L94E and L156E endoglycosidase H (EndoH) and PNGaseF digestions were 
performed (Figure 4.31). The proteins were overexpressed in N2a cells and subjected to 
enzymatic digestions and subsequent immunoblotting using an anti-human GC antibody. 
Protein fractions resistant to endoglycosidase H digestion (~70 kDa) indicate post ER 
localisation, whereas a completely deglycosylated protein indicates localisation of the protein 
within the ER (~56 kDa). The PNGaseF enzyme was utilised as a control to show the fully 
deglycosylated protein.  
The LIMP-2-binding-deficient GC mutants L91E, L94E and L156E show impaired trafficking 
out of the ER compared to wild-type GC indicated by a sensitivity to endoglycosidase H 
cleavage. The mutants L91E and L94E seem to be most affected revealing a ~75% decrease 
of post ER localisation in comparison to the wild-type (Figure 4.31 B). The results of this 
study support the data obtained from the interaction studies (see results 4.3.1). In conclusion, 
when interaction of GC with LIMP-2 is impaired as revealed by the co-IP studies, also the 

















Figure 4.31: Analysis of cellular localisation of GC mutants by endoglycosidase H digestion. 
A) Endoglycosidase H and PNGaseF digestion of ‘glutamic acid GC mutants’ (L91E, L94E, L156E) after 
overexpression in N2a cells. The subsequent immunoblot was stained for anti-human GC. Protein fractions 
resistant to EndoH digestion decipher post ER localisation, whereas fully deglycosylated protein indicates 
localisation in ER. B) Densitometry of endoglycosidase H sensitive (ER) and insensitive (post ER) band, 
calculating the post ER/ER ratio. Values are normalised to the wild-type (WT) GC. A one-way ANOVA with a 
subsequent Tukey-Kramer posthoc test was utilised for statistical analysis. ** denotes p<0.01 with comparison 
of each mutant to GC wild-type (n=3-8).  
 
The potential LIMP-2 interaction site in the GC protein was further characterised by analysing 
the Gaucher disease mutants. Thus, the same methods including immunofluorescence 
microscopy and an endoglycosidase H digestion -as described above- were utilised.  
 
The GC constructs (P159L, I161S, N188S, F213I) were overexpressed in GC-deficient cells 
and co-stained for endogenous LIMP-2 (Figure 4.32 A). A co-localisation of both proteins is 
indicated by a yellow colour in the IF pictures and expressed as a Pearson’s index (Figure 
4.32 C). Clear co-localisation with LIMP-2 could be seen for GC wild-type, N188S and F213I 
and no co-localisation was observed for the P159L and the I161S mutants (Figure 4.32 A, C). 
Triple immunofluorescence staining using an independent lysosomal marker (LAMP-2) 
confirmed lysosomal localisation of N188S but not I161S (Figure 4.33). PDI-stainings 
revealed clear co-localisation with the LIMP-2-binding-deficient mutants P159L and I161S 






























Figure 4.32: Analysis of cellular localisation of GC patient mutants by immunofluorescence microscopy. 
Visualisation of Gaucher patient mutants transfected into GC deficient MEFs by immunofluorescence. An anti-
human GC antibody was used to detect the transfected GC constructs (red) together with an antibody against 
endogenous LIMP-2 (A; green) and ER-marker protein disulfid isomerase (PDI) (B; green). Interaction of GC 
with LIMP-2 indicates lysosomal localisation whereas interaction with PDI suggests ER-retention. The degree of 
co-localisation of GC with LIMP-2 (C) and PDI (D) was expressed as a Pearson‘s index, with one being the 
highest value for interaction (n=2-6). A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was 
utilized for statistical analyses. **; *** denote p<0.01; 0.001 with comparing all mutants to cells transfected with 







Figure 4.33: Triple stainings of GC patient mutants with LIMP-2 and LAMP-2. 
For further validation of lysosomal localisation of GC a triple staining including LIMP-2 and LAMP-2 was 
performed in GC-deficient MEF cells (GC: green; LAMP-2: red and LIMP-2: blue). Co-localisation of both 
lysosomal markers LIMP-2 and LAMP-2 is indicated by a purple colour and an additional overlay with GC is 
shown in white colour and can be observed for the GC control mutant N188S, but not for the GC mutant I161S. 
The corresponding wild-type GC control is presented in figure 4.30. The scale bars indicate 10 μm.  
 
The inability of the GD mutants (P159L and I161S) to transport GC to lysosomes was also 
analysed biochemically using endoglycosidase H digestions (Figure 4.34). As shown in figure 
4.35 A, hardly any endoglycosidase H-resistant protein (~70 kDa), which deciphers post ER 
localisation, was observed for the P159L and I161S mutants, respectively. In comparison the 
control mutant N188S shows a similar pattern of protein bands and thus transport out of the 








Figure 4.34: Analysis of cellular localisation of GC mutants by endoglycosidase H digestions. 
A) The GC mutants P159L, I161S and N188S were overexpressed in N2a cells and subjected to endoglycosidase 
H and PNGaseF digestion and analysed by immunoblot using anti-human GC antibody. Protein fractions 
resistant to the endoglycosidase H enzyme, indicate post ER localisation (~70 kDa), whereas a fully 
deglycosylated protein deciphers ER-localisation (~56 kDa). B) Densitometrical analysis with calculation of the 
post ER/ER ratio normalised to the GC wild-type situation. A one-way ANOVA with a subsequent Tukey-
Kramer posthoc test was utilized for statistical analysis. * denotes p<0.05 with comparing mutants to GC wild-
type (n=2-3).  
 
Taking the findings together, two independent experiments (immunofluorescence stainings 
and endoglycosidase H digestions) in combination with the two different sets of GC mutants – 





binding domain in GC, revealing less LIMP-2 interaction with GC and decreased 
lysosomal/post ER localisation of the enzyme. 
4.3.3 Does LIMP-2 overexpression modulate GC trafficking and function? 
Having determined the binding site between LIMP-2 and GC on both proteins, it was 
evaluated if an increased LIMP-2 expression may be of potential therapeutic benefit to 
facilitate transport of GC wild-type and GC mutants to the lysosome. Studies were performed 
in two different cell systems (N2a and GC-deficient MEFs). In addition co-expression of 
LIMP-2 together with GC mutants (LIMP-2-binding-deficient as well as control mutants 
localised outside the predicted interaction motif) followed by an analysis of the subcellular 
localisation of the GC protein was used to further validate the identified LIMP-2 interaction 
site of the GC protein. 
 
Co-expression of LIMP-2 together with GC in GC-deficient as well as N2a cells led to a 
slight decrease in migration of the GC protein in SDS-PAGE. This is due to the interaction of 
the ligand GC with its specific transport receptor LIMP-2, resulting in an increased transport 
out of the ER and an increased glycosylation due to enzyme maturation in the secretory 
pathway (Figure 4.35 A, C).  
As expected for the wild-type GC as well as the control Gaucher mutant N188S showed an 
increase in the molecular weight of GC (Figure 4.35 A). In contrast, GC mutants suspected to 
be limited in LIMP-2 binding (L91E, L94E, L156E) did not exhibit a significant increase in 
molecular weight and thus post ER localisation (GC KO: Figure 4.35 A, B and N2a cells: 
Figure 4.35 C, D). Since even LIMP-2 overexpression did not result in more post ER 
localisation of the GC mutants, it can be concluded that this failure is due to a lack of protein-























Figure 4.35: LIMP-2 co-expressed with GC leads to a molecular weight shift due to transport to 
lysosomes. 
Immunoblots of GC using an anti-human GC antibody. GC mutants were co-expressed with LIMP-2 (anti-myc) 
in GC KO cells (A) and N2a cells (C) with actin was used as a loading control. The upper band of GC represents 
a higher glycosylated GC form due to ER exit. The lower protein band indicates GC retained in the ER. B, D) 
Quantification of post ER and ER forms of GC of respective western-blots. Post ER/ER ratio normalised to GC 
wild-type are indicated (n=2-3). A two-sided independent Student’s t-test was utilised to compare the effect of 
LIMP-2 co-expression within each construct. *; ** denote p<0.05; 0.01. 
 
For a better discrimination between post ER- and ER-forms of GC, endoglycosidase H 
digestions were performed in the presence or absence of a LIMP-2 co-expression. The results 
were again obtained in two different cell systems (GC-deficient MEF and N2a cells). Protein 
fractions resistant to endoglycosidase H digestion (~70 kDa) decipher post ER localisation 
and a complete deglycosylation of the protein indicates its ER-residence (~56 kDa). An 
enhanced transport of GC to post ER compartments indicated by an increase in the molecular 
weight of the GC protein (~70 kDa) was observed for wild-type GC and the patient mutant 
N188S in the presence of LIMP-2 expression (Figure 4.36). The LIMP-2-binding-deficient 
GC mutants L91E, L94E and L156E did not show a significant increase in post-ER GC after 
LIMP-2 co-expression, indicating their retention in ER-compartments (Figure 4.36). 
Interestingly, a small fraction of the L94E mutant seems to be able to overcome this ER-
retention after LIMP-2 co-expression (Figure 4.36). This indicates that this point-mutation 
















Figure 4.36: Biochemical analysis of the cellular localisation of the GC mutants by endoglycosidase H 
digestion. 
Immunoblot of EndoH and PNGaseF digestions of GC mutants detected using an anti-human GC antibody. The 
GC mutants were expressed in the absence and presence of LIMP-2 in GC-deficient MEF (A) and N2a cells 
(C). Protein fractions resistant to endoglycosidase H digestion indicate a post ER localisation (~70 kDa), 
whereas a complete digestion of the enzyme (~56 kDa) indicates the protein to be retained in the ER. A 
PNGaseF digestion was performed to control for the completeness of the carbohydrate digestion. 
Quantification of endoglycosidase H digestions, showing GC post ER/ER ratio in GC KO MEFs (B; n=1-3) 
and N2a cells (D; n=2-6). A two-sided independent Student’s t-test was utilised to compare the effect of LIMP-
2 co-expression within each GC construct. *, *** denote p<0.05, 0.001. 
 
In addition, immunofluorescence stainings of the expressed GC mutants in presence with co-
expressed LIMP-2 as detected using an anti-myc antibody were performed (Figure 4.37 A). 
The co-localisation of each GC protein with co-overexpressed LIMP-2 was expressed as a 
Pearson’s index (Figure 4.37 B). The GC wild-type and Gaucher mutant N188S show the 
same level of co-localisation with LIMP-2 (Pearson’s value ~0.85). The potential LIMP-2 
binding-deficient GC mutants L91E, L94E and L156E show less co-localisation with lowest 
co-localisation observed when the L91E mutant was expressed (Pearson’s value ~0.3) (Figure 




















Figure 4.37: Immunofluorescence microscopy to evaluate co-localisation of GC mutants and LIMP-2.  
A) Immunfluorescence stainings showing GC-deficient cells transfected with the indicated GC mutants (anti-
hGC (red)) and LIMP-2 (anti-myc (green)). The degree of co-localisation of GC with overexpressed LIMP-2 is 
indicated by a yellow colour. Areas of magnification are marked by white boxes. Scale bars indicate 10 μm. B) 
Quantification of the IF stainings using the Pearson‘s index to analyse the co-localisation of transfected GC and 
co-expressed LIMP-2 (n=2-7). A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was applied 
for all statistical analyses. **; *** denote p<0.01; 0.001.  
 
Moreover, a putative effect of enhanced LIMP-2 expression on GC function was assessed. 
Enzyme activity assays utilising an artificial substrate were performed in N2a cell lysates after 
overexpression of the individual GC constructs in presence and absence of overexpressed 
LIMP-2. Only the wild-type GC revealed a significant increase of GC activity after co-
expression of LIMP-2. To a much lesser extent the Gaucher mutant N188S as well as the 




Figure 4.38: Effect of LIMP-2 co-expression on GC activity. 
GC activity measurement of GC mutants (L91E, L94E, L156E and N188S) overexpressed in N2a cells with and 
without co-expression of LIMP-2. The GC activity was normalized (norm.) to the mock transfected control, 
indicating background/endogenous GC activity of this assay (dotted line). A One-Way ANOVA with a 






In summary, LIMP-2 overexpression exhibits a positive effect on GC trafficking and activity. 
However, these effects could only be observed if the GC protein was able to interact with its 
lysosomal transport receptor.  
4.3.4 Validation of the LIMP-2 interaction site of GC protein using LIMP-2-derived 
peptides  
As shown above, endogenous GC was successfully precipitated from cell lysates by a peptide 
derived from the binding site (helix 5) of LIMP-2 (Figure 4.14). This specific interaction was 
further exploited to study the binding abilities of the different GC mutants to this helix 5 
peptide. A pulldown assay to precipitate the overexpressed GC mutants from N2a cells using 
the helix 5 peptide was designed (Figure 4.39 A). The pulldown was visualised by 
immunoblotting. Staining for GC revealing a strong interaction of the GC wild-type as well as 
the N188S mutant to the helix 5 peptide. The interactions of the LIMP-2-derived peptide to 
the GC mutants (L91E, L94E, L156E) was reduced to one third compared to the GC wild-
type (Figure 4.39 B, C). The same mutants already exhibited impaired interaction with LIMP-












Figure 4.39: Pulldown of overexpressed GC mutants with LIMP-2-derived peptides from cell lysates. 
A) Principle of peptide-pulldown of overexpressed GC (Wildytpe (WT), L91E, L94E, L156E and N188S) from 
N2a cell lysates. B) Immunoblot of pulldown using an anti-human GC (hGC) antibody. Buffer only and 3xD 
helix 5 were used as negative binding control. C) Quantification of the signal intensity of the precipitated GC 
proteins, indicating binding of the GC wild-type as well as N188S mutant to the helix 5 peptide. The L91E, 
L94E and L156E GC mutants only exhibit weak interaction with the helix 5 peptide. Each construct was 
normalised to buffer only. A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was applied for 
statistical analysis. *** denotes p<0.001 (n=2-4). 
 
In summary, these data reveal another strategy to analyse the LIMP-2 interaction site of the 





4.4 LIMP-2 knockout mice – what impact does LIMP-2/GC have on 
α-synuclein homeostasis in murine brain? 
The enzymatic activity of GC has been directly linked to the intracellular α-synuclein 
homeostasis (Mazzulli, Xu et al. 2011, Westbroek, Gustafson et al. 2011). However, the role 
of LIMP-2, as the specific lysosomal transporter of GC, has not been assessed. In this study 
LIMP-2-deficient mice were analysed for neuronal α-synuclein accumulation and impairment 
of the central nervous system (CNS). LIMP-2 knockout mice were backcrossed into the 
C57BL/6N background exhibiting normal α-synuclein level (see introduction section 1.2.3 
and Figure 3.1). The following studies mainly focus on the midbrain and pons as these regions 
are most affected in synucleinopathies like Parkinson disease (Davie 2008). 
Immunoblot analysis of LIMP-2 deficient pons and midbrain lysates showed no expression of 
LIMP-2 and strong reduction in GC protein levels (Figure 4.40 A). A GC activity assay 
revealed a significant decline in GC-activity (less than 50 % when compared to the wild-type 








Figure 4.40: LIMP-2 deficiency causes decreased GC expression and activity in murine pons and 
midbrain.  
A) Immunoblot of pons and midbrain lysates of wild-type (WT) and LIMP-2-deficient mice showing complete 
absence of LIMP-2 protein in the knockout and only residual GC protein levels. Neuronspecific enolase (NSE) 
was used as a loading control. B) Pons and midbrain lysates were subjected to GC activity assays indicating a 
significant decrease in GC activity in both tissues of LIMP-deficient mice. An independent two-sided Student’s 
t-test was used for statistical analysis. **,* ** denote p<0.01, 0.001; n=4.  
 
4.4.1 Storage of GC substrate and undefined material 
In the following studies it was assessed to what extent the observed reduction in GC activity 
affects intracellular levels of the GC substrate glucosylceramide. Since no reliable antibodies 
are available to stain for the lipid, brain sections (pons and midbrain) of wild-type and LIMP-
2-deficient mice were subjected to a periodic-acid-Schiff staining (PAS), detecting carbo-





found in the midbrain and pons of LIMP-2-deficient mice (Figure 4.41 A). Analyses in 2, 4, 6 
and 10 months old animals further revealed a progressive accumulation of the carbohydrate 
conjugates especially in the pons of LIMP-2-deficient mice (Figure 4.41 B). Additionally 
electron micrographs of the pons revealed unidentified storage material (arrows; Figure 4.42) 












Figure 4.41: Periodic-acid-Schiff staining (PAS) of brain sections at different ages.  
A) Pons and midbrain sections of wild-type (WT) and LIMP-2 KO (-/-) mice at different ages (2, 4, 6 and 10 
months) were subjected to PAS staining. Depicted images are from 10 months old mice with inserts showing 
magnified area of image. Pc = pars compacta; Pr = pars reticulate. Scale bars indicate 50 μm. B) Respective 
quantification of PAS positive cells highlighting progressive accumulation of the carbohydrate-conjugates in 
LIMP-2-deficient compared to wild-type brain. A one-way ANOVA with a subsequent Tukey-Kramer posthoc 
test was applied for statistical analysis. # and *** denote p>0.05 and p<0.001. The stainings and densitometric 










Figure 4.42: Electron micrographs indicating storage material in the pons of LIMP-2 KO mice. 
Sections of the pons of 10 months old LIMP-2 deficient and wild-type animals were subjected to toluidine blue 
staining for ultrastructural analysis. Accumulation of storage material (highlighted by arrows) and lipid droplets 
(indicted by red asterisks) were evident in sections of LIMP-2 KO compared to wild-type. Scale bars indicate 10 
and 1 μm. EM stainings were performed by Dr. Michaela Schweizer (ZMNH, UKE Hamburg). 
 
In summary, LIMP-2-deficient mice revealed a reduction in GC protein and enzymatic 
activity in pons and midbrain. The decline in functional GC ultimately led to accumulation of 
PAS-positive deposits.  
4.4.2 Accumulation of α-synuclein 
Dysfunction of GC and accumulation of its substrate (glucosylceramide) have been shown to 
negatively influence neuronal α-synuclein levels and its degradation (see introduction 1.4.3) 
(Mazzulli, Xu et al. 2011, Westbroek, Gustafson et al. 2011). Hence, LIMP-2-deficient brain 
was analysed for α-synuclein accumulation via immunoblotting and immunohistochemistry. 
Before performing SDS-PAGE, brain lysates were separated into Triton soluble (T-Sol) and 
insoluble (SDS) fractions. Three different α-synuclein antibodies (Syn-1, C-20 and 4D6; for 
more information see material and methods chapter 3.1.3) were utilised depicting three forms 
of α-synuclein (~17 kDa, ~23 kDa and ~58 kDa), that were not present in lysates from mice 
deficient for α-synuclein (Figure 4.43). It should be considered that each antibody detects the 
various α-synuclein forms with different preferences. For the monomeric form (~17 kDa) no 
significant changes could be observed in the absence of LIMP-2 (Figure 4.43). This is in 
contrast to the 23 kDa and 58 kDa forms of α-synuclein, which showed to be elevated at least 
twice as much in the midbrain of LIMP-2-deficient mice in comparison to wild-type samples 









Figure 4.43: Immunoblot analysis revealing α-synuclein accumulation in the midbrain of LIMP-2-
deficient animals. 
Immunoblots of soluble (T-Sol) and insoluble (SDS) fractions of wild-type (WT) and LIMP-2 knockout (-/-) as 
well as α-synuclein deficient (Syn ko) midbrain samples. Three different antibodies (Syn-1, C-20 and 4D6) were 
used to detect three species of α-synuclein (17 kDa, 23 kDa and 58 kDa). Arrowheads indicate α-synunclein 
forms and the asterisks indicate non-specific bands. B) Quantification of immunoblots utilising the syn-1 and 
4D6 antibody. Unchanged levels of the 17 kDa form, but a statistical increase in the 23 kDa and 58 kDa forms of 
α-synuclein in LIMP-2 deficient samples of both fractions was observed (T-Sol and SDS). An independent two-
sided Student’s t-test was performed for statistical analysis with * and ** denoting p<0.05 and 0.01; n= 3-7. The 
α-synuclein immunoblots were performed in collaboration with Dr. Joseph Mazzulli (Northwestern University of 
Chicago, US). 
 
Neuronal accumulation of α-synuclein in pons and midbrain, including the substantia nigra 
was confirmed by immunohistochemistry, using the three α-synuclein specific antibodies 
(Syn-1, 4D6 and C-20). Immunofluorescence stainings of α-synuclein were performed in pons 
and midbrain revealing neuronal α-synuclein accumulation (Syn-1 antibody:  Figure 4.44 A; 
4D6 and C-20: Figure 4.44 B). The pons and midbrain samples were co-stained for a neuronal 
marker (NeuN) and tyrosine-hydroxylase (TH) to identify dopaminergic neurons. 
Additionally, DAB-immunohistochemical and immunofluorescence stainings confirmed 












Figure 4.44: Immunohistochemical stainings of α-synuclein in midbrain and pons. 
A) Immunofluorescence stainings of α-synuclein (green, 488 nm) in the pons and midbrain co-stained with a 
neuronal marker (NeuN; red, 594 nm) and tyrosine-hydroxylase (TH; red, 594 nm) comparing 10 month old 
littermates. White arrows point towards accumulated α-synuclein (S. Nigra: substantia nigra). B) DAB (left 
panels) and immunofluorescence (right panels) stainings of α-synuclein (green; 488 nm) using the 4D6 and C-20 
antibody (NeuN; red; 694 nm). Arrows highlight accumulated α-synuclein with inlays showing magnified 
sections of the DAB stainings. Scale bars indicate 20 μm for immunofluorescence stainings and 100 μm for 
DAB-stained sections. All stainings shown here were performed in collaboration with Dr. Michelle Rothaug 
(Biochemical Institute, University of Kiel). 
 
These results confirm an accumulation of α-synuclein in the pons and midbrain of LIMP-2-
deficient mice. This suggests a possible contribution of α-synuclein in the pathological 
processes observed in LIMP-2-deficient mice. 
 
4.4.3 Increased α-synuclein levels lead to neurotoxicity and behavioural 
abnormalities 
It has been shown that α-synuclein accumulation can cause neurotoxicity in cells and animal 





midbrain are affected by aggregation of the cytosolic protein, thus undergoing 
neurodegeneration in Parkinson disease (Xu, Kao et al. 2002, Periquet, Fulga et al. 2007).  
To study the effect of the described α-synuclein accumulation, histochemical assays were 
established to verify the viability and characteristics of neurons in brain sections of midbrain 
and pons. Apoptotic cell stainings were performed by terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) on brain sections from mice of different ages (2-10 
months). In the pons an abrupt increase of apoptotic cells (TUNEL positive) could be 
observed starting from the age of 6 months. TUNEL-staining in the midbrain of LIMP-2-
defiecient mice revealed an increase in apoptotic cell death at the age of 10 months (Figure 
4.45 A).  
In PD mouse models and patients astrogliosis as well as microgliosis have been observed 
(Hirsch, Hunot et al. 2005, Zhang, Wang et al. 2005). Hence, DAB-immunohistochemistry 
was utilised to check for both neuropathological changes in brain sections of LIMP-2-
deficient mice with markers for astrocytes (glial fibrillary acidic protein, GFAP) (Figure 4.45 
B) and microglia (macrosialin/CD68) (Figure 4.45 C). Sections of pons and midbrain from 
mice at the age of 2, 4, 6 and 10 month were subjected to GFAP and CD68 stainings. An 
increased number of GFAP- as well as CD68-positive cells could be found in both tissues of 
LIMP-2-deficient mice when comparison to wild-type mice. Furthermore, an age-dependent 
progression of astro- as well as microgliosis in the brain of LIMP-2-deficient mice could be 
observed (Figure 4.45 B, C).  
Consequently, the above described pathological changes in the brain of LIMP-2-deficient 
mice are accompanied by behavioural abnormalities. LIMP-2 knockout mice exhibited severe 
neurological impairments starting in the age of 4 months including tremor and hind-limb 
clasping, which finally resulted in partial paralysis. Finally, LIMP-2-deficient mice did not 
survive beyond 10 months and showed reduced weight (wild-type: 34,2 ± 5.4 g; LIMP-2 






















Figure 4.45: DAB-immunohistochemistry showing highly progressive neurotoxic effects of α-synuclein. 
A) TUNEL-staining of positive apoptotic cells (highlighted by arrows) showing a progressive increase in 
apoptotic cells in the pons and midbrain of LIMP-2-deficient (-/-) compared to wild-type (WT) mice (2, 4, 6 and 
10 months). DAB-stainings to check for astrogliosis (GFAP; B) and microgliosis (CD68; C) in pons and 
midbrain of wild-type (WT) and LIMP-2 KO mice (2, 4, 6 and 10 months of age) show progressively increasing 
number of positive cells. A one-way ANOVA with a subsequent Tukey-Kramer posthoc test was used for 
statistical analysis. #, * and *** denote p>0.05 and p<0.05 and 0.001; n=3-4 mice per age. All stainings show 
representative results and were taken from wild-type and LIMP-2 knockout littermates at the age of 10 months. 
Scale bars indicate 200 μm in TUNEL-stainings and 50 μm in GFAP/CD68 stainings. The stainings as well as 
the densitometric analyses were performed in collaboration with Dr. Michelle Rothaug (Biochemical Institute, 
University of Kiel). 
 
In summary, the results indicate that accumulation of α-synuclein, triggered by LIMP-2-
deficiency, is accompanied by significant apoptotic cell death and gliosis in the pons and 
midbrain. Due to these profound impairments of the CNS the LIMP-2-deficient mouse also 







4.5 How does α-synuclein affect human CNS? 
4.5.1 Does α-synuclein interfere with GC function? 
The results shown above describe an accumulation of α-synuclein in murine brain induced by 
a deficiency of LIMP-2 with a simultaneous loss of GC activity. The impaired GC function is 
thought to be the initial cause of the observed pathogenic increase in α-synuclein. Neuronal 
accumulation of α-synuclein in murine brain resulted in a cascade of events: neurotoxicity, 
inflammation (astro- and microgliosis) and neuronal death. 
To study a possible interference of the accumulated α-synuclein with GC, human 
dopaminergic neurons from midbrain derived from induced pluripotent stem cells (iPSC) 
were utilised and transduced with α-synuclein by lentiviral delivery. After 48 hours 
expression time, the effect on GC activity was measured using a newly developed method to 
measure lysosomal GC activity in living cells. These experiments were performed in the 
laboratory of Dr. Dimitri Krainc (Harvard Medical School/Massachusetts General Hospital, 
Boston, USA). To measure the lysosomal GC activity the transduced cells were treated with 
DMSO or bafilomycin, which largely prevents lysosomal hydrolase activity. A pulse chase 
experiment with a fluorescent GC substrate was performed and GC activity was measured 
every 30 minutes over a time period of three hours. The GC activity was assessed in the 
presence of DMSO and bafilomycin A1. Since bafilomycin is a specific inhibitor of the 
vacuolar type H+ ATPase, lysosomal function including GC activity is diminished in these 
cells. In order to calculate the lysosomal GC activity the total cellular GC activity (DMSO 
treated cells) was subtracted from the activity measured in the presence of bafilomycin. Since 
GC activity was expressed as the area under the curve (AUC), the area between DMSO and 
bafilomycin treated cells indicates the lysosomal activity only (for more details see material 
and methods 3.2.3.11). A significant reduction in lysosomal GC activity could be observed in 
human midbrain dopaminergic neurons after α-synuclein overexpression when compared to 















4.5.2 Does α-synuclein modulate the expression of LIMP-2? 
The role of LIMP-2 on cellular GC function and α-synuclein metabolism could be 
demonstrated in brain of LIMP-2-deficient mice. This leads to the question if LIMP-2 protein 
expression is also altered when abnormal α-synuclein levels are present in the cells. To 
address this question, Parkinson disease post-mortem midbrain samples were analysed for 
LIMP-2 protein expression by immunofluorescence. In the case of a synucleinopathy 
increased levels of neuronal LIMP-2 could be observed (Figure 4.47). Consequently, this 
resulted in enlarged vesicles (referred to as circumference in figure 4.47). Dopaminergic (DA) 
neurons within the midbrain were identified by their high neuromelanin content (Figure 4.47). 
 
 
Figure 4.47: Immunohistological stainings of LIMP-2 in control and PD midbrain sections.  
Control and Parkinson disease midbrain sections were stained for LIMP-2. Dopaminergic (DA) neurons were 
identified by their high neuromelanin content (black structures in differential interference contrast (DIC) image). 
As indicated in the stainings, circumferences of LIMP-2 positive vesicles are increased in size in PD samples 
(6.14 μm compared to 5.28 μm).The total LIMP-2 signal was divided by the circumference of vesicles 
compensating for variations in vesicle size revealing a significant increase in LIMP-2 signal in PD DA neurons 
when compared to healthy control. For statistical analysis an independent two-sided Student’s t-test was 
performed with * and *** denoting p<0.05 and 0.001; Control patients: n=5; PD patients: n=7. Scale bars 
decipher 10 μm. The samples were stained by Dr. Hermann Altmeppen (University Hospital Hamburg, UKE, 









Figure 4.46: Effect of α-synuclein on lysosomal GC activity in human midbrain dopaminergic neurons. 
Human dopaminergic neurons were transduced with a mock vector (A) and α-synuclein (B). In a pulse chase 
experiment with a fluorescent GC substrate GC activity was measured in living cells over a time period of three 
hours. The areas between the DMSO (black) and bafilomycin (Baf; red) treated samples indicate the lysosomal 
GC activity in the living cells (indicated by an arrow). The activity is depicted in arbitrary units as the intensity 
of the fluorescent substrate. C) The area between the DMSO and bafilomycin curve (AUC) was quantified 
revealing a decrease in lysosomal GC activity after α-synuclein overexpression. A two sided independent 





In summary, these results not only show that dysfunction of GC negatively effects 
α-synuclein homeostasis, but also that α-synuclein interferes with GC activity and influences 
neuronal LIMP-2 expression. The augmented expression of LIMP-2 and increased vesicle 
size in human PD midbrain sections further indicates an important role of the lysosomal 
protein in the pathological cascade in PD.  
4.6 What are the effects of LIMP-2-deficiency in humans? 
In patients a deficiency in LIMP-2 leads to the Action Myoclonus Renal Failure syndrome 
(AMRF), which is characterised by progressive myoclonic epilepsy (PME) associated with 
ataxia, undefined storage material in the brain and in most cases causing renal failure (see 
introduction 1.2.2). Although the LIMP-2-deficient mouse seems to be a valid disease model 
(Gamp, Tanaka et al. 2003, Berkovic, Dibbens et al. 2008, Rothaug, Zunke et al. 2014), 
differences between the murine and human situation exist. For example the consequences of 
LIMP-2 deficiency in AMRF patients appear to be even more severe than in mice, resulting in 
premature death between 20-35 years (Badhwar, Berkovic et al. 2004, Rubboli, Franceschetti 
et al. 2011).  
Unfortunately, the current experimental approaches are restricted to fibroblasts, making it 
difficult to evaluate α-synuclein homeostasis. The fibroblasts used here were derived from 
AMRF patient 1 (Case A) and patient 2 (Case B) (Berkovic, Dibbens et al. 2008). Like the 
majority of AMRF causing mutations, both cases result in a truncated LIMP-2 protein, which 
cannot be detected by the utilised antibody, which is designed against the c-terminus of the 
protein. Hence, immunoblots of AMRF patient fibroblasts show a complete loss of the LIMP-
2 signal (Figure 4.48 A). Furthermore, GC was dramatically reduced in AMRF patients cells 
with residual amounts of the enzyme located in the ER (endoglycosidase H positive signal; 
Figure 4.48 A). Consequently, GC activities were diminished in AMRF patient cells 
compared to control. The GC inhibitor Conduritol-B-epoxide (CBE) was used to control for 
specificity of GC activity assay (Figure 4.48 B). Also in immunofluorescence stainings with a 
LIMP-2 antibody no signal could be detected in AMRF patient cells, whereas control cells 



















Figure 4.48: Biochemical analyses of fibroblasts derived from AMRF patients. 
A) Immunoblot analysis of endoglycosidase H and PNGaseF digested lysates of human control and LIMP-2-
deficient fibroblasts (AMRF patient 1 and 2). In AMRF cell lysates no LIMP-2 signal was detectable and 
residual GC protein was completely sensitive to endoglycosidase H digestion, indicating ER retention. Tubulin 
was used as loading control. B) GC activity assays indicate very little enzyme activity of human LIMP-2-
deficient fibroblast compared to control. A GC inhibitor (CBE) was used to control for the specificity of the GC-
activity measurement. C) Immunofluorescence of control and AMRF fibroblasts (AMRF1) staining for LIMP-2 
(green; 488 nm) and the lysosomal marker LAMP-2 (red, 594 nm). No LIMP-2 signal could be observed in 
LIMP-2-deficient fibroblasts (AMRF1: Case A) whereas the LIMP-2 signal in control fibroblasts shows a co-
localisation with the lysosomal marker LAMP-2. Scale bars indicate 10 μm. 
 
The two analysed AMRF mutations resulting in a truncated form of LIMP-2 protein seem to 
have the same consequences on GC protein expression and activity as seen in the mouse 
model with a complete deficiency of LIMP-2.       
 
4.7 LIMP-2: A novel therapeutic target for the treatment of 
synucleinopathies? 
The findings in the murine and human CNS as well as in neuronal cell culture implicate an 
important role of LIMP-2 in regulating α-synuclein levels. As shown in paragraph 4.3.3, an 
increase in LIMP-2 expression leads to a shift of GC to post ER compartments and an 
enhancement of its enzymatic activity (Figure 4.35, 4.36 and Figure 4.38).  
Thus, it was of interest to evaluate if this augmentation in GC activity is sufficient to reverse 





In murine neuroblastoma cells (N2a) the cellular cell GC activity was found to be increased 
twofold after LIMP-2 overexpression (p<0.05). Additionally, the lysosomal GC activity was 
assessed in a human neuroglioma cell line (H4) constitutively overexpressing α-synuclein. 
The cells were transfected with an empty vector control (Figure 4.49 A) and a LIMP-2 
expression vector (Figure 4.49 B). The area between the two GC activity curves (DMSO and 
bafilomycin) indicates the lysosomal GC activity in living cells assessed over 3.5 hours. 
When compared to the vector control, lysosomal GC activity was increased after LIMP-2 
transfection (compare white area and grey area between both curves; Figure 4.49 A and B). 
 
 
After verifying the positive effects of increased LIMP-2 expression on lysosomal GC 
localisation and activity, the consequences of enhanced LIMP-2 levels on α-synuclein 
homeostasis were assessed. Wild-type LIMP-2 and as a control ER-resident LIMP-2 were co-
expressed in murine neuroblastoma cells (N2a) with a HA-tagged α-synuclein construct. As 
shown in the immunoblot of figure 4.50, overexpression of wild-type LIMP-2 resulted in 
decreased levels of the α-synuclein protein when compared to samples co-transfected with the 


















Figure 4.49: Whole cell and lysosomal GC activity is increased after LIMP-2 overexpression. 
Analysis of lysosomal GC activity in human H4 cells overexpressing empty vector control (A) and LIMP-2 (B). 
The area between the curves of cells treated with DMSO (black) and bafilomycin (Baf; red) show lysosomal GC 
activity (indicated by an arrow). The chase of fluorescent GC substrate was performed for 3.5 hours indicating 
enhanced GC activity in lysosomes after LIMP-2 expression (grey area). The activity is depicted in arbitrary 
units as intensity of the fluorescent substrate. The area between the two curves (DMSO and Baf) was quantified 
and graphed (C). Although the variance in the mock transfected sample seems to be large, a tendency of 













Figure 4.50: LIMP-2 overexpression leads to a decrease in α-synuclein protein levels in murine N2a cells.  
A) Immunoblot of N2a lysates after overexpression of wild-type and an ER-retention mutant of LIMP-2. An 
anti-myc antibody (9B11) was used to control for the transfection and an anti-HA antibody (3F10) was used to 
detect changes in the α-synuclein protein levels. A drop in α-synuclein signal was revealed after LIMP-2 
overexpression. Actin was used to control for loading. No significant changes in the α-synuclein level were 
identified after co-expression of the ER-resident LIMP-2 protein. B) Quantification of α-synuclein protein levels 
normalised to actin and expressed as percentage of α-synuclein level alone. For statistical analysis a one-way 
ANOVA with a subsequent Tukey-Kramer posthoc test was applied. * denotes p<0.05 and # p>0.05; n=4. 
 
In the following experiment, the observed effects in the murine N2a cells were verified in a 
human H4 cell system stably overexpressing α-synuclein (Figure 4.51). Like in the murine 
cells, immunoblots of H4 cells revealed a decrease in α-synuclein levels after overexpression 
of LIMP-2 compared to the GFP control (Figure 4.51 A, B). Furthermore, an intracellular 
shift of GC towards post ER compartments could be observed after LIMP-2 expression in the 















Figure 4.51: LIMP-2 overexpression leads to a decrease in α-synuclein protein levels in human H4 cells. 
A) Human neuroglioma cells were transfected with LIMP-2 (anti-myc) and a GFP control. Immunoblots were 
stained for the human variant of α-synuclein (LB509), GC and the neuronspecific enolase (NSE), which was 
utilised as a loading control. B) Quantification of α-synuclein protein levels normalised to NSE. C) Furthermore 
the post ER and ER fractions of the GC protein were densitometrically analysed, revealing an increase in the 
post ER fraction of GC protein after LIMP-2 expression. An independent two-sided Student’s t-test was used for 








Since α-synuclein exhibits a high turn-over rate, the effect of enhanced LIMP-2 expression 
was assessed over time in H4 cells. This human neuroglioma cell line stably overexpresses α-
synuclein under the control of a tetracycline-inducible promoter (‘Tet-off’). To study the 
clearance of α-synuclein, cells were transfected with a mock control as well as wild-type 
LIMP-2 and harvested between 0 and 72 hours. In parallel the cells were treated with 
doxycycline to stop further de novo transcription of α-synuclein. This led to a decrease in α-
synuclein protein levels. However, in the presence of additional LIMP-2 (expression of the 
protein starts after 24 hours) a faster clearance of α-synuclein could be observed (Figure 4.52 
A, B). In a same type of experiment the steady state expression of α-synuclein was visualised 
by immunoblot after 72 hours of LIMP-2 expression indicating a significant decrease of α-












    
 
Figure 4.52: Turn-over rate of α-synuclein after overexpression of LIMP-2 in human H4 cells. 
A) Immunoblot detecting α-synuclein turnover in human H4 cells after treatment with doxycycline to stop 
α-synuclein transcription. For detection of the α-synuclein protein an antibody specifically targeting the human 
variant of the protein was utilised (LB509). The expression of the LIMP-2 protein started after 24 hours (anti-
myc) and cells were harvested at time point between 8-72 hours. B) Intensity of α-synuclein protein band of 
immunoblots shown in A were normalised to the neuronspecific enolase (NSE). Results are presented as a curve 
over time highlighting enhanced clearance of α-synuclein in the presence of LIMP-2. Since the expression of 
LIMP-2 starts after 24 hours of transfection, also the protein levels of α-synuclein reveal changes from this time 
point on. The graph shows the α-synuclein protein levels from 24-72 hours and indicates a steeper slope for cells 
transfected with LIMP-2 in comparison to the mock transfected control cells (n=3). The absolute slope values are 
highlighted in the box above the graph. C) Immunoblot of H4 cell samples analysed after 72 hours expression of 
LIMP-2 stained for α-synuclein. NSE was utilised as a loading control. D) Densitometric analysis of α-synuclein 
signals (from blot shown in C) revealing a significant decrease in α-synuclein protein levels after LIMP-2 
expression. The protein level was normalised to NSE and expressed as percentage of mock transfected control. A 






These data suggest an accelerated clearance of α-synuclein after overexpression of LIMP-2 by 
increasing lysosomal GC activity. The results could be obtained in a murine (N2a) as well as a 
human cell line (H4) further emphasising the crucial role of LIMP-2 in the degradation and 
homeostasis of α-synuclein. 
4.7.1 The LIMP-2-derived helix 5 peptide: a novel therapeutic target for PD? 
Since it was shown that the enhancement of lysosomal GC and its enzymatic activity leads to 
a decrease in α-synuclein protein levels, GC is increasingly regarded as a new therapeutic 
target for the treatment of synucleinopathies. As described above a significant increase of 
lysosomal GC activity could be achieved by overexpression of LIMP-2.  
However, a more direct approach to enhance GC activity would be to target the enzyme 
directly. As shown in chapter 4.2.1, the LIMP-2-derived peptide (helix 5) was able to increase 
GC activity in vitro and also in cell culture (in J774E macrophages and GC-deficient 
fibroblasts). Consequently, the following study analyses the impact of the LIMP-2 peptide to 
also decrease intracellular α-synuclein levels.  
To optimise the cellular uptake, the LIMP-2-derived peptides were modified by a c-terminally 
linked cell-penetrating TAT-sequence, derived from the human immunodeficiency virus. This 
motif has been shown to facilitate transfer across the cell membrane via its amphiphatic 
structure (Frankel and Pabo 1988, Green and Loewenstein 1988). In addition a KFERQ-
sequence to support chaperone-mediated autophagy (CMA) and thus lysosomal import was n-
terminally linked (Horst, Knecht et al. 1999) (for peptide sequences see material and methods 
3.2.2.1).  
First, the effects of the uptake-optimised TAT peptides on GC activity were verified in vitro 
by co-incubation with recombinant GC. A similar increase (~3.5 fold) of recombinant GC 
(Cerezyme ®) activity as described for the unmodified peptides was observed (compare 
Figure 4.15 A and Figure 4.53 A). A control peptide including the triple aspartate (3xD) motif 
was used (Table 4.1) exhibiting no effect on GC activity (Figure 4.53 A). 
The ability of the TAT-peptides to decrease α-synuclein levels by cellular uptake and 
enhancement of GC activity was assessed. The α-synuclein overexpressing human 
neuroglioma cell line (H4 under a tetracycline-off promotor system) was used. H4 cells were 
incubated with the LIMP-2-derived TAT-peptide as well as the control TAT-peptide (3xD) 
and simultaneously treated with doxycycline (Dox) to suppress further de novo α-synuclein 
protein expression (Figure 4.53 B). Cells were harvested after 16, 24, 48 and 74 hours and 
showed enhanced clearance of α-synuclein when the helix 5 LIMP-2 TAT-peptide was 





(Figure 4.53). In contrast the control 3xD TAT-peptide did not show an increase in GC 












Figure 4.53: Uptake of LIMP-2-derived TAT peptides and their effects on intracellular α-synuclein levels. 
A) In vitro activity assay of recombinant GC (Cerezyme ®) incubated with uptake-optimised TAT-peptides 
(helix 5 and 3xD). GC activity was normalised to the buffer control. B) TAT-peptides (helix 5 and 3xD) were 
utilised for uptake in human neuroglioma cells (H4) and treated with doxycycline to stop de novo synthesis of 
α-synuclein. Immunoblots showing duplicates of samples harvested after 0, 16, 24, 48 and 72 hours of 
incubation with the peptides. An anti-α-synuclein antibody (LB509) was utilised to detect α-synuclein protein 
levels and the neuronspecific enolase (NSE) was used as a loading control. C) GC activity of H4 cell lysates 
after uptake of TAT-peptides (helix 5 and 3xD) indicating an increase of GC activity over time after incubation 
with the helix 5 TAT-peptide. D) Quantification of α-synuclein protein signals (immunoblot shown in B) 
revealing decreased α-synuclein levels starting from 24 hours after incubation with the helix 5 TAT-peptide 
compared to 3xD control peptide. The α-synuclein signal was normalised to the loading control NSE and the 
values are expressed relative to the starting point incubation (0 hours). A one-way ANOVA with a subsequent 
Tukey-Kramer posthoc test was utilised for statistical analyses. *; **; *** denote p<0.05; 0.01; 0.001; n=3.  
 
In conclusion these findings demonstrate that the LIMP-2-derived helix 5 peptide is able to 
reduce intracellular α-synuclein levels in a cell culture-based disease model. This indicates 
that the peptide-induced enhancement of GC activity is sufficient to reverse intracellular α-







Since LIMP-2 was described as the transport receptor of GC in the year 2007 (Reczek, 
Schwake et al. 2007), little progress has been made to identify details of their interaction. In 
2013 the crystal structure of the LIMP-2 ectodomain was solved by Neculai et al., revealing 
important information about LIMP-2 function and GC trafficking in the cell. Novel putative 
functions of LIMP-2 as well as structural properties important for the interaction with GC 
could be drawn from this protein model. Interestingly, the LIMP-2 protein structure 
uncovered the existence of a cavity traversing the entire length of molecule suggesting a 
potential function of the lysosomal membrane protein in intramolecular transport processes, 
such as lipid transport. In 2014 an independent structure analysis of the luminal domain of 
LIMP-2 was published (Zhao, Ren et al. 2014), claiming an M6P-dependent transport of 
LIMP-2 in complex with GC. To evaluate the impact of the putative M6P-tag on the cellular 
transport of LIMP-2, different cellular and in vivo experimental approaches were performed in 
this study. 
Interestingly, the LIMP-2 crystal structure exhibits an exposed helical bundle, which is 
important for GC binding. Interestingly, one single helix of the identified helical interaction 
site of LIMP-2 is sufficient to facilitate binding to GC.  This LIMP-2-derived peptide 
displayed a positive effect on GC activity. 
 
5.1 New insights on LIMP-2 trafficking and function 
Recently, crystallographic studies revealed the protein structure of the ectodomain of LIMP-2 
(Neculai, Schwake et al. 2013, Zhao, Ren et al. 2014). The description of the three-
dimensional structure improved our understanding of the molecular and structural properties 
of the protein. It enabled the performance of site-directed mutagenic studies to investigate 
details in ligand binding and gain knowledge about potential new roles of the protein. In 
general both protein structures (PDB: 4F7B (Neculai, Schwake et al. 2013) and PDB: 4Q4F 
(Zhao, Ren et al. 2014)) exhibit high similarities (see overlay Figure 1.7). In the study by 
Zhao and co-workers a putative mannose 6-phosphate (M6P) residue attached to the 
carbohydrate chain linked to N325 was identified. Based on this finding a lysosomal transport 
of LIMP-2 by interaction with the M6P-receptor was suggested possibly building a hetero-
trimeric complex together with a bound GC molecule (Figure 5.1). Additionally, plasmon 





cation-independent (CI)-M6P receptor. Further evidence for the interaction of LIMP-2 and 
CI-MPR was provided by fluorescence lifetime imaging microscopy in living cells (Zhao, 
Ren et al. 2014). Altogether this study questions the accepted view of an M6P-independent 
lysosomal transport of LIMP-2 and GC (Bonifacino and Traub 2003, Reczek, Schwake et al. 
2007, Braulke and Bonifacino 2009).  
 
   
Figure 5.1: Hetero-trimeric complex of LIMP-2 bound to GC and to the CI-MPR. 
A cartoon depicting LIMP-2 (red) associated with the CI-MPR (orange) by binding of a mannose 6-phosphate 
residue (M6P) attached to the LIMP-2 carbohydrate chain linked to amino acid residue N325. The 15 homologue 
domains of the CI-MPR are labelled and shown in orange octagons. A GC (blue) bound to LIMP-2 is shown 
with the glucosylceramide (GluCer) shown in black. The picture was adapted from Zhao et. al., 2014.  
 
To resolve the apparent paradox between the previous studies (Bonifacino and Traub 2003, 
Reczek, Schwake et al. 2007) and the data from Zhao et. al., the impact of the putative M6P-
modification on LIMP-2 trafficking was analysed in more detail. It could be demonstrated 
that LIMP-2 was able to reach the lysosomes independent of the existence of MPRs (cation-
dependent or -independent). Also in fibroblasts lacking M6P-residues due to the absence of 
the N-acetylglucosamine-1-phosphotransferase (GlcNAc-1PT) endogenous LIMP-2 was 
present in lysosomal compartments. Additionally, LIMP-2 as well as GC could be found in 
purified lysosomal fractions of livers from GlcNac-1PT-deficient animals. These results 
match published data showing lysosomal localisation of GC in fibroblasts lacking both MPRs 
(Reczek, Schwake et al. 2007). Since trafficking of LIMP-2 and GC is tightly linked, Reczek 
and co-workers already suggested an M6P-independent lysosomal sorting of LIMP-2. 
Moreover, Zhao et al. did not address the unchanged lysosomal transport of GC in human 
fibroblasts of I-cell disease patients (van Dongen, Willemsen et al. 1985, Aerts, Schram et al. 
1988). These patients lack M6P-containing lysosomal enzymes due to a defective 





that GC is trafficked to lysosomes by an M6P-independent transport. In 2007, LIMP-2 was 
identified as the transporter protein responsible for shuttling GC to the lysosomes (Reczek, 
Schwake et al. 2007). The studies performed by Zhao and co-workers neglect these important 
aspects and fail to provide experimental evidence, which is based on cell biological 
experiments. Since studies in human and murine fibroblasts and purified lysosomes did not 
indicate a M6P-dependent transport of LIMP-2, the physiological role of the described M6P-
tag found on the lysosomal membrane protein is questioned. Although the finding of a M6P-
residue in the crystal structure of Zhao et al. may be valid, it does not implicate that it is 
needed for the lysosomal trafficking of LIMP-2 and GC. The reported discrepancies in the 
two crystal structures could be due to the employment of different cell systems for the 
extraction of the recombinant protein. Zhao et al. used human HEK293S cells whereas 
Neculai et al. exploited SF-9 insect cells, which lack the GlcNAc-1-phosphotransferase (Aeed 
and Elhammer 1994).  
In an additional experiment, which was performed in collaboration with the laboratory of 
Prof. Thomas Braulke (University Hospital Hamburg), it is questioned that LIMP-2 is 
M6-phosphorylated at all. It was not possible to precipitate LIMP-2 from mouse fibroblasts 
using immobilised anti-M6P antibodies. Even in the absence of the lysosomal acid 
phosphatase Acp2 and 5, which under normal conditions dephosphorylate the proteins upon 
arrival in the lysosomes (Makrypidi, Damme et al. 2012), LIMP-2 failed to bind to the M6P 
antibodies (data not shown). In comparison cathepsin Z, a lysosomal cysteine proteinase 
suspected to be transported to the lysosomal compartment in an M6P-dependent manner 
(Santamaria, Velasco et al. 1998), could be precipitated indicating the presence of a M6P 
residue (data not shown). 
The recent understanding of the lysosomal sorting of transmembrane proteins has been 
proposed to be mediated by signals within the cytosolic domains of the proteins. Also LIMP-2 
exhibits a dileucin-based signal ([DE]XXXL[LI]), which interact with components of the 
clathrin coats such as adaptor protein complexes (AP-1 and AP-3) (Honing, Sandoval et al. 
1998, Janvier, Kato et al. 2003, Braulke and Bonifacino 2009). 
Interestingly, another theory of lysosomal LIMP-2 trafficking was proposed, describing two 
phosphatidylinositol 4-kinases (PI4Ks) to play a role in the trafficking pathway of LIMP-2 
and GC (Jovic, Kean et al. 2012). It remains unclear if the lysosomal targeting of LIMP-2 is 
mediated directly by the kinases or by their substrates, the phosphatidylinositol 4-phosphate 
(PtdIns4P). Both components have been shown to be crucial for the exit of LIMP-2 and GC 





transport of LIMP-2 but further claim the importance of the transmembrane or luminal 
domain of the lysosomal membrane protein in this trafficking pathway (Jovic, Kean et al. 
2012). Although the detailed mechanisms of the intracellular LIMP-2/GC transport still need 
to be further addressed, the results of the above mentioned experiments show that the M6P-
residue is not crucial for lysosomal trafficking of LIMP-2. 
 
5.1.1 Speculations about the function of the tunnel structure in the LIMP-2 protein 
The structure information of the LIMP-2 luminal domain (Neculai, Schwake et al. 2013, 
Zhao, Ren et al. 2014), also exhibited similarities including an unexpected finding within the 
core of the protein structure. Remarkably, a cavity traversing the entire length of the molecule 
was found in both crystal structures. This indicates a potential additional function of the 
lysosomal membrane protein besides its well-described role in the transport of GC. Since 
other members of the CD36 superfamily (the scavenger class BI (SR-BI) and CD36) are 
known as important regulators of lipid metabolism (Canton, Neculai et al. 2013), a possible 
function of LIMP-2 in lipid transport processes was evaluated in this study. The cavity within 
LIMP-2 predominantly exhibits a hydrophobic nature, which further supports the idea of 
mediating lipid transport (Neculai, Schwake et al. 2013). On the basis of the LIMP-2 crystal 
structure Neculai and co-workers homology modelled the protein structures of SR-BI and 
CD36. Subsequent mutagenesis of SR-BI suggests the transport of cholesterol(esters) from 
high-density lipoproteins (HDL) to the plasma membrane through the identified cavity (Gu, 
Trigatti et al. 1998, Gaidukov, Nager et al. 2011). Moreover, Neculai et al. show a direct 
interaction of SR-BI and CD36 with fluorescent high-density lipoprotein (HDL) and proposed 
that the identified tunnel moderates the selective lipid transfer of SR-BI and CD36 (Neculai, 
Schwake et al. 2013).  
Even though it is known that lysosomes have a function in the recycling of cholesterol, the 
mechanisms underlying intracellular cholesterol trafficking are still largely unknown. It is 
proposed that cholesterol gets unesterified through hydrolysis in lysosomes and is transported 
back to the ER were it gets redistributed within the cell (Brown and Goldstein 1986, Chang, 
Chang et al. 2006). Interestingly, a recent study additionally revealed an additional role of 
peroxisomes in intracellular cholesterol transport (Chu, Liao et al. 2015). However, the 
mechanisms how cholesterol leaves the lysosomes and moves to other organelles (e.g. ER or 
peroxisome) still remain elusive. It is conceivable that LIMP-2 can serve a second function 





So far, two proteins have been shown to be important for the lysosomal cholesterol export: 
Niemann-Pick C1 and C2 (NPC1 and NPC2). Hereby, NPC2 is proposed to deliver free 
cholesterol to the membrane-bound NPC1 for further transport of the lipid through the 
lysosomal membrane (Storch and Cheruku 2005). Although the actual details of the 
cholesterol transport mechanisms by NPC1 across the lysosomal membrane remain unknown, 
patients exhibiting mutations in either NPC-protein reveal strong lysosomal cholesterol 
accumulation (Tangemo, Weber et al. 2011). Initial studies in murine LIMP-2-deficient 
fibroblast as well as liver sections did not reveal any abnormal cholesterol levels (Figure 4.3 
and data not shown). To further verify a putative role of LIMP-2 in cholesterol transport, cells 
exhibiting aberrant cholesterol storage were utilised. Indeed, a significant decrease in the 
amount of lysosomal cholesterol could be observed in NPC patients fibroblasts after 
transfection of LIMP-2. Additionally, the same effect was observed when lysosomal 
cholesterol storage was generated artificially by treating cells with U18666A, a blocker for 
the lysosomal cholesterol exit. Cells positive for overexpressed LIMP-2 revealed a significant 
decrease in lysosomal cholesterol levels. Furthermore, cholesterol accumulation has been 
described in late endosomes and lysosomes of fibroblasts deficient for the two lysosomal 
membrane proteins LAMP-1 and LAMP-2 (Eskelinen, Schmidt et al. 2004, Schneede, 
Schmidt et al. 2011). Comparable to the other cell systems a reduction of the intra-lysosomal 
cholesterol levels could be observed after overexpression of LIMP-2 in LAMP-1/2 double-
deficient cells.  However, since there was no initial abnormality of intracellular cholesterol 
levels seen in the absence of LIMP-2, it rather points to a minor effect of the lysosomal 
membrane protein on the intracellular cholesterol distribution. The results lead to the 
conclusion that other proteins, e.g. NPC1 and NPC2 are more important for the cholesterol 
transport, whereas LIMP-2 is able to additionally support the efflux of cholesterol when the 
cell is stressed and cannot keep up with the intracellular amounts of cholesterol.  
To verify if the effect of LIMP-2 on cholesterol trafficking is indirect, as suspected for 
LAMP-2 (Schneede, Schmidt et al. 2011), or if the cholesterol transport is mediated directly 
through the proposed cavity, a ‘tunnel mutant’ was designed. A point mutation within the 
cavity results into a sterically block of the tunnel (A379W and V415W). After controlling the 
lysosomal localisation of the mutants, the effect on lysosomal cholesterol efflux was 
abolished in a preliminary study. The actual impact of LIMP-2 in the lysosomal export of 
cholesterol has to be further addressed. Also, a more sensitive cholesterol read-out other than 





activated cell sorting (FACS) protocol to stain and sort for free cholesterol could improve the 
experimental validity.   
Cholesterol is not the only hydrophobic molecule which could possibly be delivered to the 
cavity of the LIMP-2 protein. In this regard, LIMP-2 might not only transport the lysosomal 
hydrolase GC to lysosomes, but may also facilitate its catalytic reaction. The tunnel in the 
LIMP-2 protein may interact with the hydrophobic parts of the substrate (ceramide) 
presenting the hydrophilic part (glucose-residue) to the enzyme. An interaction of LIMP-2 
together with GC and its substrate glucosylceramide has been proposed by Zhao et al. (see 
cartoon in Figure 5.1). In cooperation with the laboratory of Prof. Joost Holthuis (Molecular 
Cell Biology Division, University of Osnabrück), preliminary results analysing an interaction 
of LIMP-2 with glucosylceramide as well as with ceramide were generated by using 
bifunctional fatty acids (Haberkant and Holthuis 2014). For this experimental approach photo-
activated-and-clickable lipids (pacLipids) were mixed with the recombinant GC and 
subsequently subjected to UV-light in order to crosslink the lipids to the interacting protein. 
This step was followed by a ‘click-chemistry’ reaction, where the pacLipids got labelled with 
a fluorophore, which then could be visualised in-gel after subjecting the samples to SDS-
PAGE. The intensities of the fluorescent signals on the gel indicate the strength of interaction 
to the lipids. For LIMP-2 a strong positive signal could be observed after interacting with 
ceramide. Surprisingly, GC did not bind to any lipid. Only when the pH was decreased below 
seven an interaction of GC with glucosylceramide was detectable (data not shown). Indeed, 
the preliminary data indicates an interaction of LIMP-2 with ceramide as well as 
glucosylceramide. This interaction emphasises a putative role of LIMP-2 in facilitating 
enzymatic turnover of GC. A stronger interaction of LIMP-2 with the reaction product 
(ceramide) after the hydrolysis of glucosylceramide, might be supportive for the catalytic 
reaction. To fully understand and interpret the data additional experiments will have to be 
performed. For example mass spectroscopic analysis after covalently linking the lipids to the 
recombinant proteins are currently performed and will help to identify the lipid binding sites 
of the lipids of LIMP-2 and GC. 
 
Interestingly, a recent study describes the crucial impact of the hydrophobic tunnel in 
uncoating the enterovirus EV71 after binding of the virus to the apical helical bundle of 
LIMP-2 (Dang, Wang et al. 2014). This emphasises the functional importance of the two 
structural striking characteristics revealed by the LIMP-2 protein crystal structure: the apical 





hydrophobic nature mediate more functions within the cellular metabolism as for example 
facilitating GC activity or lysosomal cholesterol export.   
5.2 The interaction of LIMP-2 and GC 
5.2.1 Analysing the GC binding site on the LIMP-2 protein 
Studies in I-cell disease patient’s fibroblasts, that lack M6P-containing lysosomal enzymes 
due to a defective phosphotransferase, revealed an unchanged transport of GC to lysosomes 
(Dittmer, Ulbrich et al. 1999, S. Kornfeld 2001). This supported the conclusion that a 
lysosomal trafficking mechanism exists, which is mediated by an M6P-independent 
transporter. This receptor remained elusive until 2007. Reczek and co-workers found LIMP-2 
as a specific binding partner of GC in an affinity-chromatography experiment (Reczek, 
Schwake et al. 2007). Since then a highly conserved coiled-coil motif (His150-Leu167) 
within the luminal domain of LIMP-2 has been described as an interaction interface for 
binding GC (Reczek, Schwake et al. 2007, Blanz, Groth et al. 2010, Zachos, Blanz et al. 
2012). A disruption of this coiled-coil motif abolished the interaction with GC (Reczek, 
Schwake et al. 2007). An ER-resident LIMP-2 mutant still shows binding to GC, implicating 
an early association of both proteins in the ER at neutral pH (Reczek, Schwake et al. 2007, 
Blanz, Groth et al. 2010, Zachos, Blanz et al. 2012). The recently solved LIMP-2 crystal 
structure revealed the genuine nature of this coiled-coil motif. It is part of an exposed helical 
bundle consisting of three α-helices: helix 4 (Asn137-Gln148), helix 5 (Val149-Gln164) and 
helix 7 (Lys181-Pro193) (Figure 5.2). The previously identified coiled-coil domain contains 
helix 5. Since the name coiled-coil implicates an interaction of one coiled structure to another 
coiled region with identical structural properties, which GC does not exhibit, this termination 
is no longer applicable and will be referred to as helix 5 in the following studies. The crystal 
structure does not only verify the previous findings, but it also allowed the design of specific 
LIMP-2 mutants. Site-directed mutagenesis was performed within the exposed helical bundle 
of LIMP-2 to verify its impact in GC binding. Protein surface exposed amino acids were 
substituted by charged aspartate-residues (D) in order to abolish the highly hydrophobic 
property of this protein region. It was observed that all point mutations in helix 5, but also in 
helix 7 of LIMP-2 greatly impaired binding to GC. Surprisingly, the K166D mutant -located 
at the distal apical protein site, but outside the helical bundle- showed a rescue in GC activity 
similar to the wild-type (Figure 4.10). This result is in apparent contrast to the Co-IP study, 
where interaction with GC of this mutant was completely abolished. Such differences show 





different cell systems. The observed discrepancy in the behaviour of the K166D mutant may 
be explained by differences of the employed cell lines (Cos7 for CoIP and murine MEF cells 
for rescue experiment). Despite this uncertainty all other data clearly underline the important 
function of the apical helix 5 and 7 of LIMP-2 in binding GC. Both helices are part of an 
exposed helical bundle, which exhibits highly hydrophobic characteristics, suggesting ligand 
binding mediated by hydrophobic interactions (Figure 4.25 and Figure 5.2). The exposed and 
hydrophobic nature of the apical helical bundle has been shown to be important for mediating 
a variety of specific functions, including binding of the enterovirus EV71 before cellular 
uptake (Dang, Wang et al. 2014). Furthermore, the two other CD36 family members (SR-BI 
and CD36) show binding of HDL as well as oxidised low-density lipoprotein (oxLDL) 
mediated by the hydrophobic helical patch (Neculai, Schwake et al. 2013). 
 
 
Figure 5.2: LIMP-2 protein model with highlighted hydrophobic interaction site. 
LIMP-2 protein structure with helical bundle indicated in red consisting of helix 4, 5 and 7. This area has been 
proposed to mediate ligand binding by hydrophobic amino acids, which are indicated in yellow forming a 
hydrophobic cleft. The structural illustration was performed with UCSF Chimera (PDB: 4F7B). 
 
To date only ten mutations have been described in the SCARB2 gene encoding for LIMP-2 
causing myoclonus epilepsy (AMRF) (Berkovic, Dibbens et al. 2008, Dardis, Filocamo et al. 
2009, Dibbens, Michelucci et al. 2009, Dibbens, Karakis et al. 2011). The majority of the 
SCARB2 mutations are null mutations and associated with a truncation of the LIMP-2 protein, 
clearly affecting normal protein function including lysosomal transport of GC (Blanz, Groth 
et al. 2010). Only one missense mutation located outside of the helical bundle has been 
described (H363N) (Dardis, Filocamo et al. 2009, Dibbens, Karakis et al. 2011). Human 





LIMP-2 mutants, which are incapable of binding GC, might be a powerful tool to study 
potential additional role of the lysosomal protein independent of its GC-transport function via 
the helical bundle. For example a transgenic mouse overexpressing a GC-binding deficient 
LIMP-2 variant could exhibit novel functions of LIMP-2, which are independent of an intact 
helical bundle. Since, the major function of LIMP-2 is restricted to GC transport, the 
appearing phenotypes in this mouse model will mainly correlate to functions of LIMP-2 other 
than interaction and trafficking of GC.     
 
Further validation of the GC-interaction site of LIMP-2 was provided by interaction studies 
with a small LIMP-2-derived peptide (helix 5). The 24 amino acids long α-helix was able to 
specifically mediate the interaction in vitro to recombinant GC (Cerezyme ®), as well as to 
endogenous enzyme from cell lysate. Hence, the peptide shows a great potential to be 
exploited for further GC-precipitation assays.  
 
5.2.2 Analysis of the LIMP-2 binding site on the GC protein 
Due to difficulties in the initial purification of recombinant LIMP-2 the identification of the 
LIMP-2 binding site on GC was not possible by a co-crystallisation approach with the two 
recombinant proteins (LIMP-2 and GC). Hence, the LIMP-2-derived peptide (helix 5), which 
was shown to mediate a specific interaction to GC, was used instead of the entire LIMP-2 
prtein for co-crystallisation experiments. Highly purified GC, clinically used for enzyme 
replacement therapy (Cerezyme ®, Genzyme, USA) was co-incubated with the peptide. An 
existing crystal structure of fully glycosylated GC (Cerezyme ®) was published in 2006 and 
exhibits three N-glycosylation sites (Figure 1.9) (Brumshtein, Wormald et al. 2006). To 
obtain co-crystals of the recombinant GC and the small helical peptide two different strategies 
were applied. Firstly, the peptide was added to existing crystals of GC. Secondly, recombinant 
GC and peptide were incubated in solution before seeding for crystallisation. Although it was 
possible to obtain good quality crystals (high diffraction and resolution), both approaches 
failed since the peptide could not be visualised. A possible explanation for this failure could 
be related to the tight crystal-packaging of GC (Brumshtein, Wormald et al. 2006). Most 
likely the interaction of single GC molecules is stronger than the binding of GC to the peptide. 
In future studies deglycosylation of the GC protein beforehand may help to increase the space 
between single GC molecules. Future co-crystallisation approaches may be performed using 






Since the co-crystallisation approach was not successful, a different strategy was applied to 
study the LIMP-2 binding site on the GC protein. Potential sites of interaction were identified 
using the knowledge about the LIMP-2 crystal structure (PDB: 4F7B). As mentioned earlier 
the highly hydrophobic characteristic of the helical bundle in LIMP-2 suggests ligand binding 
via hydrophobic interactions. Therefore, the GC protein structure was analysed for surface 
charges. Similar to LIMP-2 a hydrophobic patch was observed (Figure 4.25). The 
hydrophobic protein region in GC exhibits a distinctive fold of α-helices, similar to the helical 
bundle found in LIMP-2. The helical patch of GC consists of one long angled helix 1 (Thr86-
Ser110) and one short helix 2 (Pro150-Ala168) (Figure 5.3). Furthermore, the orientation of 
the hydrophobic amino acids within the helical bundle show a distinct hydrophobic cavity, 
exhibiting a perfect interaction site for an exposed hydrophobic α-helical structure as found 
on the apex of LIMP-2.  
To analyse the impact of this particular protein region of GC on the binding of LIMP-2, site-
directed mutagenesis was performed. The three hydrophobic leucins (L) on position 91, 94 
and 156 were individually substituted with highly charged glutamic acids (E) in order to 
lower the hydrophobic characteristics of the interaction site (Figure 5.3). Although all three 
mutants lost the ability to bind LIMP-2 in a co-precipitation approach, the mutants slightly 
differed in their binding behaviour. To study the properties of each GC mutant, a number of 
additional assays were applied, including subcellular localisation studies (immuno-
fluorescence with lysosomal and ER markers), endoglycosidase digestion assays and LIMP-2 
co-expression studies. The later experiment was designed to further verify the interaction site 
on GC protein and to evaluate if an increased LIMP-2 expression may be of potential benefit 
to facilitate transport of GC and its mutants to the lysosome.  
A mild interaction of the GC L94E mutant with LIMP-2 could be observed, whereas L91E 
and L156E were incapable of binding LIMP-2. Furthermore, the L94E mutant showed a slight 
increase in GC activity after additional LIMP-2 overexpression. Therefore the leucine reside 
at position 94 may play a minor role compared to the leucines at position 91 and 156 in 
binding of LIMP-2. Thus, the integrity and hydrophobicity of the upper part of the helical 
bundle, where the leucines 91 and 156 are located, appear to be more important in mediating 







Figure 5.3: The potential LIMP-2 interaction site on the GC protein exhibits hydrophobic characteristics.  
Structural model of GC with the helical bundle highlighted in red and all hydrophobic amino acids marked in 
yellow. For the experiments described in this study the three leucines located at position 91, 94 (in helix 1) and 
156 (in helix 2) were substituted with glutamic acid in order to destroy the hydrophobic nature of the helical 
bundle. The structural illustration was created using UCSF Chimera (PDB: 2J25). 
 
Using GC mutants (L91E, L94E, L156E), the hydrophobic properties that play a critical role 
in LIMP-2 binding were identified. To further validate the binding site of LIMP-2, clinical 
GC mutants were included in this study. Interestingly, only 13 out of almost 300 mutations 
that cause Gaucher disease have been reported in the potential LIMP-2 binding site affecting 
only 9 different amino acids (green amino acids in Figure 5.4) (Hruska, LaMarca et al. 2008, 
Malini, Grossi et al. 2014). Additionally, most of these patients present with a mild 
phenotype, mostly resembling type 1 Gaucher disease characterised by splenectomy and bone 
phenotypes but no neuropathological symptoms (Cormand, Harboe et al. 1998, Demina and 
Beutler 1998). Only two patients with mutations in the predicted interaction site (S107L, 
I161S) were described presenting neurological impairments (Demina and Beutler 1998, 
Goker-Alpan, Lopez et al. 2008). Interestingly, the consequences of the I161 mutation are 
diverse, resulting in either type 1 (Cormand, Harboe et al. 1998) or the neuronopathic type 3 
Gaucher disease (Goker-Alpan, Schiffmann et al. 2004). An explanation for Gaucher patients 
with comparable mild phenotypes in the potential interaction site, may be that the enzyme is 
recaptured from the extracellular space. Since the binding-deficient GC mutants are still 
enzymatically active, the amount of GC reaching lysosomes indirectly may be sufficient for 
several cell types to degrade sphingolipids. 
Similarly, the ability of cells in taking up molecules and even whole proteins is exploited for 
enzyme replacement therapy in Gaucher disease (Sly, Kaplan et al. 1978, Stahl, Rodman et al. 





Gaucher disease due to their high metabolic rate (Pastores 1997), efficiently engulf small 
substrates, molecules and even whole cells (Weissleder, Nahrendorf et al. 2014).  
In this study, the two clinical associated and enzymatically active GC mutations located in the 
putative interaction site (P159L and I161S) failed to bind LIMP-2. A structural explanation 
for this behaviour might be the decrease of the hydrophobicity of the helical bundle of GC 
when substituting isoleucine to serine (I161S). The P159L mutant possibly interferes with the 
secondary structure of the helical bundle and potentially neighbouring protein structures.   
 
 
Figure 5.4: GC protein model indicating all existing disease causing missense mutations.  
The GC protein exhibits almost 300 unique mutations (including 203 missense mutations shown here in 
red/green). The green amino acids indicate the nine amino acids, which might result in clinical missense 
mutations located in the LIMP-2 interaction site. The catalytic cavity is labelled in yellow (E325 and E340). The 
widely spread location of the occurring mutations indicates functional importance of the whole protein for 
optimal enzymatic function. The structural illustration was created using UCSF Chimera (PDB: 2J25). 
 
The hydrophobic helical bundle is found opposite of the catalytic cavity (E325 and E340 
indicated in yellow, figure 5.4 and 5.5) as well opposite of proposed saposin C binding site 
(green, figure 5.5) (Atrian, Lopez-Vinas et al. 2008, Lieberman 2011). Saposin C is an 
important cofactor for GC (Vaccaro, Tatti et al. 1994, Wilkening, Linke et al. 1998). For 
optimal enzyme activity GC has been shown to associate with negatively charged lipids 
residing in the limiting membrane of the lysosome (Mueller and Rosenberg 1979, Osiecki-
Newman, Fabbro et al. 1987, Grace, Newman et al. 1994). The structural model of GC 
(Figure 5.5) highlights all functionally important protein regions and thus displays the 
unrestricted accessibility of the hydrophobic interaction site of GC, further supporting its role 









Figure 5.5: Structural model of GC indicating functionally important regions. 
The protein model of GC with highlighted areas important for protein function: Glycosylation chains (grey), 
active site (yellow), saposin C (green) and lipid interaction site (orange). The potential LIMP-2 interaction site is 
indicated in red, showing its good accessibility with all functionally important regions located on the opposite 
side of the protein. In addition, the carbohydrate residues are arranged in favour for an interaction with LIMP-2. 
The structural illustration was done using UCSF Chimera (PDB: 2J25). 
 
To exclude secondary effects of the inserted mutations, it is important to check the protein 
integrity before performing structural analysis. For enzymes the activity can be used as a 
measurement of protein integrity. Only those GC mutants exhibiting considerable enzymatic 
activity were used in the interaction studies with LIMP-2. However, it should be noted that 
the specific activity was generally low, even for mutations within regions not involved in the 
catalytic function of the enzyme. Even mutations within the proposed LIMP-2 interaction site, 
which is located at the opposite side of the catalytic cavity (Figure 5.5), show reductions in 
GC activity. The L94E and N188S GC mutants showed ~60% and ~50% residual enzyme 
activity compared to the wild-type (Figure 4.26), similar to reports for the N188S mutant 
(Tajima, Ohashi et al. 2010). In general minor changes to the GC sequence by single point 
mutations lead to changes in activity highlighting the sensitivity and complex arrangement of 
the enzyme. In general, the rate of GC activity does not correlate with the severity of the 
Gaucher disease. This further highlights the complexity and the necessary contribution of 
other factors to the clinical manifestation of the disease. Considering the tight interaction and 
dependence of GC on its transport receptor LIMP-2, it was hypothesised that also mutations 
in SCARB2 could modulate the phenotype in Gaucher disease. In fact, mutations in the 
LIMP-2 protein were found to modify Gaucher disease (Velayati, DePaolo et al. 2011).   
 
Recently, another study addressed the LIMP-2 binding site on GC (Liou, Haffey et al. 2014). 
In order to locate the interaction site, the authors designed truncation mutants of GC. Taking 





elsewhere in literature (Pasmanik-Chor, Laadan et al. 1996, Liou, Kazimierczuk et al. 2006, 
Tajima, Ohashi et al. 2010), this approach seems questionable. Liou et al. proposed that the 
GC binding sequence on LIMP-2 consists of an 11 amino acid long stretch (Liou, Haffey et 
al. 2014), which forms a surface accessible loop and is in close vicinity to the helical bundle 
reported here. However, most of the mutated residues within this loop (D399-D409) point 
towards the interior of GC (Figure 5.6). Thus, the data rather suggest a secondary effect of the 
introduced mutants on the structure of surrounding areas, such as the helical bundle. It seems 
unlikely that the reported loop of GC is directly involved in LIMP-2 binding. This view is 
supported by the fact that single mutations in this region were unable to completely disrupt 
GC binding to LIMP-2 (Liou, Haffey et al. 2014). As indicated in figure 5.6 only amino acids 
I406-D409 exhibit surface exposure (yellow; Figure 5.6). Liou et al. further mutated T407 
and D409 to alanine (A) and observed impaired LIMP-2 binding. However, as illustrated in 
figure 5.6 B this effect might also be indirect by affecting the structural properties of the 
helical bundle. The aspartic acid may stabilise the surrounding protein region, including the 
helical bundle. Thus, the acid-derived proton may interact with a serine in the helical bundle 
(S97). A substitution of the aspartic acid to an alanine (D409A), a small hydrophobic amino 
acid, does not allow this kind of acid-base interaction and might lead to a collapse of the 
overall protein structure. Therefore, the identified loop might rather have an important 


























Figure 5.6: Structural analysis of the described interaction sites in the GC protein. 
A) Structural model of GC with the highlighted proposed LIMP-2 interaction sites: helical bundle (red) and the 
11 amino acid long loop (orange; with introduced point mutations from Liou et. al., 2014 in yellow). Amino 
acids D399, I402 and I403 were hypothesised to be involved in the interaction with LIMP-2. As indicated in the 
surface view only amino acids I406-D409 are exposed on the surface. B) In addition Liou et al. substituted D409 
to alanine. A possible interaction between the aspartic acid and a serine (S97) in the helical bundle might be 
responsible for the stabilisation of this protein region, which is lost when the acid is exchanged to an alanine 
(D409A). The structural illustration was performed using UCSF Chimera (PDB: 2J25). 
 
5.2.3 The overall picture: combining all data about the LIMP-2 and GC interaction 
The determination of the binding sites of LIMP-2 and GC with the help of the single crystal 
structures of both proteins (Brumshtein, Wormald et al. 2006, Neculai, Schwake et al. 2013) 
provided a deeper understanding in to how this receptor/ligand protein complex may form. It 
suggests that LIMP-2 and GC interact through contact of their helical bundles in a 1:1 
stoichiometry, which is consistent with previous crosslinking experiments obtained after co-
expression of LIMP-2 and GC in Cos7 cells (Reczek, Schwake et al. 2007).  
Our interaction model (Figure 5.7) of LIMP-2 and GC reveals that the glycosylation patterns 
of both proteins are also arranged in favour for an interaction at the proposed sites. The 
carbohydrate chains may even exert an auxiliary function contributing to the stabilisation of 
the LIMP-2-GC protein complex. Furthermore, the importance of intact glycosylation in 





which is in close proximity to the helical bundle, leads to a retention of the mutant in the ER 
(Neculai, Schwake et al. 2013). 
As another interesting feature of LIMP-2 is its role as a receptor on the plasma membrane that 
binds enteroviruses (e.g. EV71), the causative pathogen of hand, food and mouth disease 
(Yamayoshi, Yamashita et al. 2009). Importantly, the helical bundle of LIMP-2 is involved in 
the association and uncoating of the EV71 virus (Yamayoshi and Koike 2011, Dang, Wang et 
al. 2014). Therefore, the hydrophobic characters of helix 5 and 7 in the LIMP-2 binding 
interface seem to mediate this specific interaction. In addition, the glycosylation pattern of 
LIMP-2 is described to play a key role in the binding and uncoating events of the EV71 virus 




Figure 5.7: Structural model of LIMP-2 and GC showing their interaction.  
LIMP-2 and GC structural models indicate binding in a 1:1 stoichiometry by interaction of both helical bundles 
(red). The oliogosaccharide chains are indicated in yellow. Their arrangements around the proposed interaction 
site also suggest an interaction and thus stabilisation of the whole protein complex. The structural illustration 
was created using UCSF Chimera (PDB: 2J25; 4F7B) with the transmembrane domains (green) and membrane 
modelled subsequently to the protein model. 
 
A small peptide derived from the binding site of LIMP-2 (helix 5: L152-E175) was able to 
mediate interaction with GC. This primarily verified the specificity of the LIMP-2 interaction 
site, but the peptide was also used to confirm the binding site on GC. Less interaction with the 





5.3 The LIMP-2-derived helix 5 peptide: a therapeutic target?  
One important finding from this study is that helix 5 in the helical bundle of LIMP-2 is 
apparently sufficient for GC binding. This was shown for recombinant GC in an in vitro 
approach as well as for endogenous and overexpressed GC from Cos7 and N2a cell lysate, 
respectively. In contrast, the apical helix 7 was not able to mediate interaction with GC as 
efficiently. This might be due a less exposed position of helix 7 in comparison to helix 5 in 
the LIMP-2 protein (Figure 5.2).  It rather suggests a supportive role of the helix 7 in ligand 
binding than its direct interaction with GC. A non-binding peptide with a substitution of three 
aspartic acids (3xD) within the helix 5 amino acid structure was used to control for the 
specificity of binding. The inability of a LIMP-2 mutant with this 3xD motif to bind GC was 
previously shown in cell-based experiments (Blanz, Groth et al. 2010).  
 
Intravenous enzyme replacement is currently the accepted standard treatment for Gaucher 
disease. The recombinant GC is expressed in different cell systems and efficient purification 
relies on an extensive protocol (Jayapal, Wlaschin et al. 2007, Shaaltiel, Bartfeld et al. 2007, 
Starzyk, Richards et al. 2007, Zimran, Loveday et al. 2007, Weinreb 2008, Pastores 2010). 
The specific interaction of the LIMP-2-derived peptide with GC may be of impact, since it 
may be used as an alternative strategy to efficiently purify GC from cells or cell lysates. 
Further studies are necessary to assess how to optimise the enzyme purification.    
Although enzyme replacement therapy is very costly and the intravenously applied enzyme is 
not able to cross the blood-brain barrier (Altarescu, Hill et al. 2001), this therapy is still the 
therapy of choice to treat Gaucher disease. Other therapeutic strategies employ substrate 
reduction, gene therapy and small molecules (Cabrera-Salazar, Novelli et al. 2002, Cox 2005, 
Sawkar, D'Haeze et al. 2006, Sidransky, LaMarca et al. 2007).   
Chemical chaperones are small molecules, which are able to bind proteins and assist their 
correct folding (Perlmutter 2002). The hypothesised molecular mechanisms of the compounds 
involve their competitive binding to the active site of the protein. This is thought to facilitate 
proper folding of the enzymes and assures their trafficking to lysosomes where the small 
molecule is substituted by the substrate. To date, the two chemical chaperones of GC, 
isofagomine and the imino sugar N-butyldeoxynojirimycin (NB-DNJ, miglustat) have been 
described and shown to bind within the active site of the protein (Alfonso, Pampin et al. 2005, 
Brumshtein, Greenblatt et al. 2007, Lieberman, Wustman et al. 2007, Kornhaber, Tropak et al. 





GC, which subsequently leads to higher lysosomal levels of the enzyme (Alfonso, Pampin et 
al. 2005, Shen, Edwards et al. 2008).   
In this study the LIMP-2-derived helix 5 peptide increased recombinant GC enzyme activity 
about 4-fold. The detailed mechanism of the helix 5-mediated GC activation is unknown. 
However, a stabilisation of the enzyme at 37°C and pH7 after incubation with the peptide 
could be assessed. A chaperone-like function of the helix 5 peptide similar to the above 
mentioned chemical chaperones could be an explanation for the stability effect. The LIMP-2-
derived peptide appears not to bind within the active site of GC, as shown for the described 
chemical chaperones of GC. Since the LIMP-2 binding site has been shown to be located 
opposite to the active site (Figure 5.5 and Figure 5.8), it is likely that the LIMP-2-derived 
peptide, which resembles the interacting α-helix, binds to the same protein region. Thus, the 
chaperone-like stabilisation and activation of the enzyme by the LIMP-2-derived peptide 
appears not to be due to a competitive inhibitory effect.  
The characterisation of a GC activator, which does not simultaneously exhibit an inhibitory 
effect, could be of advantage for a therapeutic use since it is easier to control and adjust. For 
example, the consequences of applying a wrong concentration of a non-inhibitory activator 
(like the helix 5 peptide) would not be as disastrous as for an inhibitory molecule, which can 
potentially block the complete enzyme function.  
Considering that the LIMP-2-derived peptide binds to the same protein region as the LIMP-2 
protein, it further opens the possibility to design small molecules to target this particular 
protein domain (Figure 5.8). The development of small non-inhibitory molecules, which in 
addition are able to cross the blood-brain barrier and thus be able to target the neurological 
pathologies in certain cases of Gaucher disease.     
 
 
Figure 5.8: GC protein structure with LIMP-2 helix 5 peptide bound to the helical bundle. 
The GC protein structure with highlighted helical bundle (red) interacting with the LIMP-2 helix 5 peptide 
(yellow). The active centre on the opposite side of the protein is indicated in blue by the two catalytically active 





To study the effects of the LIMP-2-derived peptides on GC activity in vivo, the uptake of 
recombinant GC (Cerezyme ®) that was preincubated with the peptides was assessed in GC-
deficient MEF cells. These cells exhibit the perfect read-out system for the uptake of 
recombinant GC, since they do not have endogenous GC. After efficient internalisation of 
Cereyzme ® preincubated with the helix 5 peptide, an increased intracellular GC activity was 
observed in comparison to cells treated with Cerezyme ® only. This suggests a strong 
interaction of the peptide with GC, since the complex appears to stay stable even after uptake 
by the cells. It could be shown, that the helix 5 peptide has a stabilising effect on the GC 
protein, steadily enhancing its activity when incubated at 37°C and neutral pH. It is 
conceivable, that GC is preincubated with the helix 5 peptide, leading to stabilisation and an 
increase in enzyme activity before applying the recombinant enzyme by intravenous infusion. 
This initially higher activity of GC could reduce the amounts of required enzyme leading to a 
reduction of costs for this highly expensive form of therapy.        
Furthermore, the effect of the helix 5 peptide on endogenous GC after incubation with cells 
was assessed. Murine macrophages (J774E) as well as human brain neuroglioma cells (H4) 
were able to efficiently incorporate the LIMP-2-derived peptides, which led to an increase in 
intracellular GC activity. For further optimisation of the cellular and lysosomal uptake, the 
peptides were altered through addition of a cell-penetrating TAT-motif (Frankel and Pabo 
1988, Green and Loewenstein 1988) and a chaperone-mediated-autophagy marker sequence 
(Horst, Knecht et al. 1999). These modifications made the cellular uptake of the peptides 
more efficient and significantly reduced the amount of the applied peptide (from 50 μM to 1 
μM) necessary to reach comparable levels of activity when compared to the unmodified 
sequence. 
Future studies are needed to address if the helix 5 peptide shows similar positive effects on 
GC activity in vivo tested in animals. Additionally it remains unclear if the helix 5-induced 
boost of GC activity is sufficient to lead to a reduction of its substrate glucosylceramide. The 
lack of suitable animal models, which accurately recapitulate the clinical manifestations of 
human Gaucher disease, makes it difficult to further study the therapeutic effect of the LIMP-
2 peptide in vivo.   
 
The increase in GC activity in vitro as well as in cell culture induced by the LIMP-2 peptide 
indicates that helix 5 may be able to act as a direct activator. Additionally, recombinant GC 
showed increased activity when incubated with the purified luminal domain of LIMP-2, 





described in literature that the enzyme dissociates from its transport receptor LIMP-2 in a pH-
dependent manner (Reczek, Schwake et al. 2007, Zachos, Blanz et al. 2012). That would 
implicate a stabilising function of LIMP-2 before this pH-dependent dissociation from GC 
takes place. But what is the benefit of stabilising GC in the ER when the enzyme is actually 
fulfilling its function within lysosomes? Facilitating enzymatic activity within the ER may be 
important in order to regulate hydrolysis processes, since it cannot be excluded that GC has 
additional, not yet identified, functions within the ER or anywhere else besides the lysosome. 
In addition it has to be mentioned, that all performed GC activity assays were carried out at 
low pH (~5). Since the helix 5 peptide as well as the luminal domain of LIMP-2 revealed a 
positive effect on GC function under these conditions, it indicates a permanent interaction of 
the enzyme with both molecules. This seems to be in contrast to the situation in the cell.  In a 
recent study a histidine (H171) located in close proximity to the helical bundle has been 
described to be crucial for pH-dependent dissociation of ligands (Zachos, Blanz et al. 2012). 
Since this histidine is included in the helix 5 peptide sequence, it seems likely that 
conformational changes induced by this histidine are not sufficient to lead to a dissociation of 
the peptide and GC. Thus, a different study lately postulated that a different histidine close to 
the helix 5 (H150) is responsible for acting as a pH sensor to regulate ligand binding (Dang, 
Wang et al. 2014, Zhao, Ren et al. 2014). This amino acid is not included in the peptide 
structure and may explain the association of peptide and enzyme even at a low pH. A further 
explanation might be that the actual dissociation of LIMP-2/helix5 peptide and GC in 
lysosomes is incomplete. 
5.4 The role of LIMP-2 in α-synuclein homeostasis  
Besides the well-described role of LIMP-2 as a transporter for GC to lysosomes, little is 
known about its function in the central nervous system. In addition to the structural data 
provided in this study, this work addresses the role of LIMP-2 in the regulation of the cellular 
homeostasis of α-synuclein. Dysfunction of GC causes the most common lysosomal storage 
disorder Gaucher disease (Brady, Kanfer et al. 1966). Recently mutations in the GBA1 gene 
encoding for GC have also been associated with Parkinson disease (Westbroek, Gustafson et 
al. 2011) and other synucleinopathies such as Lewy body disease (Goker-Alpan, Giasson et 
al. 2006, Clark, Kartsaklis et al. 2009). At a molecular level it could be shown that the loss of 
GC activity and the simultaneous accumulation of its substrate glucosylceramide lead to the 





Since lysosomal activity of GC is tightly linked with the expression of its transport receptor 
LIMP-2, α-synuclein levels were analysed in murine brain of LIMP-2-deficient mice. For this 
study mice were backcrossed into the C57BL/6N background. In a previous study animals in 
the background of a C57BL/6J Harlan strain have failed to show any signs of 
synucleinopathy, since this strain is deficient in α-synuclein (Specht and Schoepfer 2001, 
Gamp, Tanaka et al. 2003). 
5.4.1 Consequences of LIMP-2 deficiency on lysosomal function in murine brain 
Biochemical analyses of the midbrain and pons of LIMP-2-deficient animals showed a 
complete absence of the LIMP-2 protein and significant reduction in the steady-state levels of 
GC accompanied by a dramatic decrease of enzyme activity.Since LIMP-2 is the only 
described transport receptor for the lysosomal enzyme a cellular missorting of the enzyme 
seems to be a logical consequence. In a previous study deficiency of LIMP-2 led to the 
secretion of GC in fibroblasts and primary macrophages (Reczek, Schwake et al. 2007). A 
further approach using a fluorescent probe specifically targeting active GC (Inhibody ®) 
(Witte, Kallemeijn et al. 2010) confirmed the significant reduction of active enzyme in 
LIMP-2 deficient brain (Rothaug, Zunke et al. 2014). 
The deficiency of GC activity in patients with GD type 2 and 3 leads to neurological 
symptoms (Sidransky, Sherer et al. 1992, Sidransky, Tayebi et al. 1996, Enquist, Lo Bianco et 
al. 2007, Xu, Reboulet et al. 2008, Mazzulli, Xu et al. 2011). However, patients with type 1 
GD are not affected by neurological impairments. Recently, the view of Gaucher typ 1 as a 
non-neuronopathic form has been questioned since aberrant function of GC became linked to 
an increased risk to develop PD (Hruska, Goker-Alpan et al. 2006, Westbroek, Gustafson et 
al. 2011).  
 
Efficient degradation of cellular metabolites is essential for neuronal survival. An impairment 
of lysosomal GC activity was found in post-mortem brain obtained from PD patients (Chu, 
Dodiya et al. 2009, Dehay, Bove et al. 2010). This indicates the importance of the lysosomal 
pathway in the development of neurodegenerative diseases (Nixon 2013).  
In this study an impairment of lysosomal clearance could be identified in the brain of 
LIMP-2-deficient mice. The initial consequence of the drastically reduced GC activity is an 
apparent accumulation of glucosylceramide. Since there are no specific antibodies against the 
glycolipid available, indirect detection methods were used. Electron micrographs indicated 
dense storage material and lipid droplets in neurons of the pons and additional analysis of 





indicated by staining of neutral lipids (including glucosylceramide) (Rothaug, Zunke et al. 
2014). It would be of interest to further characterise the storage material found in the brain of 
LIMP-2-deficient mice e.g. by mass spectroscopical analyses. 
5.4.2 Reasons for α-synuclein accumulation mediated by the LIMP-2 deficiency 
The loss of GC activity as well as the accumulation of its substrate glucosylceramide may 
promote α-synuclein accumulation and aggregation (Mazzulli, Xu et al. 2011, Westbroek, 
Gustafson et al. 2011, Gegg, Burke et al. 2012). However, the molecular mechanisms leading 
to this pathology are still poorly understood. The depletion of LIMP-2 resulted in elevated 
levels of α-synuclein as shown in this study. In immunoblot analyses of midbrain samples 
such increased α-synuclein levels were found in the soluble and insoluble fraction. In 
addition, three different antibodies against α-synuclein were utilised since the protein can 
appear in different aggregating stages. Each antibody recognises preferably a different form. 
Although the molecular weight of the monomer of α-synuclein has been found to be around 
14 kDa by mass spectrometry, the protein exhibits an apparent weight of 17-19 kDa on SDS-
PAGE (Weinreb, Zhen et al. 1996). This deviation in size had been explained by the highly 
charged c-terminus of α-synuclein, which leads to a low binding of SDS (Ueda, Fukushima et 
al. 1993).  
In midbrain of LIMP-2-deficient mice no increase in the protein level of monomeric 
α-synuclein was observed. In contrast the 23 and 58 kDa species were both elevated in LIMP-
2-deficient samples. Most likely the 23 kDa band is a dimer of α-synuclein, but it could also 
be an ubiquitinated form of the protein (Shimura, Schlossmacher et al. 2001). The 58 kDa 
band most likely representing an oligomeric form of α-synuclein. An α-synuclein knockout 
control was used to control for the specificity of the antibodies. Rothaug and co-workers 
performed size-exclusion-chromatography (SEC) to better assess the presence of oligomeric 
α-synuclein forms. Two different antibodies (C-20 and Syn-1) were utilised showing 
increased high molecular α-synuclein protein levels in LIMP-2 knockout samples (Rothaug, 
Zunke et al. 2014). 
This is in agreement with recent literature where loss-of-function mutations in the GBA1 gene 
were linked to aberrant α-synuclein degradation (Westbroek, Gustafson et al. 2011). Also 
cell-based and in vivo data in mice demonstrated that dysfunction of GC activity leads to the 
formation of α-synuclein aggregates (Mazzulli, Xu et al. 2011, Osellame, Rahim et al. 2013, 
Ginns, Mak et al. 2014). 
There are several hypotheses published describing how the link between mutated GC and 





α-synuclein thus promoting the aggregation of the neuronal protein (Cullen, Sardi et al. 2011, 
Yap, Gruschus et al. 2011). Another theory implies an involvement of the ER associated 
degradation (ERAD) of the mutated enzyme resulting in increased cell stress (Ron and 
Horowitz 2005, Mu, Ong et al. 2008). Supporting this view increased levels of ERAD-
markers have been found in brains of PD patients with and without mutations in GBA1, 
indicating a rather general role for the ERAD-pathway in PD (Rocha, Smith et al. 2015). 
These gain-of-function theories, which imply a direct effect of the mutant GC on α-synuclein 
levels, do not explain the observed elevation of α-synuclein in LIMP-2-deficient mice or in 
mouse models where an inhibitor of GC was applied (CBE) (Manning-Bog, Schule et al. 
2009, Xu, Sun et al. 2011). Hence it seems likely that a loss-of-function in GC results in an 
imbalance in the α-synuclein homeostasis. The dysfunction of GC may lead to a progressive 
built-up of glucosylceramide or glycosylsphingosine. In addition, in vitro experiments 
indicate that this glucosylceramide interacts with α-synuclein leading to stabilisation 
(Mazzulli, Xu et al. 2011). Surprisingly, a recent study reveals no evidence for substrate 
(glucosylceramide) accumulation in post-mortem brains of PD patients with GBA1 mutations 
(Gegg, Sweet et al. 2015). This emphasises that the mechanisms by which GC deficiency 
increases the risk for developing PD are still unclear. 
To date a direct effect of the LIMP-2 protein on α-synuclein homeostasis cannot be ruled out 
completely. So far only one study showed an interaction of α-synuclein with LIMP-2 (Gegg, 
Burke et al. 2012), which could not be reproduced by coimmunoprecipitation approaches in 
our laboratory (data not shown).   
5.4.3 Consequences of α-synuclein accumulation in mouse and human CNS 
This work suggests a distinct relationship between the expression levels of LIMP-2 and 
α-synuclein clearance. As outlined in this study, the presence of endogenous levels of 
α-synuclein in LIMP-2-deficient mice (in the C57/BL6N background) led to a severe 
neurological phenotype, which was not observed when LIMP-2 knockout mice were kept in 
the α-synuclein deficient background (C57/BL6J). This clearly suggests a link between the 
severity of disease and the abundance of α-synuclein. Furthermore, a dosage-dependent 
relationship between α-synuclein levels and disease progression has been shown in transgenic 
mice overexpressing α-synuclein (Rieker, Dev et al. 2011).  
Consequently, accumulating α-synuclein has shown to be toxic exhibiting severe effects on 
neuronal cell viability (Karpinar, Balija et al. 2009, Winner, Jappelli et al. 2011). In PD 
mouse models as well as in patients astrogliosis and microgliosis have been observed (Hirsch, 





in the pons and midbrain of LIMP-2-deficient mice. Immunostainings revealed an increased 
number of GFAP and CD68-positive cells indicating highly progressive astro- as well as 
microgliosis. Furthermore an elevation of apoptotic cells accompanied by a shrinkage of 
tyrosine hydroxyline positive cells within the midbrain of LIMP-2-defiecent mice (Rothaug, 
Zunke et al. 2014) indicated the severe progression of disease.  
Similar as in patients, these α-synuclein accumulation also resulted in severe behavioural 
abnormalities in the LIMP-2-deficient mice (Rothaug, Zunke et al. 2014). This was indicated 
by motor deficits, hind limp clasping, weight loss and premature death. Since these 
phenotypes resemble the course of disease in a PD mouse model expressing the highly 
accumulation-prone A53T mutant of α-synuclein (Giasson, Duda et al. 2002), it further 
underlines that the observed neuropathological impairments are mediated by the deficiency of 
LIMP-2. 
Whether the loss of LIMP-2 also leads to a comparable elevation of α-synuclein levels in 
AMRF-patients, lacking functional LIMP-2, still has to be evaluated. Further studies will be 
necessary to assess if aggregation of α-synuclein contributes to the neuropathic characteristics 
in AMRF patients. However, patients that lack LIMP-2 expression die young and may not be 
old enough to allow accumulation of α-synuclein (Balreira, Gaspar et al. 2008). Fibroblasts 
derived from AMRF patients indicated a loss of LIMP-2 and decreased levels and activity of 
lysosomal GC (Figure 4.48). To validate if the loss of GC consequently leads to α-synuclein 
accumulation post-mortem analysis of brains from AMRF patients will be necessary. Another 
approach would be to characterise neuronal cell types derived from induced pluripotent stem 
cells (iPSC) from fibroblasts of AMRF patients. 
Furthermore, it was assessed if and to what extent α-synuclein influences GC activity. Recent 
studies in PD patients show reduced GC-activity in brain regions with increased α-synuclein 
levels (Gegg, Burke et al. 2012, Murphy, Gysbers et al. 2014). In this work the effect of 
α-synuclein on lysosomal activity in iPSC-derived dopaminergic neurons from human 
midbrain was investigated. The results suggest that not only decreased GC activity results in 
an accumulation of α-synuclein, but also vice versa, that α-synuclein negatively influences 
GC function. A direct interaction of α-synuclein with GC resulting in enzyme inhibition may 
be a possible explanation (Yap, Gruschus et al. 2011). Another reason for this negative effect 
on GC activity could result from intracellular trafficking deficiencies. Recent studies reveal 
that oligomeric α-synuclein is able to block ER-Golgi delivery. This could be verified in 
yeast, mammalian cells and PD brain lysates (Cooper, Gitler et al. 2006, Thayanidhi, Helm et 





consequences, since the transport, maturation and thus function of lysosomal enzymes and 
potentially other -so far undescribed- proteins is affected. This trafficking deficit results in 
dysfunction of lysosomal GC and creates a negative feedback loop, which further supports 
α-synuclein accumulation (Figure 5.10).  
5.4.4 The role of LIMP-2 in the development and correction of synucleinopathies: 
identification of novel therapeutic targets  
The importance of LIMP-2 in α-synuclein homeostasis is further supported by the 
identification of increased levels of the lysosomal membrane protein in post-mortem brain of 
PD patients (Rothaug, Zunke et al. 2014). This might indicate a compensatory effect to 
overcome an impaired lysosomal targeting of GC. Single nucleotide polymorphisms (SNPs) 
in the SCRAB2 gene encoding for LIMP-2 have been described as genetic risk factors for the 
development of PD (Do, Tung et al. 2011, Hopfner, Schulte et al. 2013). However, for further 
validation of this finding a larger cohort of PD patients will be needed for genetic screens 
(Maniwang, Tayebi et al. 2013). It was shown in a recent study that the SCARB2 locus is 
associated with dementia with Lewy body (DLB) indicating the involvement of LIMP-2 in the 
development of synucleinopathies (Bras, Guerreiro et al. 2014). In addition, mutations within 
SCARB2 were recently shown to modify the neurological presentation of GD (Velayati, 
DePaolo et al. 2011). 
Data described in this study emphasise an important reciprocal role for LIMP-2 in α-synuclein 
homeostasis (Figure 5.9). Although the molecular details of this interaction still remain 
elusive, it could be shown that a depletion of LIMP-2 leads to α-synuclein accumulation in 
murine brain. This is most likely due to an impaired lysosomal transport and activity of GC. 
Decreased GC activity leads to the accumulation of its substrate glucosylceramide. This 
glycosphingolipid may directly interact with and stabilise α-synuclein, which also has been 
shown to inhibit intracellular trafficking, further affecting the delivery of lysosomal enzymes 
to lysosomes (Cooper, Gitler et al. 2006, Thayanidhi, Helm et al. 2010, Mazzulli, Xu et al. 








    
Figure 5.9: Schematic interaction between LIMP-2, GC and α-synuclein. 
LIMP-2 transports GC to the lysosome, where it hydrolyses glucosylceramide (GluCer) to glucose and ceramide. 
GluCer seems to interact with α-synuclein leading to its stabilisation. Increased levels of α-synuclein impair 
intracellular trafficking, which leads to reduced lysosomal levels of GC. Furthermore, α-synuclein might directly 
interact with GC, negatively influencing its enzymatic function. This creates a negative feedback loop, where the 
accumulating substrate of GC (GluCer) further stabilises the aggregating α-synuclein thereby accelerating its 
negative effects on GC transport and activity. 
 
Thus, methods that overcome the α-synuclein-induced ER-Golgi transport defect and that 
increase the delivery of GC to lysosomes have been suggested as a therapeutic strategy 
(Figure 5.10). Since LIMP-2 is the only reported transporter of GC it is an attractive target to 
influence lysosomal transport of GC.  
As already described by Reczek et al., a known disease causing mutant of GC (L444P) that is 
retained in the ER, was transported to the lysosomal compartments after LIMP-2 
overexpression, highlighting the high affinity of the enzyme for its receptor (Reczek, 
Schwake et al. 2007). This data and the positive effects of LIMP-2 expression on the 
lysosomal GC localisation further emphasises the role of LIMP-2 in targeting wild-type as 
well as aberrant GC to lysosomes, where the enzyme is most active. 
Furthermore, the GC activity in the whole cell as well as in the lysosomal fraction only could 
be increased after overexpression of LIMP-2. Since GC already exhibits activity while in the 
ER, it is important to control that the activity is actually increased in the target organelle of 
GC, the lysosome.  
Besides its trafficking function LIMP-2 might also act as a chaperone, stabilising and thus 
activating GC directly. As described in this study, the elevated lysosomal activity of GC 
resulted in an accelerated α-synuclein degradation in the presence of auxiliary LIMP-2. This 







Figure 5.10: Overview of strategies to reduce the accumulation of α-synuclein. 
GC gets transported to the lysosome by interaction with LIMP-2. Both proteins associate in the ER and 
dissociate pH-dependently in the lysosome. The lysosomal transport of GC can be enhanced by overexpression 
of LIMP-2 or GC chaperones. Increased levels of lysosomal GC result in a boost of GC activity followed by a 
decrease in glucosylceramide levels. Another way to reduce the concentration of the glycosphingolipid is the 
substrate reduction therapy by miglustat. Since glucosylceramide has been shown to interact and stabilise 
α-synuclein, reduction of the lipid will also reduce α-synuclein accumulation. A decreased concentration of 
soluble α-synuclein oligomers is followed by reduced blockage of the ER-Golgi transport. In summary, either 
increased lysosomal transport of GC or direct substrate reduction may lead to a decrease in α-synuclein levels 
reducing cellular toxicity and decline of cellular trafficking defects. 
 
In order to exploit the benefit of the positive effect of LIMP-2 on α-synuclein levels for 
therapy, strategies to increase the protein level of the lysosomal membrane protein should be 
considered (Figure 5.10). In this respect, gene therapy may be an option, but remaining issues 
of the viral vector safety are still an obstacle in the clinical application (Sands and Davidson 
2006, Aronovich and Hackett 2015). Another approach would be to analyse the promoter 
region of LIMP-2 to identify new therapeutic targets, which increase the expression of the 
lysosomal membrane protein on a transcriptional level. A high-throughput screening of small 
molecules evaluating changes in LIMP-2 transcription could help to discover novel effectors 





Pathology and behavioural abnormalities induced by α-synuclein accumulation can be 
reversed in a mouse model of dementia with Lewy body (DLB) (Lim, Kehm et al. 2011). This 
indicates that methods, which enhance α-synuclein clearance, are able to reverse already 
existent symptoms and may provide a therapeutic benefit. Increasing the activity of GC is one 
strategy that might downregulate α-synuclein levels and thus may prevent further disease 
progression in synucleinopathies including PD. Recent studies show a decline in α-synuclein 
accumulation as well as CNS impairment after introducing GC adenovirus-mediated into PD 
mouse brains (Sardi, Clarke et al. 2013).  
Small molecules directly targeting and activating GC are of interest. As shown in this work 
the LIMP-2-derived helix 5 peptide was able to increase GC activtity in vitro as well as in cell 
culture based studies. Furthermore, it was assessed if the peptide-induced augmentation of GC 
activity is sufficient to reduce α-synuclein levels. Indeed, enhanced α-synuclein clearance 
could be observed after adding the helix 5 peptide to the media of stably α-synuclein 
overexpressing H4 cell line. This effect was accompanied by an increase of intracellular GC 
activity, indicating that the positive effect on the α-synuclein levels is due to the peptide-
mediated increase of GC activity. Since, α-synuclein is the accumulating protein in Parkinson 
disease (Polymeropoulos, Lavedan et al. 1997), this broadens the field of a potential 
therapeutic application of the LIMP-2-derived peptide. In further studies, the effect and 
potency of the helix 5 peptide on GC activity and subsequently on α-synuclein levels will 
need to be assessed in vivo. However, a critical point will be the ability of the peptide to cross 
the blood-brain barrier. This is of interest for the treatment of synucleinopathies but also for 
the neuropathological forms of Gaucher disease (type II and III).  
Another strategy to potentially reduce α-synuclein levels may be the substrate reduction 
therapy (SRT). Since the compound miglustat has been shown to target the glucosylceramide 
synthase leading to reduced levels of glucosylceramide (Platt, Neises et al. 1994), the decline 
in glycosphingolipid levels may reduce the stabilisation of α-synuclein oligomers (Figure 
5.10). However to date, no effect of miglustat treatment on neurological phenotypes could be 
observed. So far, therapeutic benefits were perceived particularly in liver and spleen size as 






5.5 Conclusion and outlook 
This study describes the structural characteristics of the interaction of LIMP-2 with GC and 
its auxiliary effect on GC activity. After describing the GC binding site on the LIMP-2 
protein, a small peptide resembling helix 5 of this interaction site was shown to specifically 
interact with GC. Interestingly, the peptide was also able to enhance GC activity in vitro as 
well as in cells. Furthermore, this work shows a distinct relationship between LIMP-2 
expression, GC-activity and α-synuclein homeostasis. However, the detailed molecular 
mechanisms of this interaction still remain unclear. Since activators of GC accelerate the 
clearance of α-synuclein and thus prevent further disease progression in synucleinopathies, 
future experiments are necessary to address the impact of the LIMP-2-derived peptide in vivo. 
Since it was also possible to identify the LIMP-2 binding site on GC, found opposite of the 
catalytic cavity, this interaction domain is of interest for a rational drug design. Small 
molecules targeting this specific protein region may be considered as therapeutic approach for 
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Table 7.1: Abbreviations 
%  Percentage 
-/- Knockout 
+/+ Wild-type 
°C  Degree Celsius 
AMRF Action Myoclonus Renal Failure Syndrome 
ANOVA Analysis of variance 
AP Adaptor protein 
Baf Bafilomycin 
BSA bovines Serum Albumin 
CBE Conduritol B epoxide 
CD Circulardichroism 
CD36 cluster of differentiation 36 
CD-MPR cation-dependent mannoe-6-phosphate receptor 
Cer Ceramide 
CHO Chinese Hamster Ovary 
CI-MPR cation-independent mannoe-6-phosphate receptor 
CMA Chaperone mediated autophagy 




ddH2O double-destilled H2O 
dKO double knockout 
DLS Dynamic Light Scattering 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
EM Electron micrograph  
EndoH Endoglycosidase H 
ER Endoplasmic reticulum 
ERret. Endoplasmic reticulum retention mutant 
ERT Enzyme replacement therapy 
GC β-glucocerebrosidase 
GFAP Glial fibrillary acid protein 
GlcNac-1PT N-acetylglucosamine-1-phosphotransferase 
GluCer Glucosylceramide 
HPLC High performance liquid chromatography 
HRP horseradish peroxidase 




iPSC induced pluripotent stem cells 
kDa Kilodalton 
KO knockout 
LAMAN Lysosomal acid mannosidase (α-mannosidase) 
LAMP Lysosomal Associated Membrane Protein 
LIMP Lysosomal Integral Membrane Protein 
LSD Lysosomal storage disease 
M6P Mannose-6-Phosphate 





MPR Mannose-6-Phosphate Receptor 
NeuN Neuronal Nuclei: neuronal marker 
nm nanometer 
norm. normalised 
NPC Niemann-Pick Type C 
NSE Neuronal specific enolase 
pacLipids Photo-activated-and-clickable lipids 
PAS Periodic acid Schiff staining 
PBS Phosphate buffered saline 
PDB Protein data base 
PDI Protein disulfide isomerase 
pH  Potential hydrogen 
PME progressive myoclonic epilepsy 
PNGaseF Peptide -N-Glycosidase F 
s second 
SCARB scavenger receptor class B 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SNCA α-synuclein gene 
SR-BI scavenger receptor class B type I 
SRT Substrate reduction therapy 
TGN Trans-Golgi-Network 
TH Tyrosine hydroxylase 
Tris  Tris-(hydroxymethyl)-aminomethan 
T-Sol. Triton soluble 
TUNEL Terminal dUTP-biotin Nick End Labeling 
WT Wild-type  
μg  Mikrogramm 
μL  Mikroliter 
μM  Mikromolar 
 
7.2 Equipment, chemicals, enzymes, kits and buffers 
7.2.1 Machines 
Table 7.2: Overview of utilised machines.  
Description Model Company 
 
96 well plate reader Synergy HAT BioTek, Bad-Friedrichshall, DE 
Agarose gel imaging Gel Jet Imager UV system Intas, Göttingen, DE 
Agarose running chamber Sub-Cell®GT Bio-Rad, Hercules, US 
Autoclave Tecnomara Integra Biosciences, Fernwald, 
DE 
Bacteria incubator Multitron II Infra-Hat, Sulzemoos, DE 
Bench-top roller RM5 Karl Hecht KG, Sondheim, DE 
CD- spectropolarimeter Jasco-J-720-CD  Japan Spectroscopic Company, 
JP 
Cell culture incubator HeraCell240 Heraeus, Hanau, DE 
Chemiluminescence detection 
system 
LAS4000 GE Healthcare, Munich, DE 
Confocal laser scanning 
microscope 





DLS spectrometer Laser-spectroscatter 201 RiNA GmbH Netwerk RNA-
Technologie, Berlin DE 
Electroporation device Pulse controller gene pulser Bio-Rad, Hercules, US 
Fluorescence microscope Axiovert 200M Zeiss, Jena, DE 
Electroporation device Gene Pulser Bio-Rad, Hercules, US 
Heating block Thermostat 5320 Eppendorf, Hamburg, DE 
Light microscope CKX41 & SZ61 Olympus. Hamburg, DE 
Magnetic stirrer IKAMAG RCT, REO IKA, Staufen, DE 
Micropipette 1 µl Eppendorf, Hamburg, DE 
 10 µl Eppendorf, Hamburg, DE 
 200 µl Gilson, Limburg-Offheim, DE 
 1000µl Gilson, Limburg-Offheim, DE 
PCR-Cycler GenAmp 2400 PCR Perkin Elmer, Rodgau-
Jügesheim, DE 
pH-Meter Digital-pH-Meter 646 Krick, Langenselbold, DE 
Pipette Boy Accu-jet®Pro Integra Bioscience, Fernwald, 
DE 
Powerpack Powerpack 200/300 Bio-Rad, Hercules, US 
Pure water device Milli-Q Plus Millipore, Schwalbach, DE 
SDS-Page Chamber Mini-Protein 3-
Electrophoresis system 
Bio-Rad, Munich, DE 
Sensitive scales L420P Sartorius AG, Göttingen, DE 
Sterile hood VFR1806 CLAUS DAMM A/S, Alleroed, 
DE 
Tabletop centrifuge EM 900 Eppendorf, Hamburg, DE 
Tabletop cooling centrifuge Fresco21 Thermo Fisher Scientific, 
Waltham, US 
Tank blotting device Criterion
TM
 Bio-Rad, Hercules, US 
Thermomixer Thermomixer 5436 Eppendorf, Hamburg, DE 
Tissue homogeniser Precellys PeqLab, Erlangen, DE 
Ultracentrifuge J2-HS Beckman, Fullerton, US 
UV-Table Reprostar Lamag, Berlin, DE 
Vortexer Vortex Genie Bender & Hobein, Bruchsaal, 
DE 
Waterbath 1083 GFL, Burgwedel, DE 
Weighing scales Kern 770 Kern & Son, Dürrwangen, DE 
 
7.2.2 Consumables 
Table 7.3: Laboratory material. 
Description Company 
 
12-Well-Plates Sarstedt, Nümbrecht, DE 
6-Well-Plates Sarstedt, Nümbrecht, DE 
96-Well-Plates Sarstedt, Nümbrecht, DE 
96-Well-Plates (Crystallisation) Hampton Reasearch, Aliso Viejo, US 
Coverslips Assistent, Sondheim, DE 
Cryo tubes Sarstedt, Nümbrecht, DE 
Electroporation cuvettes Peqlab, Erlangen, DE 
Filter Tips Biosphere Sarstedt, Nümbrecht, DE 
Glass beakers Roth, Karlsruhe, DE 
Gloves Roth, Karlsruhe, DE 
Graduated cylinders Roth, Karlsruhe, DE 
MicoMesh Mounts (400/50) Jena Bioscience, Jena, DE 






Amersham Protran 0.2 μm NC 
GE Healthcare, Munich, DE 
Objectives (histology) Marienfeld Laboratory Glassware, Lauda-Königshofen, DE 
Objectives (tissue culture) Menzel Glass GmbH & Co. KG, Braunschweig, DE 
Parafilm American National Can
TM
,Chicago, IL, US 
Pasteur pipettes Assistant, Sondheim, DE 
PCR tube strips (8x) Sarstedt, Nümbrecht, DE 
PCR tubes Sarstedt, Nümbrecht, DE 
Pipette tips Sarstedt, Nümbrecht, DE 
PVDF-membranes, Immobilon Millipore, Schwalbach, DE 
Reaction tubes Eppendorf, Hamburg, DE 
Sterile filter (0,2 µm pore size) Sarstedt, Nümbrecht, DE 
Sterile plastic tubes Sarstedt, Nümbrecht, DE 
Surgical preparation tools FST, Heidelberg, DE 
Surgical scalpel Aesculap, Tuttlingen, DE 
Syringes  Becton Dickinson, Heidelberg, DE 
Tissue culture dishes Sarstedt, Nümbrecht, DE 
Transfer pipettes, 3,5 ml Sarstedt, Nümbrecht, DE 
Ultracentrifuge 1.5 ml tubes Beckman, Fullerton, US 
Vivaspin 500 Sartorius, stedim biotech, Göttingen, DE 
Whatman paper Roth, Karlsruhe, DE 
 
7.2.3 Chemicals/Enzymes 
Table 7.4: Applied Chemicals and enzymes. 
Description Company 
 
1 X Trypsin/EDTA PAA-Laboratories, Linz, AT 
2-Mercaptoethanol (p.a.) Roth, Karlsruhe, DE 
30% Acrylamide / 0,8% bisacrylamide, 
rotiphorese 30 
Roth, Karlsruhe, DE 
Acetic acid Sigma Aldrich, Steinheim, DE 
Agarose Lonza, Cologne, DE 
Al’s oil (Paraffin and Silicon 50:50) Hampton Research, Aliso Viejo, US 
Ammonium Persulfate (APS) Roth, Karlsruhe, DE 
Ampicillin Melford Laboratories, Chelsworth, UK 
Bafilomycin A1 Calbiochem/Merck, Darmstadt, DE 
Bovine serum Albumin (BSA) Sigma Aldrich, Steinheim, DE 
Bromphenol blue Canalco, Bethesda, US 
Calcium Chloride dehydrated Merck, Darmstadt, DE 
Citric acid Merck, Darmstadt, DE 
Complete Protease Inhibitor Cocktail Roche, Mannheim, DE 
Coomassie Brilliant Blue R-250 Bio-Rad, Hercules, US 
DAB (3,3 Diaminobenzidine 
tetrahydrochloride) 
Sigma Aldrich, Steinheim, DE 
DABCO (1,4-Diazobicyclo[2.2.2]octane) Sigma Aldrich, Steinheim, DE 
DAPI (4‘,6-Diamidine-2-phenylindol) Sigma Aldrich, Steinheim, DE 
Desoxyribonucleosidetrisphosphates 
(NTPs) (2 mM/ 10 mM) 
Thermo Fisher Scientific, Waltham, US 
Di-Calcium-hydrogen-phosphate Roth, Karlsruhe, DE 
Di-Sodium hydrogen phosphate Roth, Karlsruhe, DE 
DMSO (Dimethylsulfoxide) Serva, Heidelberg, DE 
DNA-Ladder (100 bp, 1 kb) Roche, Mannheim, DE 





DNA-Polymerase (Taq, Pfu) Thermo Fisher Scientific, Waltham, US 
DNase Roche, Mannheim, DE 
Doxycycline  Sigma Aldrich, Steinheim, DE 
DTT (Dithiothreitol) Sigma Aldrich, Steinheim, DE 
Dynabeads Invitrogen, Darmstadt, DE 
Ethanol 99,8% p.a. Roth, Karlsruhe, DE 
Ethidiumbromide Roth, Karlsruhe, DE 
Ethylendiamintetra acetic acid (EDTA) Roth, Karlsruhe, DE 
Eukitt Sigma Aldrich, Steinheim, DE 
Fetal Bovine serum Invitrogen, Darmstadt, DE 
Filipin (F9765) Sigma Aldrich, Steinheim, DE 
Fetal calf serum (FCS) PAA, Laboratories, Linz, AT 
G418 (Geneticin) InvivoGen, Toulouse, FR 
Glucose Sigma Aldrich, Steinheim, DE 
Glycerol Sigma Aldrich, Steinheim, DE 
Glycine Roth, Karlsruhe, DE 
Haematoxylin by Harris Roth, Karlsruhe, DE 
Hydrogen peroxide (30 % H2O2) Merck, Darmstadt, DE 
Hygromycin InvivoGen, Toulouse, FR 
Isopropanol (p.a.) Roth, Karlsruhe, DE 
Izit ® staining Hampton Research, Aliso Viejo, US 
Magnesium chloride Merck, Darmstadt, DE 
Methanol (p.a.) Roth, Karlsruhe, DE 
Milk powder Roth, Karlsruhe, DE 
Mowiol Calbiochem, La Jolla CA, US 
N,N,N',N'-Tetramethylethylendiamine 
(TEMED) (p.a.) 
Roth, Karlsruhe, DE 
N-butyl-deoxynojirimycin (Miglustat)   Tocris biosciences, Bristol, UK 
Page Ruler Prestained Protein Ladder 
Plus 
Thermo Fisher Scientific, Waltham, US 
Paraformaldehyde Fluka, Buchs, Switzerland 




Thermo Fisher Scientific, Waltham, US 
Polyethylenimin (PEI) Sigma Aldrich, Steinheim, DE 
Potassium Chloride Roth, Karlsruhe, DE 
Potassium dihydrogen-phosphate Roth, Karlsruhe; DE 
Potassium-hydrogen carbonate Roth, Karlsruhe, DE 
Restriction enzymes and buffers Thermo Fisher Scientific, Waltham, US 
RotiHistol Roth, Karlsruhe; DE 
Sodium chloride Roth, Karlsruhe, DE 
sodium dodecyl sulfate (SDS) Roth, Karlsruhe, DE 
Sodium hydrogen carbonate Roth, Karlsruhe, DE 
Sodium hydroxide Riedel-de-Haen, Seelze, DE 
Sodiumcitrate Merck, Darmstadt, DE 
Streptavidin (High Capacity) beads Thermo Fisher Scientific, Waltham, US 
Tetracyclin Merck, Darmstadt, DE 
Tris(hydroxymethyl)-aminomethane 
(TRIS) 
Roth, Karlsruhe, DE 
Triton X-100 Sigma Aldrich, Steinheim, DE 
Trypan blue 0.4 % Invitrogen, Darmstadt, DE 
Trypsin/EDTA Invitrogen, Darmstadt, DE 
Turbofect
®
 transfection reagent Thermo Fisher Scientific, Waltham, US 





U18666A Cayman Chemicals, Ann Arbor, US 
Xylol Roth, Karlsruhe, DE 
 
7.2.4 Kits  
Table 7.5: Overview of utilised kits. 
Description Company 
 
ApopTag®Peroxidase In situ Apoptosis 
Detection Kit  
Millipore (Schwalbach, DE) 
BCA-Protein Assay Kit Pierce; Thermo Fisher Scientific, Waltham, US 
ECL Advanced/Plus Western Blot 
Detection Kit 
GE Healthcare, Munich, DE 
Elite DAB staining kit Enzo Life Sciences, Lörrach, DE 
EndoH/PNGaseF digestion kit New England Biolabs, Ipswich, US 
High Pure PCR-Purification Kit Roche, Mannheim, DE 
NucleoSpin
®
 RNA easy Kit Macherey-Nagel, Düren, DE 
PureYield Plasmid Midiprep System Promega, Mannheim, DE 
Plasmid Miniprep Kit Thermo Fisher Scientific, Waltham, US 
RevertAid
TM
 First Strand cDNA 
Synthesis Kit 
Thermo Fisher Scientific, Waltham, US 
RNA-isolaton Macherey-Nagel, Düren, DE 
Vector Laboratories ABC kit Enzo Life Sciences, Lörrach, DE 
 
7.2.5 Buffer and solutions 
Table 7.6: Overview of general buffers. 
Name of buffer/solution Reagents 
 
0.1 M NaPhosphat buffer, pH7 Stock:  
195 ml 0.2 M NaH2PO4  
(27.6 g NaH2PO4-1H2O in 1L dH2O) 
 305 ml 0.2 M Na2HPO4 
(35.6 g Na2HPO4-1H2O in 1L dH2O) 
 500 ml dH2O 
  
EBC-buffer 




pH 7,4 (HCl) 
1 tablet Complete ® 
  
LB-Agar 10 g Bacto-Trypton  
 5 g Bacto-yeast-Extrakt 
 10 g NaCl  
15 g/L Bacto-agar  
Fill to 1000 ml dest. H2O; pH7 
autoclave and pour into 10 ml sterile dishes 
  
LB-medium 10 g Bacto-Trypton  
5 g Bacto-yeast-Extrakt  
10 g NaCl  






Phosphate buffer (0.1 M PB) 77.4 ml 1M Na2HPO4 
 22.6 ml 1M Na2HPO4 
  Fill to 1L with ddH20, pH 7.4 
  
Phosphate buffered saline solution (PBS) 137 mM NaCl 
 2.7 mM KCl 
 4.3 mM Na2HPO4 
 1.4 mM KH2PO4 
 Fill to 1L with H20, pH 7.4 
  
50 x TAE buffer  2 M Tris 
2 M Glacial acetic acid 
 100 ml 0.5 M EDTA (pH 8.0-8.5) 
Fill to 1000 ml ddH2O 
 
Table 7.7: Solutions for cell culture. 
Name of buffer/solution Reagents 
 
Dulbecco’s Modified Eagle Medium 
(DMEM) High Glucose (4.5 g/ml)  
   general cell culture medium 
+ additives: 
10 % FCS 
1 % Penicillin/Streptomycin 
   (GE Healthcare, Chalfont St. Giles,     
   UK) 
 
  
Freezing medium 1 % Penicillin/Streptomycin 
 20% DMSO 
30% FCS 
in DMEM/RPMI medium 
  
Opti-MEM medium + additives: 
   For H4 (human neuroglioma) 
   (Thermo Fisher Scientific, Waltham, 
   US) 
5 % FCS 
1 % Penicillin/Streptomycin  
200 μg/ml G418 
    200 μg/ml Hygromycin 
  
RPMI medium 1640  + additives: 
   for human fibroblasts 10 % FCS 
   (GE Healthcare, Chalfont St. Giles,  
   UK) 
1 % Penicillin/Streptomycin 
  
SM1-neurobasal (NB) medium without phenol red 
   For human neurons (iPSC-derived) + additives: 
   (Thermo Fisher Scientific, Waltham, 
   US) 
10 % FCS 
 
 
Table 7.8: Enzyme activity assay buffers. 
Name of buffer/solution Reagents 
 
Enzyme activity assay citrate buffer 0.2 M Sodium citrate 
 0. 04 % NaN3 
 0.2 % BSA 






Enzyme activity assay stop solution 0.4 M Glycine 
 pH to 10.4 with NaOH 
  
Enzyme activity assay: substrate 10 mM 4-Nitrophenyl β-D-glucopyranoside (Sigma-
Alderich N7006) 
0.2 M Citrate buffer 
 
Table 7.9: Buffer for SDS-PAGE and Western-Blotting. 
Name of buffer/solution Reagents 
 
Blocking buffer (IF) 10 % FCS, 0.2 % saponin 
  
Coomassie destaining solution 10 % Methanol 
 10 % Acetic acid (CH3COOH) 
in ddH2O 
  
Lysis Buffer cell pellets 50 mM Tris-NaOH 
 150 mM NaCl 




 1 % Triton-x 100 
 2 mM MgCl2  
 pH 7.4 
  
SDS soluble buffer (Mazzulli et al., 2006) 2 % SDS, 50 mM Tris-HCl-pH7.4 
  
SDS-PAGE-buffer 10x 1.92 M Glycine 
 250 mM Tris-HCl 
 35 mM SDS 
  
4x SDS-PAGE-loading buffer (Laemmli)  500 mM Tris/HCl pH6.8 
 4 % SDS 
 40 % Glycerol 
 0.02 % Bromophenol blue 
 400 mM DTT 
 Fill to 10 ml with ddH20 
  
Stacking gel buffer 0.5 M Tris 
 0.4 % (w/v) SDS 
 pH 6.8 
  
Seperation gel buffer 1,5 M Tris 
 0.4 % (w/v) SDS 
 pH 8.8 
  
Stripping buffer (Glycine) 100 mM Glycine 
 20 mM Mg-Acetate 
50 mM KCl 
pH 2.2 
 Fill to 1L with ddH20 
  
Stripping buffer (β-ME) 200 ml 10 % SDS stock solution  
 62.5 ml Tris/HCl pH 6.8 
 8.3 ml β-mercaptoethanol (β-ME) 






Tank-Blot-Transfer-Buffer (10X) 250 mM Tris 
 2 M Glycine 
 pH 8.3 
  
Tank-Blot-Buffer (1X) 1 x Tank-Blot-Buffer 10x 
 20 % Methanol 
 Fill to 1L with ddH2O 
  
TBS-T 20 mM Tris HCl 
 150 mM NaCl 
 pH 7.5 
 0.1 % Tween20 
  
Triton soluble buffer (Mazzulli et al., 
2006) 
1 % triton x-100  
 20 mM HEPES 
 150 mM NaCl 
 10 % glycerol 
 1 mM MgCl2 
 50 mM NaF 




 pH 7.4 
  
Washing/permeabilisation buffer (IF) PBS, 0.2 % saponin 
  
Western-Blot blocking buffer 5 g Milk powder dissolved in TBS/T 
 
Table 7.10: Buffers and solutions used for immunofluorescence (IF) and histological sections (IH). 
Name of buffer/solution Reagents 
 
Blocking/antibody solution (IH) 0.25% Triton-x-100, 4% goat serum in PB 
  
Blocking buffer (IF) 10 % FCS, 0.2% Saponin in PBS 
  
Citric acid immunohistology unmasking 
solution (IH) 
10 mM Citric acid (pH 6 - NaOH) 
  
H2O2-solution (IH) 0.3 % H2O2 in PB 
  
Masking buffer (IF) 0.12 % Glycine, 0.2% Saponine in PBS 
  
Fixation solution (IF) PBS, 4 % PFA 
  
Mounting IF/IH  
(immunofluorescence only) 
1 ml Mowiol solution  
(17 % Mowiol/33 % Glycerol in PBS; pH 6-7) 
100 µl DABCO (200 mg/ml Diazobicyclooctan; 
end conc. 50 mg/ml) 
1 µl DAPI-solution (end conc. 1 µg/ml) 
  
Washing /permeabilisation buffer (IF) PBS, 0.2 % Saponin 
  






Table 7.11: Solutions for recombinant protein/peptide assays and crystallisation. 
Name of buffer/solution Reagents 
 
Crystallisation buffer 100 mM Bis-Tris, pH 4.9-5.1 
 Ammonium sulphate: 2.0 – 2.4 M 
  
NaPhosphate buffer 
   solution for recombinant    
   proteins/peptides;   
 
   peptides were solved in 0.1 % HCl (in  
   10 vol. % of total buffer vol.) 
50 mM NaPhosphate  
150 mM NaCl 
pH7 
  
MES buffer 50 mM MES 
   solution of recombinant     
   protein/peptides for crystallisation  
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